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Abstract 
Systematic reviews - appraisal and synthesis of all primary research - are increasingly being used to 
inform policy and practice in health care. Therefore, it is important to understand how the key 
questions in systematic reviews are identified and prioritised and whether they are relevant to 
policy makers, practitioners and members of the public. Research priority setting (RPS) is usually 
defined as any interpersonal activity that leads to the selection of topics and/or choices of key 
questions to investigate1. Diverse approaches to setting research priorities are used in different 
countries, regions and organisations. There is no consensus in the literature on the most effective 
processes with which to set these priorities. However, these decisions define the quality and 
implications of the evidence, and syntheses of it, available to patients, public and policy makers to 
help them make informed decisions.  
My initial scoping work, was to design and conduct a survey across an influential international 
systematic review organisation (Cochrane Collaboration2) on how they set priorities for their 
reviews. We identified 13 structured approaches to setting priorities. As part of the project, we 
developed an evaluation framework that demonstrated whether the priority setting processes 
meet the values and principles of the Cochrane Collaboration. Subsequently, we developed an 
equity lens for research priority setting exercises to inform the design of research priority setting 
processes to ensure that they consider the priorities of disadvantaged groups along with 
advantaged groups. We used the equity lens to do a second evaluation on the priority setting 
processes in the Cochrane Collaboration. Both evaluation frameworks demonstrated that the 
Cochrane Collaboration requires better designed priority setting approaches and must be more 
transparent in reporting those processes.  
The evaluation of research priority setting exercises in the Cochrane Collaboration, along with the 
wider literature, demonstrates that research priority setting exercises cannot be evaluated in 
isolation from organisational cultures, values and context. Therefore, the next step of the project 
focused on a specific stakeholder group (major research funders) with significant influence on 
research, including support for systematic reviews. We selected 11 national research agencies in 
the UK, Netherlands, France, Norway, Denmark, Germany, Australia, Canada, and the USA. We 
devised and used a checklist based on Chalmers and Glasziou’s “avoidable research waste” 
framework (and evaluated the processes and policies of these agencies using this checklist). As 
                                                          
1
 There is no currently agreed definition for research priority setting. This is the definition that we developed 
in a discussion with experts in research priority setting in the Cochrane priority setting methods group  
2
 The organisation was originally called Cochrane Collaboration (and still is its legal name) but it was later 
rebranded (January 2015) as Cochrane. I used the term Cochrane Collaboration throughout this document   
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previous evaluations had demonstrated, this second evaluation found a lack of transparency in the 
process of setting priorities for research and other related organisational and policy issues.  
Increased funding is needed for methodological research to evaluate research practices and to 
monitor how funding research projects is done and reported.  
My evaluation of funding agencies and the Cochrane Collaboration found a similar lack of 
transparency and accountability in the context of conflicting values among stakeholders that 
decreases accountability and scrutiny of researchers and their institutions. However, the projects 
have led to organisational and policy changes in the two key stakeholder groups (the Cochrane 
Collaboration and selected funding agencies). Officials of national health research funding agencies 
have approached me to collaborate with them to address the issues raised by my work on reducing 
research waste. This led to the establishment of Funders Forum - the Ensuring Value in Research 
(EViR) Funders’ Collaboration and Development Forum - to enable agencies in various countries to 
exchange their experience in addressing issues and creating work groups to address them. The 
Forum is chaired by individuals from three major research funders: NIHR (UK), ZonMW 
(Netherlands) and Patient-Centered Outcomes Research Institute (PCORI; USA).  The Forum 
organises several meetings to establish common principles, standards and work plans to achieve 
the common objective around reducing research waste and adding value for research for a national 
research funder.   
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Executive Summary3  
This summary is an overview of the research projects and subsequent publications which comprise 
this dissertation. It identifies the stakeholders who participated in these projects, and it 
summarizes the history, objectives, methodology, results, and implications for policy and practice 
of each project.  
Research priority setting is generally a group activity that leads to decisions about topics and key 
questions to investigate in research projects, so we need to understand how, why and by whom 
such priority setting decisions are made. My projects document the characteristics and limitations 
of the research priority setting processes in selected key organisations, and how research priority 
setting relates to the allocation of resources in these organisations. The projects demonstrated that 
lack of transparency and accountability was a key problem across most of these organisations. 
Conflicting views, values and principles among those involved in these processes is a significant 
cause of this problem. My principal recommendation is that organisations that set priorities for 
systematic reviews should improve how they integrate the diversity of these views and values in 
their processes and structures.  
The projects which were the basis of each publication in this dissertation involved two groups of 
stakeholders: 1) members of formally organized research groups within the Cochrane Collaboration; 
and 2) officials in public national agencies funding health research in Europe, North America, and 
Australia. This first group of projects evaluated the processes for allocating resources to particular 
topics of research in the Cochrane Collaboration; the second group assessed analogous processes 
in research agencies in 11 countries. In studying both groups, I considered financial and/or 
nonfinancial resources allocated to research topics and projects.  
The Cochrane Collaboration groups were an appropriate set of stakeholders. The work of Cochrane 
groups and the overall organisation has been increasingly influential in decisions about policy and 
practice for patient care and public health around the world. It also has an important role in the 
history of systematic reviews. Priorities set by members of the Cochrane Collaboration define what 
new and updated systematic reviews are available to inform decision making by policy makers, 
clinicians and, increasingly, by patients.  
We also selected major funding agencies in particular countries because, in addition to determining 
what systematic reviews will be available, these agencies also fund primary research, which provide 
the data for new and updated systematic reviews. We selected agencies in Europe, Australia and 
                                                          
3
 The structure of the PhD in the Plymouth University guidelines for PhD by published work does not require 
an executive summary. However, I added one to facilitate navigating through the different sections of the 
dissertation. 
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North America as a diverse range of major funders. We decided not to include funders based in 
developing countries in this project as their social, economic and cultural context is different. 
The dissertation has five chapters. Chapter 1 summarizes a growing literature about the history of 
systematic reviews as a product of evidence-based health research; the state of the methodology 
for research priority setting when the projects in this dissertation began; and the history of each 
project. Chapter 2-4 presents the research publications which are the subjects of this dissertation. 
These include four key publications (1-4) based on the major research projects in which I was 
involved, nine related publications (5-13) grounded in my research, and one conference 
presentation (14).  Chapter 5 summarises the methods, findings, and practical results and 
implications of these publications. There are four appendices: appendix 1 explains selected 
research output relevant to this project, appendix 2 is an overview of reviews on research priority 
setting strategies and appendix 3 is an introduction to research priority setting for research groups 
in the Cochrane Collaboration. Finally, appendix 4 outlines a guide for using the equity lens to 
develop priority setting exercises for Cochrane Review Groups.  
With regard specifically to the published works, Chapter 2 starts with two commentaries that set 
the context for the publications in Chapter 3. The first commentary provides an overview of  the 
Cochrane Collaboration and its history, a summary of methods used in research priority setting, 
and limitations and gaps in the literature that led my colleagues and me to generate 
recommendations for the Collaboration and other organisations (15). The chapter then presents 
case studies from inside and outside the Cochrane Collaboration on incorporating the views of 
disadvantaged groups in the process of research priority setting and setting a research agenda for 
public health interventions. These exposed differences between issues raised by patients and 
clinicians than those than prioritized by research (8, 16).  
Chapter 3 includes my work describing and evaluating the research priority setting processes in the 
Cochrane Collaboration. The chapter has two sub-sections: (a) evaluating the priority setting 
process in the Cochrane Collaboration and (b) assessing the results of priority setting by the 
Cochrane Collaboration in the context of priorities identified by the authors of the Global Burden of 
Disease. The projects included in part (a) were initiated with a small research grant from the 
Cochrane Collaboration, and a small grant from Plymouth University enabled me to organise a 
priority setting meeting in Plymouth (17). The first project started in 2008 and involved designing a 
survey and conceptual framework to evaluate the research priority setting processes in the 
Cochrane Collaboration. I adapted this conceptual framework to take account of the principles and 
values of the Cochrane Collaboration (2). As part of the first project, I organised several workshops 
and meetings to discuss its results. Participants in these workshops and meetings suggested more 
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detailed guidance on how priority setting processes within Cochrane could be designed to reduce 
health inequalities. Prompted by this suggestion, my next project (1) developed a tool to select, 
interpret and use data that could inform efforts to reduce inequality in health care. I called this tool 
an “equity lens” because it provides a more systematic approach to prioritising topics with a view 
to reducing inequity in health. The development of the lens was based on consultation workshops, 
literature reviews, and the experience of using two previously developed tools (18, 19).  
Since the start of the project in 2008, there has been a sharp increase in the number of studies 
discussing or exploring the issue of priority setting for systematic reviews in Cochrane and other 
organisations across the world. This increase is likely a result of the struggle that many 
organisations that conduct or sponsor systematic reviews face because of increased demand for 
reviews to inform decisions in health care. The increasing volume of published primary clinical 
research also intensifies the challenge of keeping systematic reviews up to date. The proliferation 
of reviews and primary research led me to participate in designing and conducting a survey (9) 
about the challenges that Cochrane groups face in conducting priority setting exercises. Problems 
highlighted by the results of this survey included “balancing workload”, “allocating time to conduct 
or implement priority setting exercises”, “resource allocation”, “translating priorities into research 
questions appropriate for Cochrane Reviews”, and “engaging with stakeholders”.  
Section b in chapter 3 presents a series of papers which emerged from a project titled “Mapping 
Cochrane to the Global Burden of Disease” (7, 10-14). Some Cochrane groups had considered the 
burden of disease in their priority setting process (or thought they should). However, no high-
quality data were available to analyse how well the Cochrane Library took account of the global 
burden of disease. I am not suggesting that global burden of disease should be the only factor to 
inform the research priority setting process, but rather that, if data about the burden are used in 
setting priorities, it should be data of high quality. I was involved in mapping the following topic 
areas: skin diseases (10), otolaryngeal diseases (13), injuries (11), neglected tropical diseases (7), 
and oral health (14). Here are some examples of the gaps that we identified: edentulous diseases 
had a higher percentage of total 2010 Disability-Adjusted Life Years (DALY) compared to 
periodontal diseases, but they are less frequently addressed in the Cochrane Database of 
Systematic Reviews (11 versus 13 reviews)(14). Similarly, skin diseases including acne vulgaris, 
bacterial skin diseases, urticaria, pruritus, scabies, cellulitis, and alopecia areata were 
underrepresented in the Cochrane Database of Systematic Reviews compared to corresponding 
disability-adjusted life years (DALY) (10). My role in most of the Global Burden of disease projects 
was limited but it demonstrates the whole picture of my research in this field. 
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In chapter 4, I focused on major funders of health research, another major group of stakeholders. 
These funders prioritise and then finance systematic reviews and/or primary studies that could 
inform future new or updated systematic reviews. This research sought overall evaluation of the 
structures and processes of research priority setting and then funding processes (3, 20) by 11 
national research agencies in the UK, Netherlands, France, Norway, Denmark, Germany, Australia, 
Canada and the USA. We devised and used a checklist based on the Avoidable Research Waste 
framework (21-27). The final section of this chapter is a commentary that addresses a key issue for 
funding agencies: how systematic reviews could inform future research (6). The commentary also 
provides further information of whether and how the prioritisation of primary research and 
prioritisation of systematic reviews are correlated.  
These projects have led to organisational and policy changes in the two key stakeholder groups 
(the Cochrane Collaboration and selected funding agencies). The results of my research stimulated 
the development of a new Methods Group within the Cochrane Collaboration and formed the basis 
for guidance for research groups within the Cochrane Collaboration, thus impacting over 100 such 
groups around the world. The Collaboration leadership recognized the importance of this research 
by awarding us the Bill Silverman Prize in 2012. Dame Sally Davies (Chief Medical Officer of NHS 
England) praised our work at the UK and Ireland Cochrane Contributors meeting in March 2013. 
She highlighted the work as a key development that ensures that Cochrane Reviews are relevant to 
the needs of the NHS. Moreover, research groups inside and outside the Cochrane Collaboration 
have used my publications to inform their own research priority setting processes.  Officials of 
national health research funding agencies have approached me to collaborate with them to 
address the issues raised by my work on reducing research waste. For instance, the National 
Institute for Health Research (NIHR) invited me to several meetings with other funders to address 
the issues that the project has raised. In May 2016, ZonMW (a key health research funder in The 
Netherlands) and the French Ministry of Health attended a funders’ meeting as part of the NIHR 
10-year anniversary in London. This meeting led to the establishment of a Funders Forum to enable 
agencies in various countries to exchange their experience in addressing issues and creating work 
groups to address them. The Forum had its first meeting on 27 January 2017 in London. It was 
chaired by individuals from three major research funders: NIHR (UK), ZonMW (Netherlands) and 
Patient-Centered Outcomes Research Institute (PCORI; USA). 
As I have noted above, a key problem across most of these organisations is a lack of transparency 
and accountability that obscures the extent to which their priority setting processes achieve their 
goals and targets. A good example is the current situation in the Cochrane Collaboration. Following 
publications by me and others and the work of the Cochrane Priority Setting Methods Group, the 
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governing board of the Cochrane Collaboration announced a policy requiring all review groups to 
set priorities for topics of systematic reviews. However, it became clear over time that these 
groups have different agendas and goals and opinions about what is best for the Cochrane 
Collaboration overall. I am currently helping to organise a leaders’ meeting to address these issues. 
My evaluation of funding agencies found a similar lack of clarity, transparency and accountability in 
the context of conflicting values among stakeholders.  
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Chapter 1   Critical appraisal 
This chapter starts with a brief history of systematic reviews followed by a description of the 
concept of research priority setting and a categorization of processes for conducting it. Next, I 
describe events and discussions that led to each project reported in the publications in this 
dissertation, including a review of the literature available when these projects were designed and 
implemented. I summarize the findings of each project and their implications in chapter 5. 
In 1753, James Lind described a critical and chronological view of what had been published on 
scurvy before designing and conducting a new clinical trial – an early example of a systematic 
review. In 1904, Karl Pearson used statistical techniques to synthesize the data across clinical trials 
to introduce scientific rigour to evidence synthesis. Pearson used the methods presented by 
George Biddell Airy in his textbook to statistically summarise the results from different studies that 
has been previously used in astronomy (28),(29, 30).  Karl Pearson used these methods to analyse 
data comparing infection and mortality among soldiers who had volunteered for inoculation 
against typhoid fever in various places across the British Empire compared to other soldiers who 
had not volunteered.  As part of this evaluation, he was specifically thorough in evaluating the 
consistency and irregularity across individual results and keen to discover clues for future research 
based on this. In the early 1970s, there were examples of collaborative overviews where 
researchers shared their data to reduce waste and enhance progress. Towards the end of the 
1970s, there was a call for evidence by Archie Cochrane “It is surely a great criticism of our 
profession that we have no organised a critical summary, by speciality or sub-speciality, adapted 
periodically, of all relevant randomised controlled trials”.  A few years later, the international 
Cochrane Collaboration was established in 1992. The Cochrane Collaboration set itself a goal to 
help people make well-informed decisions about healthcare by preparing, maintaining and 
promoting the accessibility of systematic reviews of effects of health care interventions. During the 
following years, most researchers and organisations around the world began to conduct systematic 
reviews.  These systematic reviews are increasingly used to inform healthcare, health services and 
policy making decisions (30). 
International discourse about using systematic reviews to inform policy and practice for health care, 
public health, and clinical practice started in the 1980s with consensus development conferences in 
the UK and US.  Systematic reviews were reported in a wide variety of fields, but particularly in 
cancer,  cardiovascular disease, and care during pregnancy, childbirth and early infancy (30). Since 
then, systematic reviews have increasingly become central in conversations that shape policy.  
These conversations take account of the effectiveness of drug and non-drug clinical interventions, 
including interventions that address care processes and service configurations, education, poverty, 
the socioeconomic determinants of health, and environmental influences on health (31). As 
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systematic reviews have increasingly informed policy and practice, it has become more important 
that the key questions they address are relevant to policy makers, practitioners and the public.  
In a growing number of countries including the United Kingdom, Germany, and the USA, systematic 
reviews are informing policy decisions about reimbursing drugs, shaping clinical guidelines, and 
organizing health programmes (32). Many of these reviews are commissioned by policy making 
organisations, which vary in the extent to which they engage with other health care stakeholders 
(e.g. patients and clinicians) in setting priorities.  
What is Research Priority Setting? 
Research priority setting (RPS) is usually defined as any interpersonal activity that leads to the 
selection of topics and/or choices of key questions to investigate4.  Diverse approaches to setting 
research priorities are used internationally. There is no consensus in the literature on the most 
effective processes with which to set these priorities. We provided an overview of different steps 
involved in research priority setting exercises in one of our publications (1). A refined version of it is 
available in Figure 1 - Steps in involving the preparation, conduct and implementation of research 
priority setting exercises. I further evaluated the critical reviews on research priority setting that 
are available in Appendix 2 –An overview of reviews on priority setting strategies.  
 
 
                                                          
4
 There is no currently agreed definition for research priority setting. This is the definition that we developed 
in a discussion with experts in research priority setting in the Cochrane priority setting methods group 
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research priority setting exercises 
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Policy makers for research, particularly organisations, categorize RPS in different ways. Some 
research managers categorise RPS exercises as retrospective and/or future-oriented, focusing on 
current uncertainties or problems existing in society with the long-range goal of benefitting policy 
and practice in the future. Other managers categorise RPS mainly as the application of technical or 
interpretive/consultative methods to identify data and encourage stakeholder involvement in 
participating in reviews and/or using findings from them to inform policy and practice (33, 34). 
However, research priority setting exercises do not always clearly belong to one category. For 
instance, research priority setting exercises that emphasize involving stakeholders still use data to 
inform the decision-making process. In those that are predominately data driven (e.g. that 
emphasize the value of information analysis), people make value-driven assumptions in 
interpreting the data to inform the decision making.  
People who study or conduct research prioritisation frequently fail to report in adequate detail 
how the value judgements of individual stakeholders affect the interpretation and use of data in 
the process. For example, the US National Academy of Medicine Committee on Health Care 
Technology recommends collecting or estimating “data for the prevalence of specific conditions, 
the unit cost of the relevant technology, various uses of the technology, the burden of illness 
addressed by the technology, and the potential of the results of technology assessments to affect 
health outcomes and costs” (35). The difficulty with this approach is that the collection, analysis 
and presentation of data are buried under layers of assumptions and value judgements that may 
not account fully for the values and perceptions of different stakeholders affected by the process. 
This variation can justify different decisions about collecting or analysing data. For example, 
different approaches to defining the burden of illness can lead to different decisions on research 
priorities (33, 36).  
Beyond the methods used in the research priority setting exercises, the social and political 
environment surrounding these exercises and the skills and experience of the individuals involved 
in the process affect their performance. RPS invariably occurs in particular contexts, i.e. the political, 
organisational, financial and legal environments. Moreover, most of the skills required to conduct 
these exercises are broadly technical, such as managing information.  However, interpersonal skills, 
including effective communication, relationship building with stakeholders, coordinating and 
chairing discussions, and the ability to analyse political situations in order to decide on appropriate 
strategies and tactics, are also crucial (5, 37, 38).  
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Here is an example of the complexity introduced by the organisational and political environment: in 
2008, my colleagues and I attempted to find reviews and studies that present evidence about what 
makes a research priority setting exercise successful. It soon became clear to us that “success” is a 
vague phrase and its definition varies among the organisations and particular stakeholders involved 
in a research priority setting process (1, 2, 15).  
Similarly, regarding building relationships with stakeholders, the James Lind Alliance (JLA) has 
raised issues about how to ensure inclusion of groups in the priority setting process and about the 
importance of facilitators in managing political conflict among different stakeholders. The JLA also 
raised issues about particular groups “not being involved” in research priority setting processes. For 
example, the JLA decided to do priority setting with patients and clinicians, involving researchers 
only as observers and policy makers as they already have substantial influence on research 
agendas(39). The issue of inclusion/exclusion of different groups has also arisen in other situations. 
For instance, a review of priority setting exercises in the Zambia engaged the issue of whether the 
involvement of global donors could skew research priorities away from local priorities (40).  
In summary, the complexity of setting RPS methods and processes within their contexts presents a 
challenge to understanding and evaluating them. Organisational knowledge accrued from 
facilitating priority setting exercises in different locations and the experiential knowledge of 
individual participants in these processes are central to understanding and judging them. 
Reviewing previous priority setting exercises has identified several uncertainties regarding the best 
methods for setting health research priorities and the need for more guidance on the process of 
setting research priorities in health care (15, 41). Research priority setting can be technical (e.g., 
using economic analysis) or interpretive (e.g., with stakeholder involvement). Montorzi et al. 
further categorized research priority setting exercises as those focusing on existing data sets like 
burden of disease and others that focus on what questions would be important for future research 
(foresighting approaches) such as horizon scanning (34). One issue that was widely discussed in the 
critical reviews was stakeholder involvement: who to involve in the process (should participants be 
funders, health professionals, researchers, or patients?) and how to involve them (42, 43). There 
have been concerns that social, political and power relations can inhibit certain stakeholders to 
engage productively in the process. Some strategies suggested to improve the stakeholder 
engagement process include using systematic approaches (e.g. Delphi consensus) and managing 
conflicts of interests in a more transparent way (44-48). Transparency was an issue that regularly 
arose in these reviews, such as transparency in reporting the criteria of priority setting or the 
quality and availability of data used to inform decision making (42, 45). Because I recognised that 
the published literature is limited by the publication choices of researchers, authors and editors, 
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we had discussions and workshops to identify other issues not covered in the current literature. 
These issues have been incorporated in the evaluation framework that was developed for 
Cochrane groups (1, 2, 15).  
Research priority setting in the context of a systematic review organisation 
Systematic reviews have been used to assist decision making by patients, clinicians, and policy 
makers. Some reviews are directly commissioned by policy making organisations, which may or 
may not engage with other stakeholders, such as patients and clinicians. Other systematic reviews 
are commissioned and/or conducted by research organisations that claim to be independent of 
policy makers. 
The Cochrane Collaboration   
The Cochrane Collaboration (www.cochrane.org) is one of the best-known and most influential 
research organisations in health care. It is a network of independent researchers, professionals, 
patients and carers who work together to produce and maintain systematic reviews that inform 
decision making in health care. Despite its reputation and impact, in 2008 (when the project to 
study research priority setting began), its leaders had scant formal knowledge about how internal 
decisions were made about which questions are most worth addressing through Cochrane Reviews 
and when reviews should be updated. The Cochrane Collaboration employs staff to assist the 
volunteers in these groups. The Cochrane Policy Manual also highlights the qualifications and 
characteristics of authors: 
“Whilst enthusiasm and time are the first essential qualities in an author, each needs to combine 
knowledge about the topic in which s/he is interested with a willingness to apply methodological 
rigour to the review process. This combination of qualities rarely exists within a single individual. 
More often, it will be necessary to arrange author partnerships, to try to ensure that content and 
methodological expertise is both applied in preparing reviews. Such partnerships are generally 
preferable to working alone, even when both partners possess both types of expertise, to ensure the 
reproducibility of the judgements that are necessary in preparing reviews. One author will 
sometimes miss something that the other will pick up. It is also very likely that they will complement 
each other in various ways, and it is often more fun to work with someone else 5.” 
My conversations with members of the Collaboration demonstrated that author teams don’t 
always meet the published criteria. Researchers who have been involved with the Cochrane 
Collaboration since its inception told me that the model in the policy manual was grounded in the 
assumption that clinicians would voluntarily bring their questions and uncertainties to the 
                                                          
5
 This is an extract from a Cochrane Collaboration organisational manual that was decommissioned in 
December 2016 (after the study was conducted). There will be an updated version available in future. 
However, the old manual is no longer available.  
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Cochrane Collaboration and that its central staff would help them address these concerns. As a 
member of the Collaboration since 2006 (in several volunteer leadership or executive roles) and a 
trustee from 2011 (my term as a trustee will end in 2017), I observed that Cochrane groups are 
strongly committed to the central values and principles of the Collaboration which include building 
on the enthusiasm of individuals, collaboration and enabling wide participation(49). When I joined 
the Collaboration, Cochrane groups were following an unwritten policy (driven by the principles of 
the Collaboration) to help and engage with any volunteer reviewer in conducting systematic 
reviews. These volunteer reviewers might have limited knowledge of systematic reviews, difficulty 
writing scientific articles or difficulty in communicating and writing in English. The review groups 
might reject a request to do a review if the question was already addressed by a review in the 
Cochrane Library or seemed inappropriate.  However, there were wide variations in how these 
decisions were made. I have heard and seen that review groups struggled with workload but were 
worried that rejecting an author violates the fundamental values of the collaboration to be 
inclusive and collaborative. Moreover, Cochrane groups have a variety of funding sources that 
include government agencies, universities, hospital trusts, charities, and personal donations. 
Consequently, they are required (sometimes implicitly, sometimes explicitly) to take account of the 
priorities of their funders as well as the values and expectations of the larger Cochrane 
Collaboration.  
These tensions led, in October 2011, to approval by the Cochrane Board of Trustees of a policy 
requiring minimum competence of authors of reviews(50). This policy stimulated a gradual cultural 
change in which Cochrane Review Groups asserted greater leadership in making decisions about 
which topics are relevant and should have priority in their field and evaluating the competencies of 
the author team. 
In 2007, the Collaboration’s Board of Trustees established the Prioritisation Fund, a one-off call for 
proposals to suggest mechanisms for increasing the relevance of Cochrane Reviews (another 
principle of the Collaboration). A year later, the US Cochrane Centre organized a conference on 
priority setting in systematic reviews (51). I was part of a team led by Peter Tugwell of Canada that 
received a grant from Cochrane to examine priorities of low and middle income countries for 
review topics (I was at that time the coordinator of the Cochrane Developing Countries Network, a 
position I left at the end of 2008)6. As coordinator, I led a survey in 2008 (2) of the processes for 
setting priorities for Cochrane Reviews. To conduct the survey, I contacted two key types of 
Cochrane groups: the Review Groups, which are the central editorial units for different areas of 
                                                          
6
 Afterwards, it became a Cochrane field (i.e. a thematic network) and was later eliminated. The initiative was 
replaced by a wider one called Global Evidence Synthesis that Cochrane is a partner of it.  
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health problem which decide topics for Cochrane Reviews; and Fields/Networks, which support 
review groups to include cross-cutting themes (such as children or the elderly) in their portfolios.  
Evaluation of priority setting processes in Cochrane: 
To conduct the survey and evaluate responses, we needed a framework to evaluate the priority 
setting processes in the Cochrane Collaboration. In 2008, there were no frameworks to evaluate 
success or accountability in research priority setting exercises. We looked at models and 
frameworks used in setting health priorities in the health sector and consulted experts in the field 
of health research priority setting. In 1997, Norman Daniels of Harvard University had raised 
questions about the fairness and legitimacy of decisions about which health services are prioritised 
and funded. Daniels proposed a framework called Accountability of Reasonableness to address 
these issues (2, 52). This framework has been widely used in evaluating health service priority 
setting processes in various geographical settings (53-56). We selected it as one of the models to 
inform our evaluation.  
In 2009, Shannon Sibbald conducted Delphi exercises with scholars in the field of priority setting as 
well as decision makers from health systems in five countries and interviews with patients/health 
system users, and a focus group of public policy makers to develop a conceptual framework for 
evaluating “success” in priority setting (57). This framework had some overlap with the 
Accountability for Reasonableness framework. We discussed how these frameworks related to the 
values and principles of the Collaboration and developed criteria to evaluate processes in the 
Collaboration (2).  
At several stages of the project, we discussed emerging results with Cochrane contributors to learn 
whether we missed any priority setting exercises (or misinterpreted them), whether we missed key 
elements in evaluating the priority setting processes, and sought feedback on how to address the 
issues identified in responses to the survey. We then presented the results of the survey in a 
workshop at the annual Cochrane Colloquium in 2008, using only Daniels’ Accountability of 
Reasonableness framework.  The workshop demonstrated that many Cochrane groups were 
unfamiliar with the literature on methods for setting priorities(58). This recognition led to an 
exploratory meeting at the next colloquium about whether to establish a new methods group on 
priority setting within Cochrane. Leaders of several Cochrane groups, authors and external partners 
who attended the meeting identified challenges that the proposed methods group could address 
(58). These challenges included “dealing with health inequalities in developing and conducting 
priority setting”.  
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Equity Lens for setting priorities in research 
After several workshops/discussion forums about the Cochrane survey results, my colleagues and I 
recognized a need to improve the process of agenda setting and priority setting for Cochrane 
Reviews to ensure transparency and inclusiveness and to consider health equity.  That is, we 
wished to identify and prioritise systematic reviews of interventions that could potentially reduce 
inequity by addressing the effectiveness of interventions that are particularly relevant to 
disadvantaged groups.  
The need to consider inequity in setting priorities for systematic reviews and primary research has 
been considered outside the Cochrane Collaboration. The Child Health and Nutrition Research 
Initiative (CHNRI) expressed concerns that allocation of investment in certain research topics can 
increase health inequity (59). In 2005, a group at the South African Cochrane Centre conducted a 
study that identified that systematic reviews more often address health problems that are 
priorities in high-income countries (HICs), while neglecting problems in low- and middle-income 
countries (LMICs) (60, 61). A paper by Ortiz in 2007 (62) described the Cochrane Developing 
Countries Initiative, which Zulma Ortiz and I co-chaired, and criticized the lack of relevance of 
Cochrane Reviews to developing countries. The Cochrane Developing Countries Network has since 
evolved into the Global Evidence Synthesis initiative (63) hosted by the American University of 
Beirut with a central focus on capacity building for research synthesis worldwide. Several efforts 
have been initiated to develop equity-oriented priority setting strategies (62, 64).  For example, a 
recent paper highlighted the importance of increasing non-elite stakeholders’ participation in 
promoting health equity in national health research priority setting (65). There is still considerable 
room for improvement, however, particularly considering the limited resources available in low 
and middle-income countries. 
As an international organisation, the Cochrane Collaboration is committed to ensuring that 
questions relevant to disadvantaged groups or issues relevant to reducing health inequality are 
addressed in systematic reviews. To address this issue, I conducted a review of the literature about 
current tools and conceptual frameworks for exploring equity in setting priorities for research, and 
we facilitated discussion sessions on this topic.  This work resulted in a new tool (called the Equity 
Lens for Research Priority Setting). This tool has been piloted in evaluating priority setting 
processes within Cochrane (1) and in shaping suggestions and recommendations for improvement 
(8).  
Challenges that the Cochrane Collaboration faces in setting priorities 
Since the start of my project in 2008, there has been a sharp increase in the number of studies 
discussing or exploring the issue of priority setting of systematic reviews in the Cochrane 
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Collaboration and other organisations across the world. The increase is mainly a response to the 
struggle faced by many organisations that fund and conduct systematic reviews because of 
increased demand for systematic reviews to inform decisions in health care. In addition, the 
increasing volume of published primary clinical research intensifies the challenge of keeping 
systematic reviews up to date. Two issues constrain the development and implementation of 
priorities: (a) many, perhaps most, systematic reviews (and the research studies that are the data 
for reviews) are not conducted, driven or shaped by systematic prioritisation exercises involving 
policy makers, practitioners and patients; and (b) systematic reviewers may change questions 
derived from priority setting exercises by stakeholders before conducting reviews.  
Following my study evaluating priority setting processes in the Cochrane Collaboration, increasing 
numbers of Cochrane groups conducted priority setting exercises. I did a survey of the challenges 
the groups faced in conducing these exercises (9). The response rate was low but the results were 
consistent with my informal discussions with the facilitators of other groups like the James Lind 
Alliance (an organisation that conducts research priority setting exercises with patients, carers and 
clinicians). Five broad themes emerged across the responses: (a) achieving balance in workload and 
time allocation across different reviews; (b) securing adequate time to conduct or implement 
priority setting exercises; (c) allocating resources to priority setting exercises and their results; (d) 
translating priorities into research questions appropriate for Cochrane Reviews; and (e) engaging 
with stakeholders.  
Stakeholder engagement is the most commonly reported of these challenges in conducting priority 
setting exercises. The issues involved in stakeholder engagement include their understanding the 
concept of research prioritisation; the needs of particular categories of stakeholder; equitable 
involvement of the range of stakeholder groups; the composition of stakeholder groups (who is 
involved in these groups and what their background is); and maintaining engagement. 
One of the greatest challenges was how to translate a question from the priority setting exercise to 
an answerable question in systematic reviews. This problem might have derived from changes in 
how Cochrane groups set priorities. Historically, topics for Cochrane Reviews were suggested by a 
volunteer author who used a standard template for setting key questions. Systematic review 
methods guidance/handbooks describe this template with the acronym PICO: Population, 
Intervention, Comparison and Outcome (66). Issues around setting and context are conventionally 
considered under Population and timing (how the intervention is implemented or when the 
outcome is measured) is considered under Intervention, Comparison and Outcome. The questions 
developed using the PICO template, however, are not necessarily compatible with how 
stakeholders conceptualize their priorities and questions. When reviewers attempt to translate 
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priorities for systematic review topics into a key question for a particular review, they can, 
inadvertently or not, modify the problem that made the review a priority. The problem of 
translating research priorities into answerable questions for systematic reviews has been 
increasingly recognized by systematic review organisations because they have to work with policy 
makers and other stakeholders. The selection of the key question for a review in these 
organisations is usually the product of negotiations between reviewers and stakeholders. This 
might be one reason that sometimes a similar policy priority e.g. effectiveness of HPV vaccination 
might lead to a variety of key questions generated by PICO analysis in different systematic reviews 
conducted by different national organisations. Policy makers might suggest that a new systematic 
review needs to have high priority because existing reviews do not address the key policy questions 
that they want to address (this might be policy makers wanting a review that clearly focuses on 
issues in their country). Sometimes, the structure of priority setting for a review or a key question 
might be solely driven by the policy agenda. For example, if care of the elderly becomes a strategic 
priority, policy makers might insist on a review focusing on this population even if reviewers or 
clinical trialists do not agree that these groups respond to the intervention differently from the 
average adult.  
The problems in the prioritisation, production and publication of systematic reviews 
The publication of systematic reviews and meta-analyses has increased rapidly in recent years. 
Unfortunately, this increased production of systematic reviews causes problems e.g. conflicting 
findings in systematic reviews in the literature or selective use of data retrospectively to fit the 
expectations of the editors and reviewers. Moreover, many published reviews do not add 
significantly to the literature and thus waste resources. For example, a systematic review might be 
repeated to ensure that it reaches a more favourable conclusion and become a marketing tool by 
the pharmaceutical industry (31, 67-70).  
Despite issues about the production and publication of systematic reviews, they increasingly inform 
policy makers and clinicians. More policy makers and clinicians have acquired knowledge and skills 
to understand the methods and uses of systematic reviews. Because of increased use of systematic 
reviews, the integrity of processes to prioritize and conduct them is critical. To ensure the process 
is not corrupted and biased, several policy-level initiatives should be established. Examples of these 
initiatives are:  (a) policy makers being more involved in setting priorities for the topics and key 
questions that systematic reviews address; (b) organisations that train health professionals 
ensuring that appraisal and interpretation of systematic reviews is covered in the educational 
curriculum; (c) funding only primary research supported by reference to systematic reviews of 
existing evidence (31). 
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I have demonstrated that the process of prioritizing systematic reviews cannot be independent of 
processes for addressing other organisational and structural issues. Therefore, the next study in 
which I participated focused on research funding agencies. I evaluated their priority setting process 
and the wider issue of how their processes relate to a recently published framework to “reduce 
research waste”.  
Reducing research waste initiative and health care research funding agencies 
In January 2014, the Lancet published a series of articles on increasing value and reducing waste in 
biomedical research (22-24, 26). The series pointed out potential sources of waste related to five 
main questions: 
(i) Are the questions addressed relevant to users of research?  
(ii) Is the research design, conduct and analysis appropriate? 
(iii) Is research regulation and management efficient?  
(iv) Are full reports of the research accessible?  
(v) Are the reports of research usable and unbiased?  
The Lancet series began by addressing the waste of resources resulting from decisions about what 
research to conduct. Research waste was defined in two ways in this series: 1) when the needs of 
potential users of research evidence are ignored; and 2) when what is already known or being 
researched is overlooked (71).  
Before designing and implementing the project, I had several discussions with researchers around 
the world during workshops and panel discussions about what influences their decisions on 
selecting research questions. Two examples are a research priority setting workshop at Modena 
University (Italy) in 2013 and a panel discussion at the International Evidence Based Health-care 
Society conference in Kish (Iran) in 2016. 
(A) In 2013, during a workshop on research priority setting that I led at Modena University (as 
part of a MSc programme), I asked the participants how they select the research projects 
that they conduct.  Some said that they make decisions based on funding availability, while 
others highlighted that they are following research agendas set by their supervisors.  Some 
also said that they researched topics relevant for patient care.  
(B) In December 2016, there was a discussion panel on reducing research waste at the 
International Evidence based Health-care Society conference in Kish (Iran). An issue raised 
was that a substantial number of research funders and managers invest heavily in funding 
stem cell research and biotechnology. These investments produce publications in high 
impact factor journals without addressing fundamental public health problems in Iran. The 
research managers conduct these types of research to increase the reputation of 
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universities in Iran and to obtain more international acceptance for Iranian science and 
scientists.  
These two examples of the complexity of decisions about priorities demonstrate that decisions on 
setting priorities are related to wider issues of social, political, culture, and organisational 
structures. They highlight the importance of understanding the role of each stakeholder in the 
research system along with the internal complexity of each organisation. This can help us to 
understand the drivers of setting priorities.  
Therefore, I accord attention in the articles that comprise this dissertation to national and 
international health-related research funders. Research funders have a lot of control over decisions 
about priorities, especially in countries where researchers must apply for funding and 
reappointment or promotion are dependent on being awarded grants. Although research funders 
are my focus in this project, I recognise that many researchers are employed by universities and 
that universities influence research priorities by funding salaries for both faculty and staff and 
providing space. However, the role of universities in setting priorities is beyond the scope of the 
current project. 
For the publications included in this dissertation, I evaluated the work of research funders, 
examining different aspects of their efforts to reduce research waste rather than focusing on 
priority setting. Focusing on reducing waste increased the interest of funding agencies in the 
project and their responsiveness to the questions put to them. Of 11 national research funding 
agencies, of varying sizes, in Europe, North America and Australia, all but one responded to our 
questions. Table 2 provides an overview of the funding available of some of the funding agencies 
that we looked at in our project, based on a publication by Viergever et al (72).  
The results of this project were published and presented in several journals and forums. I published 
the summary and preliminary results of an assessment of the policies and processes of six research 
funders as part of a Lancet paper (3). The full data are published in another Lancet publication (20). 
I presented the initial results of my study at the Evidence Based Research Network Conference in 
Bergen, Norway in December 2014, and further results at the REWARD/EQUATOR conference in 
Edinburgh, Scotland in October 2015. The National Institute for Health Research (NIHR) invited me 
in November 2015 to present the results in a meeting with ZonMW (a key health research funder in 
The Netherlands) and the French Ministry of Health to discuss how we can address the issues that 
the project had raised. The project was also presented at the Cochrane Colloquium (October 2015) 
in Vienna, both as an oral presentation and as a special session I led on using systematic reviews to 
inform future research. Both events generated much interest and prompted me to look in depth at 
how research funders are (or should be) using systematic reviews in the process of informing 
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primary research. I was subsequently invited to present the data at an event celebrating NIHR’s 10-
year anniversary in London in May 2016, which engaged major funders nationally and 
internationally. Discussions during this meeting led to the proposal of a forum for funders. This 
forum is addressing some of the issues raised by our evaluation. The Funder’s Forum is enabling 
funding agencies to share their experiences addressing issues and create working groups to address 
them. The Forum had its first meeting on 27 January 2017 in London and it was chaired by 
individuals from three major research funders: NIHR (UK), ZonMW (Netherlands) and Patient-
Centered Outcomes Research Institute (PCORI – USA). The second meeting was organised in 
Amsterdam on 1 June 2017 hosted by ZonMW in Utrech (Netherlands). The third meeting was in 
Washington (USA) hosted by PCROI in Nov 2017.  
 
Table 2 - Annual health research expenditures of selected major public and philanthropic 
funders of health research – reporduced partially from Viergever 2016 (72) 
Public and philanthropic 
health research funding 
organisations 
Country 
Type of 
funding 
organisation 
Year for 
which 
funding 
data were 
collected 
Total health 
research 
expenditures (in 
million 2013 US 
$) 
National Institutes of 
Health (NIH) 
USA Public 2013 26,081.3 
UK Medical Research 
Council (MRC) 
UK Public 2013 1,321.5 
Canadian Institutes of 
Health Research (CIHR) 
Canada Public 2012 883.6 
Australian National Health 
and Medical Research 
Council (NHMRC) 
Australia Public 2013 777.6 
Deutsche 
Forschungsgemeinschaft / 
German Research 
Foundation (DFG) 
Germany Public 2012 630.6 
UK Department of Health / 
National Institute for 
Health Research (NIHR) 
 UK Public 2012 491.2 
ZonMw / Netherlands 
Organisation for Health 
Research and Development 
Netherlands Public 2012 172.7 
 
 
 
29 
The next three chapters are published papers of the projects that I have outlined in Chapter One. 
Chapter Two is a review of methods to set priorities for systematic reviews.  Chapter Three 
addresses drivers in setting priorities for systematic reviews in a systematic review organisation. 
This chapter has two sections:  1) evaluating the priority setting processes in the Cochrane 
Collaboration; and 2) comparing the content of the Cochrane Database of Systematic Reviews with 
the Global Burden of Disease to guide future priority setting processes.  Chapter Four is an 
evaluation of the process of allocating funding to research projects in key national funding agencies. 
Finally, Chapter Five provides a summary of the projects.  
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Chapters 2-4 have been removed due to copy right restrictions 
Chapter 2 – Published work - Review of methods to set priorities for 
systematic reviews  
a) Nasser M, Welch V, Ueffing E, Crowe S, Oliver S, Carlo R. Evidence in agenda setting: 
new directions for the Cochrane Collaboration. J Clin Epidemiol. 2013 May;66(5):469-
71.  
DOI: 10.1016/j.jclinepi.2012.08.006 
b) Bhaumik S, Rana S, Karimkhani C, Welch V, Armstrong R, Pottie K, Dellavalle R, 
Dhakal P, Oliver S, Francis DK, Nasser M, Crowe S, Aksut B, Amico RD. Ethics and 
equity in research priority-setting: stakeholder engagement and the needs of 
disadvantaged groups. Indian J Med Ethics. 2015 Mar 16;-(-):1-4.  
DOI:    10.20529/IJME.2015.030 
PEARL: https://pearl.plymouth.ac.uk/handle/10026.1/9524  
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Chapter 3 – Published work - Drivers in setting priorities for systematic 
reviews in a systematic review organisation 
 
Evaluating the priority setting process in Cochrane  
 
a) Nasser M, Welch V, Tugwell P, Ueffing E, Doyle J, Waters E. Ensuring relevance for 
Cochrane reviews: evaluating processes and methods for prioritizing topics for 
Cochrane reviews. J Clin Epidemiol. 2013 May;66(5):474-82.  
DOI: 10.1016/j.jclinepi.2012.01.001 
b) Nasser M, Ueffing E, Welch V, Tugwell P. An equity lens can ensure an equity-
oriented approach to agenda setting and priority setting of Cochrane Reviews. J Clin 
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Chapter 5 – General Discussion/Conclusion 
This chapter covers the methods and results of each project included in this dissertation, describing 
the wider impact that these publications have had on practices within the research community. I 
apologize for repeating myself, which I do in some sections to remind readers about what was 
written in Chapter 1, usually at greater length. 
Evaluating the process of setting priorities in the Cochrane Collaboration 
Colleagues and I received a small grant in 2008 to study research priority setting processes in the 
Cochrane Collaboration. We began by searching for reviews of research priority setting processes 
(Appendix 2 –An overview of reviews on priority setting strategies). I documented a summary of 
the key issues raised in these reviews in the research priority setting section in Chapter 1, where I 
also described the values, principles and history of the Cochrane Collaboration.  
 
Developing an evaluation framework and evaluating priority setting in the Cochrane Collaboration 
Following the review of literature and the description of the context of the Cochrane Collaboration, 
I worked with my collaborators to develop a framework to evaluate research priority setting in the 
Cochrane Collaboration and in other organisations that conduct systematic reviews. We were 
particularly eager to ensure that the different elements of the framework related to the Cochrane 
Collaboration’s principles and values.  
In 2008/2009, tools were available to evaluate decisions about setting priorities in health care but 
not for health care research specifically (2). Two conceptual frameworks informed the evaluation of 
health priority setting: the Sibbald et al., 2009 conceptual framework for successful priority setting, 
which considers values (57, 73); and the ‘‘Accountability for Reasonableness’’ framework, which 
addresses equity and fairness (74). We adapted these tools for research priority setting, 
incorporating the Cochrane Collaboration’s values and objectives with the results of published 
critical reviews of priority setting (15). Our tailored evaluation framework incorporated a checklist 
with nine themes that characterized “good” research priority setting exercises (10).  Our 
framework also added more detailed instructions for judging how it could be applied by systematic 
review organisations. We used our evaluation framework to evaluate the Cochrane Collaboration 
processes as part of a survey across the Cochrane review groups and fields (Table 3; Table 4). Our 
evaluation focused on the process of research priority setting rather than outcome because we did 
not have sufficient data for a meaningful outcome evaluation.   
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Table 3 - The four conditions of ‘‘Accountability for Reasonableness’’: reproduced from Martin 
2003(74)  
Relevance  
 
Rationales for priority setting decisions must rest on reasoning (evidence and principles) that 
‘‘fair-minded’’ people can agree is relevant in the context. ‘‘Fair-minded’’ people seek to 
cooperate according to terms they can justify to each other; which narrows, though does not 
eliminate, the scope of controversy, which is then further narrowed by specifying that reasons 
must be relevant to the specific priority setting context.’’  
 
Publicity  
 
‘‘Priority setting decisions and their rationales must be publicly accessible. Justice cannot abide 
secrets where people’s well-being is concerned.’’ 
Appeals ‘‘There must be a mechanism for challenge, including the opportunity for revising decisions in 
light of considerations that stakeholders may raise.’’  
 
Enforcement ‘‘There is either voluntary or public regulation of the process to ensure that the first three 
conditions are met.’’  
 
Table 4 - Sibbald et al. (2009) (73) framework for a successful priority setting: process elements* as 
mapped to the Cochrane Collaboration. Reproduced from Nasser, M., et al. (2) 
Process element  
 
How it relates to  Cochrane  
 
Stakeholder 
engagement 
The organisation, which in this study is the Collaboration, needs to 
identify the relevant internal and external stakeholders and ensure 
that these stakeholders are effectively involved in the priority setting 
through partnership and empowerment. “Enabling wide 
participation” is one of the principles of the Collaboration, and 
“relevance” cannot be achieved without knowing the preferences and 
interests of all stakeholders. 
Use of explicit  
process 
The Collaboration needs to ensure that the priority setting process is 
transparent to all stakeholders to enhance trust and confidence of the 
stakeholders in the process and the product. To achieve 
“collaboration” and “wider participation” in Cochrane and avoid 
duplication of effort, building trust and confidence is crucial. 
Information 
management 
This refers to the information that is collected and selected to make 
an informed decision during the priority setting possible. To ensure 
relevance, we need to have access to sufficient information and data 
on the need of the community, health status, current policies, and so 
forth. 
Consideration of 
values and context 
As part of the goal to enable wider participation, Cochrane 
encourages increasing diversity. To ensure true involvement of 
individuals from different culture and backgrounds, their values need 
to be considered. 
Revision or appeal 
mechanism 
This refers to a formal mechanism for reviewing decisions. This 
ensures the quality of the final decision (which is one of the principles 
of the Collaboration) and provides an opportunity to identify failures 
and errors or contribute additional information in the process. 
* This table provides an overview of process elements, not outcome elements. Data on the outcome of the priority setting process 
of the Collaboration was not available so we could not evaluate it.  
 
The survey had a high response rate and provides insight into the prioritisation process of the 
Collaboration (2). I did not include methods groups (which focus on developing methods for 
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conducting systematic reviews) or Cochrane centres (which focus on training and capacity building 
and coordinating Cochrane activities in particular countries).  Instead, I contacted the 66 Cochrane 
groups (Table 8) which focus on different health problem topic areas. Of the 66 Cochrane groups 
contacted, 52 responded (78%). Of the 52 respondents, 29 (56%) had a process to inform the 
selection or prioritisation of topics for Cochrane Reviews. Fifteen Cochrane groups had a 
transparent and structured approach, but two of these were joint initiatives between Cochrane 
groups. The remainder did not report a priority setting process with identifiable steps or structure 
for decision-making. Therefore, there were 13 structured prioritisation projects. With only two 
exceptions, these prioritisation processes were being used to identify new topics for Cochrane 
Reviews. One group focused instead on prioritisation of already published Cochrane Reviews to 
develop a dissemination strategy, and another focused on prioritising existing Cochrane Reviews 
which needed to be updated. 
 Table 5, Table 6  and Table 7 provide a summary of the priority setting methods for all the 
Cochrane groups and their evaluation. Table 8 outlines the Cochrane groups that responded to the 
survey and did not use a prioritisation process in 2008. Our evaluation focused on the process of 
research priority setting rather than its outcome because we did not have access to sufficient data 
to do a meaningful outcome evaluation.   
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Table 5 - Priority setting in Cochrane Groups in 2008 (part 1):  Methods, Tools, Criteria, and Inclusiveness 
Cochrane Groups (if the 
information is publicly available, 
they were named, otherwise they 
were anonymised and named as 
group1, group2 and so on) 
Methods, tools, criteria: How to do priority setting Inclusiveness (Who is involved) 
Bone, Joint and Muscle Trauma 
Group (75) 
Approach 1 – (jointly with the Health of Older People Field) 
Feedback from the members of both groups on priority topics on the 
general area of hip fracture and rehabilitation for future Cochrane 
Reviews, summary table was prepared and the register of the CRG 
was searched for trials. After a selection procedure which included 
the establishment of pre-specific criteria, the project group agreed 
on a priority topic for a new Cochrane Review. 
 
Approach 2 – The information specialist searched the specialized 
register to identify topic areas in which there are trials without 
Cochrane Reviews. 
Approach 1 - Editorial Board of Bone, Joint 
and Muscle Trauma group and members of 
the Health of Older People field. 
 
Approach 2 - NA 
Cochrane Consumer Network 
(76) 
An online survey was developed. All Review Group review titles 
(from the Cochrane Library 2007, Issue 3) were listed as health 
topics and divided into broad categories such as prevention, 
treatment, and rehabilitation (English and Spanish). A 
Communication Strategy was developed. Eleven criteria for setting 
priorities were selected as part of a workshop held at the Dublin 
Cochrane Colloquium in 2006. The criteria were piloted by the 
Cochrane Consumer Network (CCNet) Geographical Centres 
Advisory Group. 
 
The survey was aimed at consumers and 
patients. 
522 valid responses were received.  
21.3% were male, 73.2% were female. 5.5% 
did not respond. 13.4% of respondents were 
aged less than 30 years; 52.5% were 30 to 55 
years; and 28.4% were older than 55 years.  
North America 37%; South America 4%; UK 
13%; Scandinavia 0.3%; Continental Europe 
6%; Eastern Europe 0.3%; Middle East 8%; 
Africa 4%; Asia 5%; Australia and New 
Zealand 18%. Caregiver 2.3%; consumer 
(advocate) 26.6%; patient 19.7%; health 
professional 20.5%; researcher 14.2%; other 
(including journalist, communicator) (9.2%); 
or did not provide an answer to this question 
(7.4%). 
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Effective Practice and 
Organisation of Care Group (only 
Australian satellite) (77) 
The project involved a survey of senior policy makers to identify 
priority policy issues that can be informed by EPOC systematic 
reviews along with content analysis of annual reports of 
Commonwealth, States and Territories. They also conducted 
interviews held over two months (June/July 2008) with approx. 40 
policy makers. Finally, there was a Delphi process to achieve 
consensus and ranking of topic priorities. 
Policy makers, National Institute of Clinical 
Studies (NICS), The National Health and 
Medical Research Council (NHMRC), 
Australian Cochrane Centre (ACC) 
Eyes and Vision Group (78, 79) They started with  the “evidence gap” project and screening the 
guidelines of eyes and vision, selecting American Academy of 
Ophthalmology (AAO) guideline on glaucoma, extracting research 
questions with the existing evidence, undertaking a search of the 
existing (or planned) systematic reviews and clinical trials in the 
Cochrane Library, circulating the research questions and related 
evidence to a larger group including editors, guideline developers 
and consumers to rank the topic, aggregated data presented to an 
international expert panel to obtain consensus, evaluate the 
programme. 
Editors, Guideline Developers, Consumers 
Incontinence Group (80) Participating organisations consulted memberships to identify 
“uncertainties” affecting treatment decisions. “Uncertainties” were 
also identified in published research recommendations. 
 
Prioritisation involved two phases: 
1) shortlisting of “uncertainties” by organisations; 
2) patient-clinician prioritisation using established consensus 
methods. 
 
Prioritised “uncertainties” were verified by checking any available 
relevant up-to-date published systematic reviews. 
United Kingdom clinician and patient 
organisations whose remit includes urinary 
incontinence were invited to participate; 8 
patient and 13 clinician organisations 
responded. 
Cancer Network (81) The network identifies national cancer priorities based on incidence 
and mortality and categorizing reviews in the field of prevention, 
treatment, supportive and palliative care, diagnosis, screening for 
each cancer priority and identifying the gaps in the library. 
It did not involve individuals in priorities; 
priorities are based on mortality and 
incidence data 
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Musculoskeletal Group (82) The following steps were used: 
(1) Conduct an initial assessment of the current Global evidence 
mapping method (83) by comparing it to other priority setting 
research approaches. 
(2) Through expert consultation, identify new decision factors and 
processes that can be incorporated into the method to improve its 
results. 
(3) Create a new version of the GEM methodology. 
(4) Conduct a pilot exercise in collaboration with the Cochrane 
Musculoskeletal Group to set priorities in the Osteoarthritis area. A 
minimum of 60 stakeholders representing the different groups will 
be engaged throughout the pilot exercise. (82) 
A minimum of 60 stakeholders representing 
different groups: Clinician, researchers, 
patients/consumers, policy makers/decision-
makers 
Public Health Review Group (84) Terms of reference (TOR) for taskforce members were sent to the 
ten members involved in the priority setting of topics and there was 
a first teleconference identifying background and proposed phases 
of the project. The existing reviews of health promotion and public 
health topics were identified and presented to the taskforce 
members, so they knew what had already been covered. Finally, the 
briefing for 3rd teleconference includes criteria options for 
prioritising topics and a proposed framework. With this guidance, 
the Taskforce set about putting forth suggested topics.  
Only Policy makers 
Group 1 Surveys of consumers, editors and reviewers of the review group are 
conducted and then discussed by the editorial board.  Possible titles 
are put online.   Titles are also suggested through the process of 
restructuring of the register of the CRG.  
Members of Cochrane entity (consumers, 
editor and authors) 
Group 2 There were two steps used to conduct the priority setting exercise: 
1) Identifying clinically relevant areas with sufficient number of 
RCTs. Searching the Trial register of the group and grouping the 
trials on areas with a high yield of RCT and , CCTs, generating a list of 
reviews, excluding non-clinically important topics, circulating 
between editors of the CRGS, finalizing the review title. 
2) Ongoing project, to search the national research register, 
categorize results in the six groups that are the scope of the review 
group, generate a list of areas that are in the scope but no RCTs, 
Editors 
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circulating between editors. 
Group 3  Prioritisation of titles relevant to abortion with the global 
stakeholders and request of reviews from World Health 
Organisation (WHO) and Family Health International (FHI).  
Global Organisations e.g. World Health 
Organisation, Family International Health, 
United Nations 
Group 4  A request was made widely to group members and a wider group of 
partner organisations to suggest large number of reviews. 
Afterwards, in a meeting of twenty people from all over the UK 
including health professionals, researchers and consumers, 20 titles 
were selected. Funding covers the cost for a support group to train 
new reviewers to od the priority reviews.  
As the funding source was the department 
health of the UK, it only included individuals 
from the UK but included a wide range of 
individuals This included the following 
partners: Cancer Networks, British 
Gynaecological Cancer Society (BGCS), The 
British Society for Colposcopy and Cervical 
Pathology (BSCCP), Royal College of 
Obstetricians and Gynaecologists (RCOG), 
The National Forum of Gynaecological 
Oncology Nurses (NFGON), Ovacome (The 
ovarian cancer support charity), Jo’s Trust 
(Jo's Cervical Cancer Trust), The National 
Institute for Health and Care Excellence 
(NICE), Centre for reviews and dissemination 
(CRD), The National Cancer Research 
Institute (NCRI) and NHS programme 
Directors 
Group 5  Reviews needed updating were circulated ranked for 1,2,3. The 
editors ranked according to their knowledge of new trials in the area 
and the current clinical importance in neonatal surgery. 
Members of the group 
Group 6  The topics lists are regularly circulated amongst) staff and 
stakeholders. Moreover, the information specialist (trial search 
coordinator) looked for trials in the register not covered by the 
Cochrane Review Group.  
Involving different stakeholders in the field of 
neuromuscular health including the editorial 
board and European neuromuscular 
partners, secretary of state for health, the 
chief medical officer at the department of 
health and staff at the National Institute for 
Health and Care Excellence (NICE) 
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Group 7  The prioritised reviews in an annual editorial board meeting with 
editors from developed and developing countries and consumer 
panel coordinator. In addition to this, NICE helps the review group to 
prioritise reviews that are relevant to their guidelines. 
Editors, Consumers 
Group 8  Every 6-12 months, the group compiles suggestions from Group 
members and circulates the suggested list, asking members to 
prioritise it. The top five titles are posted on the website and reviews 
are undertaken wherever possible. 
Members of the group 
Group 9  Priority setting is part of the editorial process. The Group had these 
strategic objectives: to increase the proportion of high impact 
reviews, editorial base efficiency and the group’s profile.  A high 
impact review:  is likely to generate consideration interest in the 
international public health community; has the potential to change 
policy or treatments with substantive impact on the UN Millennium 
Development Goals; is frequently cited in the scientific literature; is 
of considerable interest; is likely to capture high levels of press 
coverage; and should have two or more potential trials.    
Editors 
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Table 6 - Priority setting in Cochrane Groups in 2008 (part 2): mapped to the Accountability for Reasonableness Framework (74) 
Cochrane Groups (if 
the information is 
publicly available, they 
were named, otherwise 
they were anonymised 
and named as group1, 
group2 and so on) 
Relevance Publicity Appeals Enforcement 
 
Bone, Joint and Muscle 
Trauma Group 
Approach 1 – To identify priority 
review relevant to hip fracture and 
rehabilitation in elderly people based 
on the views of experts and the 
existing trials 
 
Approach 2 – topics that are not 
covered by the group b 
ut have trials 
Approach 1 – A commissioning brief for producing 
the priority review was developed and sent to 
potential review team authors who had expressed 
an interest in becoming involved in the review in 
the feedback we received from members of the 
Field and BJMT Group. The project was published 
in specialist journals, websites, newsletters or 
societies 
 
Approach 2 – not reported 
No No 
Cochrane Consumer 
Network 
To prioritise existing Cochrane 
Reviews for consumers and the 
public in low and high-income 
countries as a way of promoting 
evidence-based health care and the 
Cochrane Library - for use by 
individuals (with their healthcare 
providers), patient support groups 
and organisations and to encourage 
the implementation and use of 
Cochrane Reviews by the public. 
A Communication Strategy was developed to 
inform people about the survey and invite them to 
participate, reviews identified will be assessed as 
to how they can be applied by consumers (using 
specific questions); the content of the review 
conclusions and plain language summary; how up 
to date the reviews are; any gaps in 'knowledge'. 
This assessment will be made available to authors 
and review groups with an offer of input from 
Cochran consumer network when the review is 
updated. 
No No  
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Effective Practice and 
Organisation of Care 
(EPOC) Group 
Identify and help produce EPOC 
reviews that are relevant to the 
Australasian region. Involvement of 
end users in priority setting of the 
satellite – identify research questions 
of relevance.  
 
The survey intends not only to capture the views of 
policy makers but also to increase policy makers 
awareness of the work of EPOC and their sense of 
ownership. 
Dissemination of survey results to policy makers - 
awareness  
of satellite priorities and reviews in progress. 
Encourage policy makers to be involved in the 
review team. Work with Australasian Cochrane 
Centre to produce policy summaries of the 
completed reviews and dissemination of review 
results. 
There is no 
mechanism of 
Appeal designed 
but the interested 
policy makers are 
intended to be 
involved in the 
peer review 
process which 
provides a 
potential 
opportunity of 
Appeal 
No 
Eyes and Vision Group  The process aims to identify topics 
that are identified as clinical relevant 
in guidelines, identified as priorities 
by clinicians and consumers taking 
into consideration the existing 
systematic reviews and clinical trials. 
The list of clinical questions would be published on 
the group website and if accepted also on DUETS 
website. 
No Yes, the website 
provides the 
opportunity for 
everybody to 
contribute in 
developing a 
priority list 
Incontinence Group (80) Identifying treatment uncertainties 
for both patients and clinicians that 
are not addressed by systematic 
reviews. 
UK Database of Uncertainties about the Effects of 
Treatments (UK DUETs) database and reported to 
funding agencies 
No No 
Cancer Network Identifying gaps in the management 
and diagnosis of cancers that affect 
or kill most of the people. 
Presented to local authorities and in colloquium. No No 
Musculoskeletal Group  The prioritisation process intends to 
identify priorities from different 
groups and incorporate health equity 
and the social determinants of health 
into the analysis. 
The results will be presented in two conferences 
and the results will be published in BMC health 
services. Furthermore, results will be posted to the 
CMSG website. 
Yes Yes 
Public Health Review 
Group 
Priority of policy makers and those 
involved in public health policy. 
The list was published on the website and 
presented in conference. 
 No but authors 
could further 
refine the topics 
or change it when 
No 
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they overtake it. 
Group 1 
 
Priorities and interests of members. 
Topics with clinical trials conducted 
on that topic 
The list was published on the website.  No The process can 
be initiated by 
authors and other 
members 
Group 2 The rational is to undertake reviews 
on areas clinically relevant with 
adequate number of available trials 
The project was presented as a poster and the 
titles were sent for call of proposals. 
No No 
Group 3 
  
Topics that are relevant to global 
organisations or a priority in 
developing countries (e.g. abortion). 
The list was published on the website.  No NO 
Group 4  Selecting reviews based on views of 
stakeholders from different relevant 
organisations and the relevancy of 
the topics to improving patient 
outcome and importance to NHS and 
includes a wide range of topics. 
The titles were made available through the cancer 
networks and NHS Gynaecological Cancer 
Networks and presented in meetings. 
Not for the 
prioritisation 
program but the 
stakeholders act 
as peer reviewers 
of the reviews. 
No 
Group 5  The titles are prioritized by 
knowledge of editors on clinical 
importance and knowledge of new 
trials. This is reasonable but not 
sufficient. 
The list was published on the website No No 
Group 6  It is reasonable as it covers the 
priority of stakeholders and the gaps 
in the primary research. 
No No No 
Group 7  Identify priority topics that editors 
from developed and developing 
countries and consumer agree upon 
and identifying national priorities to 
develop guidance in the UK. 
No No No 
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Group 8  Identifying the most relevant 
question in the view of members of 
CRG. 
The list was published on the website It is every 6-12 
months updated 
so people could 
suggest other 
priorities. 
Individuals can 
suggest titles 
regularly and they 
are asked to 
prioritise them 
regularly. 
Group 9  The editorial intends to identify high 
impact reviews with the potential to 
be delivered in an acceptable period. 
No No The CRG is 
attempting to 
identify a good 
author team that 
would be able to 
implement the 
prioritized topic. 
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Table 7 -Priority setting in Cochrane Groups in 2008 – further information on characteristics of the priority setting exercises (part 3) 
Cochrane 
Groups (if the 
information is 
publicly 
available, 
they were 
named, 
otherwise 
they were 
anonymised 
and named as 
group1, 
group2 and 
so on) 
Evaluation of 
the existing 
evidence 
coverage 
Criteria for priority 
setting 
 
Communication, 
dissemination and 
feedback of 
information 
Investigator or 
curiosity driven 
research 
Implementation, monitoring and 
evaluation, sustainability 
 
Bone, Joint 
and Muscle 
Trauma 
Group 
Search of the 
register of CRG 
1) There must be no 
current Cochrane 
Review on this topic. 
2) It must fall under the 
BJMT group scope. 
3) There should be at 
least 2 fully published 
trials. 
4) The topic must have 
been identified as a 
priority by the 
feedback.  
The members and 
contributors of the CRG 
would be informed 
about the list of topics 
The members of the 
entity could suggest 
questions that could 
be a potential also 
curiosity driven 
Dissemination of findings through 
specialist journals, websites, newsletters 
or societies 
Cochrane 
Consumer 
Network 
It is based on the 
existing 
systematic 
reviews. 
Title of the review 
clearly conveys its 
meaning, Health and 
wellbeing; Clear 
benefits; Harms 
A Communication 
Strategy was developed 
to inform people about 
the survey and invite 
them to participate.  
No "Reviews identified will be assessed as to 
how they can be applied by consumers 
(using specific questions); the content of 
the review conclusions and plain language 
summary; how up to date the reviews 
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weighed against 
benefits, Prioritised in 
healthcare system; 
Newsworthy, Topic can 
be addressed with 
randomised controlled 
trials; Relevant or 
familiar healthcare 
setting (higher 
response for health 
professionals as 
compared with 
patients); Intervention 
is available to use; Cost 
of the intervention 
needs to be weighed 
against the benefits. 
are; any gaps in 'knowledge'. This 
assessment will be made available to 
authors and review groups with an offer 
of input from CCNet when the review is 
updated. - This work is to help identify 
what can assist consumers to make 
informed healthcare decisions, promote 
(access to) Cochrane Reviews and CCNet. 
What we do not want is for people to be 
disappointed once they go to the actual 
review”. 
 
Effective 
Practice and 
Organisation 
of Care 
Group (only 
the Australian 
satellite has a 
specific 
strategy)  
Content Analysis 
of Annual 
Reports of 
Commonwealth, 
States and 
Territories. 
Priority policy issues of 
Australia, the themes of 
EPOC review group. 
Professional, Financial, 
Organisational and 
regulatory 
interventions. 
Dissemination of survey 
results to policy 
makers, work with 
Australian Cochrane 
Centre to produce 
policy summaries of the 
completed reviews and 
dissemination of review 
results. 
 
No The Satellite intends to prepare the 
Cochrane Reviews, encourage policy 
makers to be involved and prepare policy 
summaries. 
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Eyes and 
Vision Group  
Search for 
clinical trials and 
systematic 
reviews. 
1) Clinical relevance 
2) Priority of those who 
rate the topics 
3) Availability of 
evidence 
Presentation in 
congresses, informing 
on website and if 
possible on DUETs, -
Obtain feedback from 
CEVG Editors as to 
utility of project; 
-Obtain feedback from 
others conducting 
systematic reviews in 
eyes and vision (e.g., 
AAO) as to 
utility of project. 
Individuals could 
have suggested 
titles based on their 
perception on 
clinical importance 
and priority 
In Phase III of the Project, we will evaluate 
the 
prioritizing process using the following 
measures: 
-Estimate approximate length of time to 
complete each step of prioritizing project; 
-Assess the number of clinical questions 
for which there are reviews completed 
and an indication of whether they are 
up-to-date; the number of questions 
with at least one controlled trial but no 
review; number of clinical questions 
with no apparent relevant controlled 
trials 
Incontinence 
Group (James 
Lind Alliance 
partnership 
project)  
The researchers 
evaluated 
whether the 
identified 
uncertainties 
were addressed 
by a Cochrane 
Review on one 
side and on the 
other side, they 
have identified 
some of the 
uncertainties 
through the 
ongoing 
Cochrane 
Reviews and 
protocols 
Individuals were asked 
to identify and rank the 
ten uncertainties that 
they would most like to 
see prioritised for 
research. The ranked 
responses from all 
organisations were 
then collated in a single 
database and scored by 
ranking and other 
factors for 
examplebeing 
submitted more than 
once by different 
organisations.  
 
The findings of the 
James Lind Alliance 
partnership (JLA) will be 
used by the Group to 
prioritise new and 
updating Cochrane 
Reviews. It will be 
published and formally 
reported to research 
organisations such as 
the NHS Health 
technology assessment 
(HTA) Programme and 
the Medical Research 
Council (MRC). 
No A concurrent qualitative evaluation will 
be conducted alongside the JLA Working 
Partnership to ensure that the strengths 
and limitations are identified and 
reported(85). Funds have been identified 
and a very able researcher with a 
background in social anthropology 
appointed to undertake the study.  
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Cancer 
Network 
Mapping 
available 
Cochrane 
Reviews on the 
topic 
Highest incidence and 
mortality rate 
 
Do not have already a 
Cochrane Review 
Presented to local 
authorities and in 
colloquium 
No No 
Musculoskele
tal Group  
A scoping 
literature with 
stakeholder 
consultation 
would be 
undertaken to 
identify 
osteoarthritis 
research topics. 
The scoping will 
produce an 
evidence map, 
which will be 
used to frame 
subsequent 
stages. 
 The following 5 
dimensions are being 
considered to prioritise 
topics: Clinical, 
Importance, Novelty, 
controversy, Equity, 
Social Determinants 
Based on the 
responses, the 
questions are ranked 
into 2 broad categories 
- high or low priority for 
example if clinical 
importance, equity 
along with either 
novelty or controversy 
is high or moderate, the 
topic is high priority. 
Results of the priority 
setting exercise will be 
posted to the entity 
website. 
The experts and 
stakeholders could 
suggest further 
titles based on their 
personal interest 
Yes, results will not only be published on 
the website but will also be presented at 
the 2010 World Congress on 
Osteoarthritis to enable changes in the 
osteoarthritis community. 
Public Health 
Review 
Group 
Search for 
Cochrane and 
non-Cochrane 
systematic 
reviews on the 
topic. 
(1) Burden of disease, 
magnitude of problem, 
urgency; 
(2) Importance to 
developing countries; 
(3) Avoidance of 
duplication; 
(4) Opportunity for 
action. 
Presented on website 
and conferences. 
No The field has changed to a CRG to address 
the need for conducting these reviews. 
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Group 1 Searching the 
register 
They did not use any 
criteria to make 
decision beyond 
looking 
They did not have these 
steps 
They did not 
consider this 
They did not have these steps. 
Group 2 Searching for 
Clinical Trials 
1. clinical relevance 
2. Number of RCT/CCTs 
available 
It was presented as a 
poster 
No The titles were used as call of proposals. 
Group 3  No Priority of global 
agencies 
No No They would try to work with active author 
teams for important and urgent topics. 
Group 4 Searching the 
register 
1) Improving patient 
outcomes 
2) Importance to NHS 
priorities 
3) Achievability and 
resources required 
4) Impact on efficacy 
and efficiency  
 
The titles were put 
available through the 
cancer networks and 
NHS Gynaecological 
Cancer Networks and 
presented in meetings. 
The stakeholders were  
also involved in peer 
reviewing the reviews. 
Individuals can 
suggest clinically 
relevant reviews 
The reviews were undertaken by authors 
teams and the group team funded an 
information specialist and statistician to 
support reviewers in undertaking the 
review 
Group 5  No Clinical importance, 
knowledge of clinical 
trials 
Putting on the website Yes, individuals can 
suggest and rank 
titles 
No 
Group 6 
  
NO Priority of editors and 
priorities of 
international 
organisations 
No Yes, individuals can 
suggest titles that 
they consider 
clinically important 
No 
Group 7  No Interest of those who 
rate the priorities, 
National Institute for 
Health and Care 
Excellences (NICE) 
priorities 
No Yes, the editors and 
consumers can 
suggest titles that 
they consider 
interesting 
No 
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Group 8  No Interest and priorities 
of those who rates 
They are published on 
the website and 
members can regularly 
provide further 
feedback 
Yes, individuals can 
suggest titles based 
on their interest 
The author teams can request to 
undertake the titles and some are taken 
by the CRG 
Group 9  There should be 
at least 2 trials 
available for the 
review topic, no 
further 
evaluation of 
evidence 
coverage 
High impact review (1-
4):  
1) likely to generate 
considerable interest in 
the international public 
health community 
2) the potential to 
change policy or 
treatments with 
substantive impact on 
the United Nations 
Millennium 
Development Goals 
(MDG), 3) frequently 
cited in the scientific 
literature, is of 
considerable interest 
and likely to capture 4) 
high levels of press 
coverage 
5) the review should 
have two or more 
potential trials. 
No No The author team would be appraised 
along with the title registration form. This 
would be done if the author team has 
demonstrable topic expertise (published 
peer reviewed articles in the topic), 
completed at least 1 Cochrane Review or 
equivalent, contact author has time to 
dedicate to review (3 to 6 months for 
review with >3 trials). The CRG would 
help in building teams, helps finding 
financial support e.g. salary, author 
meeting, build in deliverables to contract 
and the CRG actively manages the review 
team by checking on progress, dialogue, 
conference calls.  
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Table 8 - List of Cochrane groups in December 2008 
Type of entity List of Cochrane groups in December 2008 
Cochrane Review 
Groups 
1. Acute Respiratory Infections Group  
2. Airways Group  
3. Anaesthesia Group  
4. Back Group  
5. Bone, Joint and Muscle Trauma Group  
6. Breast Cancer Group  
7. Childhood Cancer Group 
8. Colorectal Cancer Group  
9. Consumers and Communication Group Cystic 
10. Cystic Fibrosis and Genetic Disorders Group  
11. Dementia and Cognitive Improvement Group  
12. Depression, Anxiety and Neurosis Group 
13. Developmental, Psychosocial and Learning Problems Group  
14. Drugs and Alcohol Group  
15. Ear, Nose and Throat Disorders Group  
16. Effective Practice and Organisation of Care Group  
17. Epilepsy Group  
18. Eyes and Vision Group  
19. Fertility Regulation Group  
20. Gynaecological Cancer Group  
21. HIV/AIDS Group  
22. Haematological Malignancies Group  
23. Heart Group  
24. Hepato-Biliary Group  
25. Hypertension Group  
26. Incontinence Group  
27. Stroke Group  
28. Tobacco Addiction Group  
29. Upper Gastrointestinal and Pancreatic Diseases Group  
30. Wounds Group 
31. Infectious Diseases Group  
32. Inflammatory Bowel Disease and Functional Bowel Disorders Group  
33. Injuries Group  
34. Lung Cancer Group  
35. Menstrual Disorders and Subfertility Group  
36. Metabolic and Endocrine Disorders Group  
37. Methodology Review Group  
38. Movement Disorders Group  
39. Multiple Sclerosis Group  
40. Musculoskeletal Group  
41. Neonatal Group  
42. Neuromuscular Disease Group  
43. Oral Health Group  
44. Pain, Palliative and Supportive Care Group  
45. Peripheral Vascular Diseases Group  
46. Pregnancy and Childbirth Group  
47. Prostatic Diseases and Urologic Cancers Group  
48.  Public Health Group  
49. Renal Group  
50. Schizophrenia Group  
51. Sexually Transmitted Diseases Group  
52. Skin Group  
 
Cochrane Fields and 
Networks 
1. Behavioral Medicine Field  
2. Cancer Network 
3. Child Health Field 
4. Complementary Medicine Field  
5. Consumer Network 
6. Developing Countries Network 
7. Health Care of Older People Field  
8. Health Equity Field  
9. Neurological Network  
10. Occupational Health Field  
11. Prehospital and Emergency Health Field 
12. Primary Health Care Field  
13. Rehabilitation and Related Therapies Field 
14. Vaccines Field 
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The results of our study showed that priority setting strategies across the Cochrane Collaboration 
are fragmented. There have been attempts to address these issues but there is more work is 
required. For example, the sources and definitions of topic relevance for reviews vary significantly 
among groups. Most Cochrane Review Groups consider patients’ views probably the most 
important category for rationalizing priorities. However, in practice, they took different approaches 
to this, as outlined in Table 5 and Table 6 . None of the groups had a formal appeal mechanism as 
part of the process of prioritisation beyond the revision and feedback features of the Cochrane 
Library. To address these issues, Cochrane requires better designed priority setting processes and 
more transparency about who is involved, how these individuals are involved and what 
data/information is used to inform the decision-making process. Better designed priority setting 
approaches can improve the relevancy of Cochrane Reviews published in the Cochrane Library and 
thus increase the impact of its reviews on health and related outcomes.  
Cochrane needs to develop supportive policies to encourage priority setting and provide necessary 
resources and methodological guidance. After publication of the above project, there have been 
attempts to improve priority setting in the Cochrane Collaboration. The Cochrane editorial unit 
asked all Cochrane groups to develop a priority setting process and report back to the unit. 
Consequently, there are now more Cochrane groups attempting to incorporate our published work 
along with other methodological research to inform their priority setting processes. However, the 
Cochrane Collaboration is still not reporting transparently how these priority setting processes are 
conducted. This limits the ability of external stakeholders to challenge the current processes or 
provide suggestions how to improve them. In conversations that I had with some of these 
stakeholders, there has been concern that, despite the attempt to engage with a wider stakeholder 
group in Cochrane, priority setting is still inward looking and does not address the needs of some 
key users of the Cochrane Library. The Priority Setting Methods Group provides some methods 
guidance (Appendix 3 - An introduction to Research Priority Setting (RPS) for research groups in 
Cochrane. However, further methodological research is needed. We need comparative studies of 
the effectiveness of different methods and processes for research priority setting. In addition, 
further research on the most appropriate approaches for taking account of context (e.g., cultural 
factors, political structures, and so forth) is critical.  
Some Cochrane groups have either used burden of disease as a criterion in the ranking process of 
systematic review topics or they have used the global burden of disease data as background 
information to inform their decision making. The next project - Global Burden of Disease- Cochrane 
Collaboration project - assessed the extent to which the burden of disease influenced which 
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Cochrane reviews ended up in the Cochrane Library, and it also provided better quality data to 
inform future research priority setting exercises.  
 
Comparing The Cochrane Library to the Global Burden of Disease data 
The design of a priority setting exercise might focus on using certain data, information or views of 
certain stakeholders to meet its objectives. For example, several review groups and the central 
editorial unit considered Global Burden of Disease as one of the important criteria or indicators to 
inform their decision making. This was either officially highlighted as a criterion or was mentioned 
by the editors or stakeholders as a criterion that they consider during the consensus process. To 
see how much these issues influenced the content of the Cochrane Library, we undertook a 
mapping of Cochrane Reviews in relation to the Global Burden of Disease. I was involved in the 
projects looking at skin diseases (10), otolaryngeal diseases (13), injuries (11), neglected tropical 
diseases(7), and oral health (14). For most of these, I contributed to the methodology, the data 
analysis, and writing the article.  I played a larger role as lead for the oral health project, for which I 
collected, analyzed the data and prepared the final report. The oral health project was presented at 
a conference.  The comparison of the published Cochrane reviews with the ranking of diseases 
based on disability-adjusted life years (DALYs) prepared by the Global Burden of Disease project are 
available in  
Table 9. There are other mapping projects finished and ongoing beyond this project for eyes and 
vision (86), heart disease, cancer, infectious disease, and renal and urologic diseases, but I am not 
involved in these.  
Table 9 - The mapping of the Cochrane Library compared to the Global Burden of Disease (GBD) 
using the ranking of diseases based on the disability-adjusted life years (DALYs) 
Disease area Results  
Oral Health The conditions were ranked in decreasing order based on their disability-
adjusted life years (DALYs) - esophageal cancer, edentulism, dental caries, 
periodontal disease, mouth cancer, cancer of other parts of the pharynx and 
oropharynx, nasopharynx cancer, cleft lip and cleft palate. All conditions are 
represented with at least one systematic review and one protocol in the 
library. Edentulism had higher % total 2010 DALY compared to periodontal 
diseases but has been less represented in the Cochrane Library (11 versus 13 
reviews) and in terms of the total number of clinical trials included within the 
reviews (87 versus 101 trials)(14).  
Skin Diseases All 15 skin conditions were represented by at least 1 systematic review in CDSR; 
69% of systematic reviews and 67% of protocols by the CSG covered the 15 skin 
conditions. Overall, the number of published reviews/protocols was well 
matched with disability metrics for 5 of the 15 studied skin diseases, while 3 
skin diseases were overrepresented, and 7 were underrepresented. Comparing 
the number of reviews/protocols and their DALY measurement, dermatitis, 
melanoma, nonmelanoma skin cancer, viral skin diseases, and fungal skin 
diseases were well matched. Decubitus ulcer, psoriasis, and leprosy 
demonstrated review/protocol overrepresentation when matched with 
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corresponding DALYs. In comparison, acne vulgaris, bacterial skin diseases, 
urticaria, pruritus, scabies, cellulitis, and alopecia areata were 
underrepresented in CDSR when matched with corresponding DALYs (10). 
Otolaryngology 
diseases 
All 10 otolaryngologic conditions were represented by at least 1 systematic 
review in CDSR. The number of reviews and protocols in CDSR was well 
matched with GBD 2010 disability metrics for only 1 disease, mouth cancer. 
Upper respiratory infections, otitis media, thyroid cancer, and cleft lip and cleft 
palate were overrepresented in CDSR, and esophageal cancer, "other hearing 
loss," nasopharynx cancer, larynx cancer, and "cancer of other part of pharynx 
and oropharynx" were underrepresented. The representation of 
otolaryngologic conditions in CDSR correlates poorly with DALY metrics (13).  
External causes of 
injury 
Eleven of the 12 causes were represented by at least one systematic review or 
protocol in CDSR; the category collective violence and legal intervention had no 
representation in CDSR. Correlation testing revealed a strong positive 
correlation that was statistically significant. Representation of road injury; 
interpersonal violence; fire, heat, and hot substances; mechanical forces; 
poisonings, adverse effect of medical treatment, and animal contact was well 
aligned with respect to DALY. Representation of falls was greater compared to 
DALY, while self-harm, exposure to forces of nature, and other transport injury 
representation was lower compared to DALY. CDSR representation of external 
causes of injury strongly correlates with disease burden. The number of 
systematic reviews and protocols was well aligned for seven out of 12 causes of 
injury (11). 
Neglected tropical 
diseases 
Overall, there was poor correlation between CDSR representation and DALYs. 
Yellow fever, echinococcosis, onchocerciasis, and schistosomiasis 
representation was well-aligned with DALY. Leprosy, trachoma, dengue, 
leishmaniasis, and Chagas disease representation was greater, while 
cysticercosis, human African trypanosomiasis, ascariasis, lymphatic filariasis, 
and hookworm representation was lower than DALY. Three of the 18 neglected 
tropical diseases (NTDs) had reviews/protocols of diagnostic test accuracy. Our 
results indicate the need for increased prioritisation of systematic reviews on 
NTDs, particularly diagnostic test accuracy reviews (7). 
 
Equity in setting priorities for topics of Cochrane Reviews 
In the next step of the project, we developed a tool that can be used to evaluate and inform the 
development of equity-oriented research priority setting within and outside the Cochrane 
Collaboration. In developing this tool, we attempted to evaluate how well the Cochrane 
Collaboration addresses questions from both advantaged and disadvantaged groups relevant to 
reducing health inequalities. 
The tool (“equity lens”) looks first at the process of setting priorities and whether (a) the priority 
setting process provided opportunities to incorporate the views of stakeholders from less 
advantageous background or (b) the individuals involved in the priority setting process have 
collected and used data reflecting health inequalities. Afterwards, we assessed whether using the 
tool resulted in research priorities relevant to disadvantaged groups or to reducing health inequity. 
Moreover, the tool evaluates whether the dissemination and implementation of the results 
reaches the right people. To situate the tool, we selected a definition of health equity: ‘absence of 
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systematic differences in health, both between and within countries that are judged to be 
avoidable by reasonable action’’ (87).  
 
Development of the lens occurred at a consultation workshop, through literature reviews and by 
using two previously developed tools: (1) an equity tool for evaluating clinical guidelines (18) and (2) 
the PROGRESS-PLUS mnemonic that describes a range of disadvantaged groups. PROGRESS-PLUS is 
an extension of Evans’ and Brown’s framework PROGRESS (Place of residence, Race/ethnicity, 
Occupation, Gender, Religion, Education, Socioeconomic status, and Social capital), with ‘‘PLUS’’ 
representing additional dimensions such as age, sexual orientation, and disability (1). Table 10 - 
Equity lens for agenda setting and research priority setting is an overview of the equity lens for 
research priority setting that I have developed for this project. 
We used the equity lens to evaluate the priority setting of 15 Cochrane Groups. In the 2008 survey 
of Cochrane groups, 29 groups reported that they had processes to inform their topic selection. 
Some groups had only limited and unclear approaches.  For example, one Group used certain 
information to feed into their process but they did not report a process for making the decision. 
The evaluation using the equity lens focused on the 15 groups with more structured and 
transparent approaches, as outlined in Tables 5, 6, and 7.  Due to the limited data collected by the 
review groups, we were only able to evaluate some of the processes (e.g. who is involved in the 
process), not the outcomes (e.g. whether the topics prioritised were relevant to disadvantaged 
groups). It was clear that very few Cochrane groups have explicit strategies addressing the need of 
different socio-demographic groups. The process of developing the equity lens demonstrated that 
there is a wide variety of approaches to integrate these issues into the process.  However, there is 
limited evidence to show whether it makes a difference in the finally selected priorities.  
 
Table 10 - Equity lens for agenda setting and research priority setting (1) 
 
The questions focusing on the design and conduct of research priority setting exercises (process 
section) 
1. Are different stakeholders who might be affected by the choice of research (review) 
topics involved in the prioritisation process (different age, sex, sexual orientation, 
disability, ethnicity, and religion, place of residence, occupation, education, 
socioeconomic status, and social capital groups)? In which steps are they involved? 
2. Does the prioritisation project consider reducing inequity as part of its objectives?  
3. Are the selected methods and tools to identify prioritize, implement, disseminate, and 
communicate research topics understandable, transparent and relevant for different 
stakeholders (different age, sex, sexual orientation, disability, ethnicity, religion, place 
of residence, occupation, education, socioeconomic status, and social capital groups)? 
4. Are specific strategies considered to minimize the barriers to reach disadvantaged or 
less accessible populations?  
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5. In the stage of situation analysis (evaluating the current health research coverage, 
identifying gaps, evaluating healthcare needs, etc.), does the analysis consider the 
differences in the prevalence, severity and urgency of health problems along with 
potential differences in the impact or value of the health care interventions assessed 
across different subgroups (age, sex, sexual orientation, disability, ethnicity, religion, 
place of residence, occupation, education, socioeconomic status, and social capital)?  
6. Do the criteria for prioritisation consider the potential differences in the severity and 
urgency of health problems in disadvantaged populations or less accessible groups as 
opposed to the health problems in privileged populations?  
7. Do the criteria for prioritisation consider the potential differences in the impact of a 
health care intervention in disadvantaged populations as opposed to the health 
problems in privileged populations?   
8. Do the criteria for prioritisation consider that different population groups might have 
different values and preferences?  
9. Are different stakeholder groups (representing age, sex, sexual orientation, disability, 
ethnicity, and religion, place of residence, occupation, education, socioeconomic status, 
and social capital groups) provided with an opportunity to provide feedback and appeal 
the process and results of the prioritisation process? 
The questions related to the results of the research priority setting exercise and the following 
implementation of them (section) 
1. Did the prioritisation result in more research topics (in this case Cochrane reviews) that are 
relevant to disadvantaged groups? 
2. Did the dissemination and implementation strategy increase the likelihood that funders and 
research institutes become aware of the prioritised research topics and consider them as part 
of their research agenda or strategic planning? 
3. Did the dissemination and implementation strategy increase the likelihood that the prioritised 
research topics that are relevant to disadvantaged groups get funded and conducted? 
4. Did the dissemination and implementation strategy increase the likelihood that researchers 
who work with disadvantaged groups conduct or get involved in the prioritised research 
projects (in this case the research project is a Cochrane systematic review review)? 
5. Did the dissemination and implementation strategy increase the likelihood that 
disadvantaged groups or decision makers or practitioners who work with disadvantaged 
groups get involved in the prioritised research topics? 
6. Does the dissemination and implementation strategy increase the likelihood that policy 
makers and decisions makers who work with disadvantaged groups use the result of the 
prioritised research topics? 
7. Did the results of the prioritised research topics changed policies, legislation or clinical 
practice in favour of disadvantaged groups? 
8. Did the appeal and enforcement strategy increase the likelihood that disadvantaged 
groups or decision makers, researchers and practitioners who work with disadvantaged 
group had provided feedback and comments on the prioritisation process or results? 
 
 
 
 
 
 
 
58 
Table 11 - Using the equity lens for priority setting processes in 15 Cochrane groups(1) 
Equity Lens The strategies taken by the Cochrane Groups to 
address the question from the equity lens 
1. Are different stakeholders who 
might be affected by the choice of 
research (review) topics involved in 
the prioritisation process (different 
age, sex, sexual orientation, 
disability, ethnicity, and religion, 
place of residence, occupation, 
education, socioeconomic status, 
and social capital groups)? In which 
steps are they involved? 
 1 group targeted consumers, 2 groups targeted policy 
makers, 1 group targeted both clinicians and 
patients,  
 1 group involved stakeholders from different 
countries, different ethnic backgrounds, and both 
genders,  
 1 group involved diverse stakeholders by providing 
the survey in English and Spanish  
 1 group collaborated with a group focussed on a 
particular demographic to ensure that they are 
appropriately represented. 
2. Does the prioritisation project 
consider reducing inequity as part 
of its objectives?  
 1 group (only) specifically aimed to introduce 
health equity and the social determinants of health 
into the prioritisation process.  
 2 groups emphasized that they would try to 
include the priorities of individuals based in LMICs 
(among others). 
3. Are the selected methods and 
tools to identify prioritize, 
implement, disseminate, and 
communicate research topics 
understandable, transparent and 
relevant for different stakeholders 
(different age, sex, sexual 
orientation, disability, ethnicity, 
religion, place of residence, 
occupation, education, 
socioeconomic status, and social 
capital groups)? 
4. Are specific strategies 
considered to minimize the barriers 
to reach disadvantaged or less 
accessible populations?  
 2 projects used online surveys a) one survey was 
provided only in English; b) the second one was 
available in both English and Spanish.  
 1 project, which aimed to involve patients and 
clinicians, made specific attempts to ensure that the 
provided information was understandable for both 
groups. 
5. In the stage of situation analysis 
(evaluating the current health 
research coverage, identifying gaps, 
evaluating healthcare needs, etc.), 
does the analysis consider the 
differences in the prevalence, 
severity and urgency of health 
problems along with potential 
differences in the impact or value 
of the health care interventions 
assessed across different subgroups 
(age, sex, sexual orientation, 
disability, ethnicity, religion, place 
of residence, occupation, 
 1 project searched for evidence and categorized 
the identified studies from the search according to 
stages of the condition, consequences of ill health, 
and social determinants potentially affecting the 
condition.  
 1 project used the WHO Health Report 2002 (18, 
19) as a basis for categorizing the identified 
literature that can demonstrate the differences in 
severity and prevalence between Low and Middle-
Income countries (LMIC) and High-Income countries 
(HICs). 
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education, socioeconomic status, 
and social capital)?  
6. Do the criteria for prioritisation 
consider the potential differences 
in the severity and urgency of 
health problems in disadvantaged 
populations or less accessible 
groups as opposed to the health 
problems in privileged 
populations?  
 1 group, the priority setting group considered five 
dimensions in setting priority research topics. Two 
of them were relevant to this question. 
In the below ones, depending on how the panel 
interpreted these criteria, this might have led to the 
inclusion of priority questions that addressed 
question 6. 
 1 group considered burden of disease, magnitude 
of problem, and urgency as criteria.  
 2 groups considered the priorities of a health care 
system as one of the criteria.  
7. Do the criteria for prioritisation 
consider the potential differences 
in the impact of a health care 
intervention in disadvantaged 
populations as opposed to the 
health problems in privileged 
populations?   
 1 group considered a criterion that partially 
addresses this question: potential impact of the 
intervention on changing policy or treatment 
especially in areas of the United Nations Millennium 
Development Goals (MDGs). 
8. Do the criteria for prioritisation 
consider that different population 
groups might have different values 
and preferences?  
 None of the processes considered values and 
preferences. 
9. Are different stakeholder groups 
(representing age, sex, sexual 
orientation, disability, ethnicity, 
and religion, place of residence, 
occupation, education, 
socioeconomic status, and social 
capital groups) provided with an 
opportunity to provide feedback 
and appeal the process and results 
of the prioritisation process? 
None of the processes ensured that different socio-
demographic groups had the opportunity to provide 
feedback and appeal the results 
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The impact of the priority setting projects 
The Collaboration has recognized the importance of our priority setting research projects in several 
ways. For instance, these projects were the basis for developing a new Methods Group within the 
Cochrane Collaboration. The Cochrane Priority Setting Methods Group was launched in 2011. This 
Group connects researchers working on priority setting methodology with Cochrane groups and 
disseminates the latest research on priority setting to Cochrane reviewers. It translates the 
research on priority setting processes mentioned above into policy guidance, checklists and 
guidance documents for research groups within the Cochrane Collaboration. The policy guidance is 
directed at all Cochrane groups (> 100 groups) around the world and several groups have 
developed better ways of prioritising topics for Cochrane Reviews7. The Methods Group organized 
and conducted workshops to communicate key issues that had emerged, to raise awareness, and 
to increase public engagement in research. I worked with other groups to integrate the results of 
the projects in other training programmes e.g. online training resources on research priority setting 
for Cochrane Canada and the Pan American Health Organisations (PAHO), training session for the 
UK-based Cochrane Review Groups at the 2013 UK and Ireland Cochrane Contributors Meeting, 
and training resources for the Yorkshire and Humber Research Design Service (part of the NHS).  
The importance of our priority setting research was recognized by the Collaboration in awarding us 
the Bill Silverman Prize in 2012 and by Dame Sally Davies at the UK and Ireland Cochrane 
Contributors meeting in March 2013. Dame Sally highlighted our work as a key development in the 
Cochrane Collaboration to ensure that its reviews are relevant to the needs of the NHS. It was also 
used to inform the development of a research priority setting process for systematic reviews on 
consumer and communication topics at La Trobe University in Australia (88). 
The priority setting projects shaped a research impact story in the last Research Excellence 
Framework (REF) 2014 exercise as part of Plymouth University’s submission entitled “Advancing 
methods for prioritising health research”8. The REF panel has provided the following feedback 
about this impact story: “Some of the case studies were considered to be of very considerable 
impact in terms of their reach and significance, especially in relation to genetic counselling 
competencies and prioritising health research”. 
Since the start of my priority setting research in 2008, there has been a sharp increase in the 
number of studies discussing or exploring the issue of priority setting of systematic reviews in the 
Cochrane Collaboration and other organisations across the world. This may be due to the struggle 
that many systematic review organisations (national and international) face with the increased 
                                                          
7
 https://methods.cochrane.org/prioritysetting/resources/priority setting-cochrane-groups-examples  
8
 http://impact.ref.ac.uk/CaseStudies/CaseStudy.aspx?Id=4645 
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demand for systematic reviews to inform decisions in health care. The increase in the conduct of 
primary clinical research also leads to challenges in keeping systematic reviews up to date. Due to 
the diversity of the aim and scope of these organisations, I decided for the next part of the project 
to focus on a specific group of organisations involved in deciding what systematic reviews and 
primary research get funded: national health research funders. 
How do national health research funders reduce research waste?  
As seen in the first set of the publications in this dissertation (1, 2, 15), research priority setting 
cannot be evaluated in isolation from the organisational cultures, values, context, etc. in which 
they occur. Internal organisational factors and external drivers affect how priority setting processes 
are planned and what is expected to happen as a result. Accordingly, I broadened the scope of my 
second evaluation to include characteristics of structures and processes of the research funding 
agencies that can influence the process of setting priorities, the outcomes of priority setting or the 
implementation of the outcomes. The framework used for this project was based on a framework 
developed by Iain Chalmers and Paul Glasziou in 2009 (21) and further expanded in a Lancet series 
(22-27) focusing on avoidable waste in the production and reporting of research. We adapted the 
overall framework into a checklist to evaluate the work of public research funders based on 
publicly available information (Table 12). The objective of the project was to explore how funders 
(a) promote and monitor waste-reducing measures in the research that they support, and (b) 
support methodological research (research on research) and research infrastructure. 
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Table 12 - adaptation of the reduce research waste framework into an evaluation 
framework for research funders 
Decisions on which research proposals are priorities 
 How do funders set their overall research agenda and commissioned research projects? 
 Do they report an overall vision or principle for the organisation? Does this include a 
balance between basic, applied and translational work? 
 Do they require applicants for funds to do additional primary research to refer to 
systematic reviews of existing evidence showing why the proposed research is justified? 
 Do they report a process to set their research agenda? What is the balance? (General 
details on the process, level of transparency, the people involved in the process (6 Ps - 
public, patient, provider, press, policy-maker, private sector + Researcher), criteria for 
making decisions, the process that the decisions are made, the scoring structure for boards 
and panels) 
 Do they engage with stakeholders in setting this research agenda? Does this include the 
end users of research (e.g. clinicians, patients, policy makers, as well as other researchers)? 
 Do they have certain pieces of information (e.g. prioritised agenda by other public 
agencies) that they use to inform these decisions? 
 How do funders make decisions to fund between the individual proposals submitted to 
them? 
 Do they report a process to make these decisions? 
 Do they engage with stakeholders to make these decisions? Does this include users of 
research? 
 Do they have certain pieces of information that they require in proposals to justify new 
primary research? Does this include systematic reviews or preparations of systematic 
reviews? How is this checked and monitored? Does the funder support such systematic 
reviews?  
Requirements in conduct of the research proposal and reporting it 
 Does the funder require registration of research? If yes, which types? 
 What is the funder’s policy on public access to protocols for completed or ongoing 
research? 
 What is the funder’s policy on public access to data from completed research? 
 Does the funder promote use of relevant reporting guidelines (CONSORT, ARRIVE, STROBE, 
PRISMA, etc)?  
 What assistance, rewards, or incentives does the funder use to encourage: (i) publication of 
research? (ii) dissemination of research? (iii) re-use of data by other researchers? 
Policies of funders to wider support researchers, research organisations and research 
infrastructure 
 What support is provided for training of, or assistance for, researchers in research 
methods? 
 What support does the funder provide for good research infrastructure (non-equipment), 
such as: research networks, study registries, data repositories, and open access? 
 Does the funder monitor their research output and impact?  
 Do they provide funding for others do undertake “research on research” or methods to 
improve research production such as reporting guidelines?  
 
We selected 11 national research funding agencies in order to include large and small funders, 
some of them with a wide research agenda addressing diverse topics and others with a more 
focused research agenda. These were:  
 the National Institute for Health Research (NIHR - England);  
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 the Medical Research Council (MRC - UK);  
 the National Health and Medical Research Council (NHMRC - Australia);  
 the Canadian Institutes of Health Research (CIHR – Canada); 
 the National Institutes of Health (NIH – USA);  
 Deutsche Forschung Gesellschaft/ German Research Foundation (DFG – Germany);  
 French Ministry of Health; l’Agence Nationale de la Recherche (ANR – France);  
 Nederlandse organisatie voor gezondsheidsonderzoek en zorinnovatie/ The Netherlands 
Organisation for Health Research and Development (ZonMw - Netherlands);  
 Danske Regioner / Danish Regions (DR – Denmark); and 
 the Regional Health Authorities in Norway (RHA – Norway).  
I searched for information addressing our questions by:  
a. Browsing funding agency websites and following links providing information about the 
organisations, funding opportunities, information and guidance for reviewers, researchers 
and members of the public.  
b. Identifying, downloading and reviewing any handbooks for applicants and reviewers for 
grant committees, or documents on objectives and strategies. This included any regulations 
and guidelines issued by the funding agencies on their funding allocation process, but we 
did not look systematically at legislation and other central government policy documents 
from which regulations and guidelines derive, unless this was raised by the funding 
agencies when we contacted them.  
c. Searching websites, handbooks and other documents using the following specific terms: 
systematic review, meta-analysis, reporting guidelines, trial registry, CONSORT, PRISMA, 
STROBE, SPIRIT and ARRIVE (acronyms for reporting guidelines). I also used these terms 
together with the names of the funding agencies and scanned the first 20-30 results.  
As background information on the funding agencies, I examined the composition of project grant 
committees and the affiliations of members, broadly categorized into academics and clinicians, 
policy makers, industry, and members of the public. I looked at the composition of the committees 
but did not explore their authority. My collaborator looked at the website of the Danish and 
Norwegian funding agencies as they were not available in English. A research collaborator double 
checked the data that I extracted. We contacted all funders to verify the data. All except for the 
Danish funders responded.  
We published the initial results in The Lancet.  Our paper included data from other projects looking 
at compliance to reduce research waste frameworks conducted by medical editors, universities, 
academics, etc. (3). The full results have been published subsequently  in The Lancet (4). In the next 
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sections, I provide details beyond the published data in the Lancet reports. I explain why I did not 
include these data in the final publication. Moreover, I collected additional data through 
opportunistic sourcing – conversations with key individuals who develop and implement policies in 
funding agencies. We used this information to interpret and contextualise the data from the survey. 
Opportunistic sourcing is a recognised methodology in policy sciences, investigative and 
interpretative journalism to acquire human and documentary primary sources (89).  
 
Summary of the context and characteristics of funding agencies 
Of the 11 research funding agencies, DFG (Germany) and ANR (France) had the broadest research 
agendas, which included research unrelated to health. DFG funds research in any field of science, 
including engineering, life sciences and natural sciences and the humanities, including social 
sciences. ANR funds research on climate, energy and urbanisation. All the other funders focus on 
health research. Some - NIHR and the French ministry of health, for example - mainly fund applied 
and clinical research. At the beginning of the study, I intended to categorise the research 
focus/agenda/vision of each funding agency as applied research (clinical and public health), basic 
sciences, or translational research. After data collection, I realised that my attempt to categorise 
research foci could be misleading. There was a mismatch between my interpretations of the words 
and terms used to describe the visions and research agendas of funding agencies (as outlined by 
them) and the perceptions of researchers working in those countries and applying to those funding 
agencies. For example, the overall vision and agenda of a funding agency can be focused on 
improving people’s health but the researchers would highlight that the same agency can 
disproportionately focus on allocating funding to basic science. This is in line with the overall 
conclusion of this dissertation about the lack of transparency in the processes used by funding 
agencies and research organisations (Figure 2).  
 
Figure 2 - Overview of the focus of the research agenda of research funders 
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Evaluating the research agenda and structure of these funding agencies provided an insight on 
individuals and organisations that influence and shape them. National and international policies 
and events can influence the decisions made in these organisations. Some examples are as follows: 
 The UK MRC works in partnership with nine government departments, research councils and 
charities to lead an initiative aimed at supporting informatics research, infrastructure and 
scientists.  
 The English NIHR invested in two national priorities identified by policy makers in the UK: 
dementia (the Prime Minister’s Dementia Challenge) and antimicrobial resistance (identified 
by the Chief Medical Officer).  
 The US National Institutes of Health (NIH), a part of the U.S. Department of Health and 
Human Services, is the principal US medical research funding agency. NIH is strategically 
responsive to Congressional legislation that adjusts NIH's programmes to meet changing 
research needs. When I conducted the study, NIH had a operating budget of $30.15 billion, an 
increase of $1 billion (program level) over the fiscal year 2013. NIH has 27 Institutes and 
Centers, each with a specific research agenda, often focusing on particular diseases or body 
systems. NIH leadership plays an active role in shaping the agency's research planning, 
activities, and outlook (Table 13). 
 When this study was conducted, Australia’s NHMRC’s priority actions were set out in the 
NHMRC Strategic Plan 2013-15 tabled in the Australian Parliament on 18 January 2013. These 
included: “(a) create new knowledge through support of discovery research; (b) Accelerate 
research translation and build Australia’s future capability for research and translation; (c) Set 
high standards in ethics in health care and research; and (d) Work with partners – States and 
Territories, health bodies, health industries and community and consumer groups”. NHMRC’s 
work is underpinned by the principles of “fairness, transparency, independence, 
appropriateness and balance, research community participation, confidentiality, impartiality, 
quality and excellence” (Table 14). The members of the council of the NHMRC include the 
chairs of each of its principal committees, the chief medical officer, head offices of 
commonwealth and state/territory, along with individuals with specific expertise and 
experiences e.g. health needs of aboriginal people, expertise in consumer issues, business and 
nursing professions. The committees are the research committee, the Australian health ethics 
committee, the human genetics advisory committee, the health care committee and the 
prevention and community health committee. 
 The Dutch ZonMW’s main commissioners are the ministry of health, welfare and sport and the 
Netherlands Organisations for Scientific Research, so its focus is on projects related to 
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improving health and health care in The Netherlands.  The organisation not only focuses on 
conduct of health research but also on implementing research findings. In a meeting, a senior 
member of ZonMW provided an example in which the funder decided to fund a replication of 
a clinical trial in The Netherlands despite available results of other clinical trials in other 
countries. They decided to fund this trial as it had important implications for subsequent 
implementation of the results in The Netherlands.  
Table 13 - the list of NIH institutes and centres 
NIH Institutes 
 
1. National Cancer Institute (NCI) — NCI  
2. National Eye Institute (NEI)  
3. National Heart, Lung, and Blood Institute (NHLBI)  
4. National Human Genome Research Institute (NHGRI)  
5. National Institute on Aging (NIA)  
6. National Institute on Alcohol Abuse and Alcoholism (NIAAA)  
7. National Institute of Allergy and Infectious Diseases (NIAID 
8. National Institute of Arthritis and Musculoskeletal and Skin Diseases 
(NIAMS)  
9. National Institute of Biomedical Imaging and Bioengineering (NIBIB 
10. Eunice Kennedy Shriver National Institute of Child Health and Human 
Development (NICHD)  
11. National Institute on Deafness and Other Communication Disorders 
(NIDCD) — Est. 1988 
12. National Institute of Dental and Craniofacial Research (NIDCR) — Est. 
1948 
13. National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK)  
14. National Institute on Drug Abuse (NIDA)  
15. National Institute of Environmental Health Sciences (NIEHS)  
16. National Institute of General Medical Sciences (NIGMS)  
17. National Institute of Mental Health (NIMH)  
18. National Institute on Minority Health and Health Disparities (NIMHD 
19. National Institute of Neurological Disorders and Stroke (NINDS)  
20. National Institute of Nursing Research (NINR) — Est. 1986 
21. National Library of Medicine (NLM) — Est. 1956 
NIH centres 1. Center for Information Technology (CIT)  
2. Center for Scientific Review (CSR)  
3. Fogarty International Center (FIC) 
4. National Center for Complementary and Alternative Medicine (NCCAM)  
5. National Center for Advancing Translational Sciences (NCATS)  
6. NIH Clinical Center (CC) — Est. in 1953 
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Table 14 - Processes to set the research agenda for the funding agency (high level decisions 
rather than for individual grant submissions) 
NIHR (UK) Investigator initiated research – decisions are made by a panel of stakeholders including 
researchers, policy makers and patient representatives; applications must meet minimum 
criteria e.g. involving patients in developing research proposals.  
Priority driven research (themed calls) – This can be driven by policy makers priorities. 
NETSCC (NIHR Evaluation, Trials and Studies Coordinating Centre) builds partnerships with 
external organisations and has an open online web form for the submission of potential 
research questions. They also support the James Lind Alliance Programme of Priority setting 
partnerships that engage with clinicians and patients to priorities. An advisory board is 
involved to identify overlapping topics.  
NIHR introduced an “adding value to research” framework to meet the targets of the 
“reducing research waste” initiative. Both programmes are monitored against these criteria.  
MRC (UK) The overall strategic plan guides the specific objectives and goals for each funding panel. 
The strategy board, the research boards and the four overview groups (public health, global 
health, and translation and research careers) are heavily involved in setting the research 
objectives.  
CIHR 
(Canada) 
Investigator Initiated research - must be of internationally accepted standards of scientific 
excellence and improve health for Canadians.  
Priority driven research (themed calls) - is designed to respond to Canada’s strategic health-
related research priorities developed by their Governing Council and Science Council, by 
evaluating government priorities, emerging needs, trends and important knowledge 
deficits in the Canadian health research landscape.  
DFG 
(Germany) 
The DFG is the self-governing organisation for science and research in Germany. It serves all 
branches of science and the humanities. In a multi-layered decision-making process, 
proposals are evaluated by voluntary reviewers according to scientific criteria; and then 
assessed by chosen members of the Review Board, with the final decision taken by each 
Grants Committee which consists of researchers, representatives of federal and state 
governments, and the Donors’ Association for the Promotion of Sciences and the 
Humanities. Any eligible researcher may submit a funding proposal at any time and on any 
research topic. As the DFG does not specify a topic for proposals, but, instead, reacts to 
proposals on any topic, it promotes research primarily in “response mode”, thereby 
complementing the agenda driven and programme oriented funding by the ministry of 
research and education (BMBF) in Germany. 
NHMRC 
(Australia) 
Has an overall strategic vision and health care, preventive and community health and 
genetic committees to advise them along with principles of: Fairness, Transparency, 
independence, Appropriateness and balance, Research community participation, 
Confidentiality, Impartiality, Quality and excellence. It is mostly concerned with investigator 
initiated research. 
ZonMw 
(Netherlan
ds) 
The main commissioning organisations of ZonMw are the Ministry of Health, Welfare, Sport, 
and the Netherlands Organisations for Scientific Research. ZonMw involves several 
stakeholders to define the programmes and agenda for allocating research funding. 
Programmes have different perspectives: simulating scientific quality, developing certain 
scientific fields, developing and researching innovations in health care, development and 
research for specific target groups, coordinating large-scale introduction of proven 
valuable innovations. Prioritised Research Agendas of professional associations as well as 
those of social organisations and movements (like gender and health) are used in some 
programmes to help judge the relevance of the proposals. 
NIH (USA) The U.S. congress sets NIH institutes and centers funding levels and directs NIH attention to 
areas of research interest or emphasis. The NIH Division of Coordination, Planning and 
Strategic Initiatives in the NIH Office of the Director identifies important areas of scientific 
opportunity, rising public health challenges, and gaps in knowledge that deserve special 
emphasis. Trans-NIH planning for the Common Fund involves broad stakeholder input from 
multiple scientific and public inputs. The mission of each NIH Institutes and centres generally 
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focuses on a different disease, organ, or stage of life. The individual ICs set their own 
research priorities considering the following factors, IC mission, available funding, scientific 
needs and opportunities, gaps in funded research, burden of disease, and public health 
need, such as an emerging threat. Priorities are partially driven by the research community 
with their investigator initiated proposals. Each of the NIH institutes and centers update 
their strategic plans regularly and make them publicly available on the RePORT portal. NIH 
funding strategies are updated and made public annually through the website. 
FoH 
(France) 
The general research agenda and scope of the institute is set by the policy makers according 
to a national health strategy which supports further investment in primary care research. 
There are seven general programmes that accept funding applications:  
1. National clinical hospital research programme, PHRC-N ;  
2. National clinical research in oncology, PHRC-K ;  
3. Inter-Regional Programme hospital clinical research, PHRC-I;  
4. National Health economics research programme, PRME-N ;  
5. The medico-economic research program in oncology, PRME-K;  
6. Research Program on the performance of the healthcare system, PREPS;  
7. The nurse and paramedic Research Hospital Program, PHRI.  
They use consensus processes to reach grant funding decisions.  
ANR 
(France) 
ANR has a work programme with four interlinked components, each with a specific budget 
and governance- (major societal challenges, at the frontiers of research, building the 
European research and France international attractiveness, economic impact of research 
and competitiveness). They work across the European Horizon 2020 framework programme. 
There are both targeted calls (mostly collaborative), and a general call for proposals with a 
two-stage selection process. 
DR 
(Denmark) 
The five regions are responsible for allocating resources within their geographical areas. They 
seem to engage with policy makers and are guided by the priorities of the ministry of 
health. They suggest the following ways in which resources can be allocated: (a) First-come-
first-served (b) Preadmission evaluation with or without explicit criteria for choosing 
between projects (c) Co-funding (d) Quota system with or without criteria for choosing 
between projects. 
RHA 
(Norway) 
Each RHA has established a research strategy (available on the website) based on regulations 
and initiatives from the national health authorities with some local or regional adaptions. 
For example, the central RHA has six research programs: (a) Patient centered clinical 
research; (b) Translational research; (c) Medical technology (e.g. imaging); (d) Informational 
and communicational technology; (e) HUNT (population study), biobanks, and registries; 
and (f) Health services research. The regional liaison committees involve representatives 
from the RHA, universities in the region, and clinicians, policy makers, researchers and some 
patients. There are also initiatives to increase collaboration between different regions, for 
example by the involvement of the Norwegian Research Council.  
 
The selection of funding agencies was intended to demonstrate diversity of public national 
research funding agencies in developed countries. In two instances, I selected two funding agencies 
in the same country (UK and France). In both cases, one funding agency has a predominately basic 
science focus and the other one an applied research focus. In both cases (and others), I could not 
identify a national strategy describing how this funding organisation coordinates their research 
agenda and priorities with other organisations in their country. In a conversation with a staff 
member of one of the funding agencies, I was told that funding agencies in the UK meet or 
communicate with each other to ensure some coordination between their work. There are no 
details publicly available on how this collaboration works. Regarding the UK, there is an overall 
diagram that is intended to demonstrate the research pathway and the position of two major 
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health-related funders (Figure 3). The research pathway assumes that research starts with a new 
idea from basic scientists. Ideas which are successful in the lab move forward to applied research. 
MRC mostly funds basic science research although it also funds some clinical trials and public 
health projects. NIHR supports applied research as the next step of development. This theoretical 
pathway is an inadequate representation of research processes.   Basic science research ideas 
sometimes arise from applied research projects and occasionally from issues raised by members of 
public. Based on the dominant model, it can be seen that priorities in applied research tend to be 
driven by priorities in basic science research. However, basic scientists are not aware of, or 
involved in, major clinical and public health issues to drive priorities.  
 
Figure 3 - The research pathway to outline the work of NIHR and MRC (ref: 
http://www.nihr.ac.uk/documents/about-) NIHR/Briefing-Documents/1.1-The-National-Institute-
for-Health-Research.pdf 
The structure of funding programmes in NIHR 
As part of a separate project, I have data on NIHR funding mechanisms which were not covered in 
the published papers. The project focused on engaging with policy makers regarding the 
prioritisation of systematic reviews. I interviewed several people in the UK, including Professor Tom 
Walley, director of the NIHR Health Technology Assessment and Efficacy and Mechanism 
Evaluation programmes, on how funding to prioritise systematic reviews is decided and allocated.  
There are underlying principles that drive the work of NIHR e.g. ensuring patient benefit and 
reducing research waste. NIHR is closely related to the National Health Service (NHS) in the UK. 
There is a specific focus in their funding programme looking at projects that potentially could lead 
to improved patient health within five years. NIHR also introduced an ‘adds-value’ framework in 
research. Adding value in research ensures that NIHR-funded research answers questions relevant 
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to stakeholders; uses appropriate designs and methods; is delivered efficiently, provides full results 
accessible in publications; and produces reports that are complete, unbiased and usable.  
NIHR has a range of programmes focusing on different research topics, including health services 
and delivery research, invention for innovation, health technology assessment (HTA) and public 
health research. All the programmes have the same underlying principle: commissioning research 
which meets the information needs of healthcare and public health professionals, practitioners, 
policy makers, patients and the public. All of the research proposals require a systematic review 
before publication and need patient involvement before submission.  
The key funding for systematic reviews on health care topics in the UK comes from NIHR, 
predominately through the systematic review and health technology assessment (HTA) programme. 
However, other programmes - e.g. health services research and research for patient benefit - might 
also fund systematic reviews. The decisions on the funding of a programme of systematic reviews 
are made mainly by the director.  In part, this is through block funding to the Cochrane 
Collaboration. Although the NIHR director may be engaged in the process, the Cochrane 
Collaboration makes independent decisions on prioritising topics. As Cochrane is an organisation 
containing diverse  groups, it has a diverse range of approaches to prioritising topics (and in some 
cases, it is very vague how decisions are made). In addition to the central funding to the Cochrane 
Collaboration, NIHR provides incentive funding for Cochrane Reviews that directly benefit the NHS 
in England. The committee making those decisions includes patient representatives and individuals 
with experience in policy and systematic reviews.  
The HTA programme has a diverse approach to setting priorities for systematic reviews. There is a 
HTA prioritisation panel but other individuals and organisations can affect the decisions: 
 The HTA prioritisation panel operates a complex process starting with the identification of 
topics, the involvement of a panel of NHS experts, and comparisons with  other resources 
allocated in the NHS. The group includes NHS mangers, patient representatives, 
commissioners and advisers but the final decisions are always taken by the director.  
 The existence of the National Institute of Clinical and social care Excellence (NICE) has a 
clear role in shaping the decisions made by funding agencies. Some projects commissioned 
through the health technology assessment programme have been selected to fill  gaps and 
to inform NICE policy decisions 
 Policy makers and managers in the NHS can suggest topics. In certain situations, NIHR can 
respond quickly to a policy request if an urgent decision is needed. For example, in 2009, 
the ‘flu’ pandemic led to a systematic review being commissioned to be completed in three 
 
 
71 
months in order to inform NHS mangers. Commissions like these can come from higher or 
lower level policy makers 
The HTA programme also accepts applications in a responsive format – researchers can submit 
grants on any topics (as long as they are relevant to patients). However, these applications tend to 
be more complicated to review, with economic analyses, Individual patient data analyses, or realist 
reviews (a model of research synthesis that is designed to address questions on complex social and 
health care interventions and programmes. It is an explanatory analysis what works, in what 
circumstances, in what respects and how (90)). In addition to the HTA programme, the health 
services research programme can also commission (or be responsive to) systematic review projects. 
In all these cases, conflict of interest can be an issue. Individuals might not report conflicts of 
interest and they may have academic/intellectual conflicts of interest on a specific topic. They may 
thus advocate for their “pet” research topic and not consider sufficiently systematically the existing 
evidence on the need (or lack of need) of a new research project.  
Results of the survey of research funders 
The key results of the survey are outlined in Chapter 4. 
The fundamental issue that these studies (and the previous studies) identified was the lack of 
transparency in the process of setting priorities for research and other related organisational and 
policy issues. Lack of transparency or misleading information can negatively affect public trust in 
scientific organisations (and consequently science itself). Public viewpoints drive politicians, their 
views and actions. Politicians have a key role in continuing the support of funding agencies.  
Several research funding agencies have promising strategies (or plan to have them) to address key 
aspects of the “Reduce research waste” framework (21). However, there are many gaps in their 
efforts and substantial uncertainty about how to reduce waste. In the agencies we studied, grant 
committees were dominated by academics and clinicians. NIHR and ZonMW had the most 
extensive involvement of members of the public. There is no international agreement or 
consistency in policies and procedures intended to reduce research waste and increase the 
efficient allocation of scarce resources for research on questions that are important to the public 
and practitioners. The process to set a research agenda involves many stakeholders in complex 
interactions but these processes are difficult to monitor and consequently difficult to capture. An 
example of data collected from funders is available in Table15. 
I did not find any studies evaluating the impact of decisions about strategic objectives, setting 
priorities and designing the infrastructures of research funding agencies on the selection and 
composition of research topics. This may be important because research priority setting exercises 
involving patients and clinicians have shown that the priorities of patients and clinicians can differ 
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from those of researchers: patients and clinicians want more evaluation of educational 
interventions, physical and psychological therapies, and service development, while most clinical 
trials are conducted on drugs, vaccines, and biologics (16, 31, 91). In another example, a research 
priority setting process focusing on burn survivors found that patients’ priorities were control of 
itching and oedema in scars and donor sites, but these were not reflected in researchers’ priorities 
(92). One of the key researchers (funders) mentioned that they also struggled to get any researcher 
to conduct research on “itching and oedema in scars and donor sites” despite availability of funding. 
It is unclear from our survey how extensively funders monitor waste-reducing policies. A staff 
member of one of the funding agencies raised the issue of the lack of resources to monitor 
compliance with the “Reduce research waste” framework (21). It is unclear why these funding 
agencies do not allocate funding in ways that would ensure an accountable process for funding 
research. It seems that, in most countries, the processes of governance do not hold funding 
agencies accountable for measuring whether and how they address the questions raised by the 
“Reduce research waste” framework. We suggest that at least two aspects of monitoring would be 
worth considering: (a) how well researchers following the protocols and methods needed to 
conduct research that will deliver the research quality envisaged in the funding application and (b) 
how should any changes of the funding be managed to ensure high quality research and 
sustainability? 
There were several meetings at which the results of the projects were presented to funding 
agencies. One of the issues that was raised and discussed was the need to compare the regulation, 
policies and processes to prepare and submit grant applications. There was a recognition that some 
steps are unnecessarily burdensome and waste resources for researchers and funders. This has also 
been raised in previous studies and anecdotes (23). Further discussion and evaluation of processes 
across the funding agencies and sharing experiences could help to inform the design and 
implementation of better processes and policies across these organisations.  
There are several academic initiatives aiming to improve the quality of research and reduce 
research waste. These initiatives have made more progress in some disciplines than in others.  
Conducting systematic reviews to improve practice and research or introducing reporting 
guidelines to improve reporting of research articles was first introduced for clinical research. These 
initiatives have been extended to other areas e.g. animal research. However, the latter are at 
earlier stages and are less developed and need further work to reach similar standards to those in 
clinical research(93-95). This explains some of the differences across funding agencies that focus 
primarily on applied research and those that focus on a broader range of scientific disciplines.  
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Table 15 - Overview of research funder’s performance against criteria of the Reduce Research 
Waste framework (see guidance at the bottom of each column regarding on the colouring of each 
column) 
 Does the funder 
promote the use of 
relevant reporting 
guidelines?  
Do they have any 
targeted 
programmes to 
support, prioritise 
and/or fund 
systematic reviews?  
Are applicants 
who seek 
support for new 
research required 
to refer to 
systematic 
reviews of 
existing 
evidence?  
Does the funder 
provide 
targeted/ 
prioritised 
funding to 
undertake 
“research on 
research”?*  
NIHR YES. 
NIHR clearly 
recommends the 
use of reporting 
guidelines available 
on the EQUATOR 
network website.  
YES. 
"There are 
commissioned and 
researcher led 
programmes that 
fund systematic 
reviews amongst a 
wider portfolio of 
research.” 
NIHR also funds 
several UK-based 
Cochrane Review 
Groups. 
  
YES. 
Only funds 
research that is 
supported by a 
systematic review 
of existing 
evidence. For 
commissioned 
calls, the review 
is done by the 
funder. 
YES. 
The NIHR/MRC 
Methodology 
Research 
Programme 
explicitly 
includes 
“research on 
research” as 
part of its remit, 
and has funded 
guideline 
initiatives such 
as EQUATOR 
and COMET in 
the past. 
MRC YES. 
The ARRIVE 
guideline is clearly 
mentioned. 
CONSORT is 
mentioned briefly 
in good practice 
guidelines. 
NO. PARTIAL. 
The global Health 
Clinical Trial 
Programme 
requires 
systematic 
reviews. 
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CIHR YES. 
They refer to the 
CONSORT 
guidelines.  
YES. 
CIHR has a 
knowledge synthesis 
programme which 
funds systematic 
reviews. 
PARTIAL. 
Encourages (but 
does not require) 
a systematic 
review to be 
included in 
proposals for 
clinical trials. 
NO. 
However, they 
have funded 
research on 
research 
through other 
funding 
schemes and 
provided data 
and funding to 
other 
organisations, 
such as the 
Rand 
Corporation, to 
undertake 
“research on 
research”. ** 
DFG YES. 
DFG recommends 
the use of 
CONSORT, PRISMA 
and STARD. 
NO. PARTIAL. 
Only for clinical 
trials 
NO. 
NHMRC PARTIAL. 
Guidelines are not 
clearly mentioned 
as required for 
project grants but 
there is one 
programme grant 
in which CONSORT 
was required in the 
grant application. 
NO. NO. NO. 
ZonMw YES. PARTIAL.  PARTIAL. NO.  
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The animal 
research project 
departments 
recommend the 
use of ARRIVE 
guidelines. 
They do not have a 
programme that 
structurally provides 
grants for systematic 
reviews. However, in 
several programmes 
commissioning one 
or more reviews is 
often a first step in 
selecting and 
prioritizing topics 
and research 
questions. Also, they 
occasionally ask for a 
systematic review on 
a specified subject as 
part of a broader 
research 
programme. 
Only for clinical 
trials 
They are 
developing a 
funding 
programme for 
research on 
research 
focusing on 
“research 
integrity” that 
will be opened 
in 2017.  
NIH YES. 
A comprehensive 
list of reporting 
guidelines is 
recommended to 
researchers. 
NO. 
Programmes to 
support systematic 
reviews are more in 
line with the mission 
of the Agency for 
Healthcare Research 
and Quality (AHRQ). 
NO. NO. 
However, they 
have internal 
staff working on 
research on 
research.  
PHRC  NO. NO. 
They have no specific 
programme for 
systematic reviews. 
However, they do 
accept systematic 
reviews in their 
NO. YES.   
They fund the 
Cochrane 
Centre in France 
that has an 
extensive focus 
on “research on 
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process.  research”. They 
had a budget 
line for this item 
until 2015 but it 
is not clear 
whether it will 
continue.  
ANR NO. NO. NO. NO. 
The generic call 
contains a 
dedicated line 
for research 
methods in the 
Life, Health and 
Wellbeing 
challenge. 
DR NO. NO. NO. Unclear 
RHA NO. NO. NO. NO. 
 Green – If several 
reporting 
guidelines are 
required, Yellow – 
if one of the 
reporting 
guidelines are 
required (or 
encouraged), Red – 
If not 
recommended 
White – if unclear 
Green – they have a 
programme, Yellow 
– they have 
sometimes 
programme 
targeting systematic 
reviews Red – no 
targeted 
programme. White - 
Unclear 
Green - if SR for 
all proposals 
Yellow - If SR only 
for clinical trials 
Red - if no rules 
White – if unclear 
Green – they 
have a 
dedicated 
research on 
research 
funding 
programme; 
Yellow – they 
have either an 
internal 
research on 
research 
programme or 
they have 
funded research 
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Funding for methodological research  
There is a need for more funding for methodological research in healthcare research. In the 
research community, methodological research (or meta-research)9 (96) has been central to the 
evaluation and analysis of research practices to identify how these practices affect the availability, 
quality and usability of research. Publication bias is a good example of the importance of this form 
of research (97). Methodological research showing that publication bias is a problem led to 
changes of policies and actions to address this issue. There is still a lot to be done about publication 
bias but methodological research was (and still is) key to identifying the problem, planning 
interventions to address it and monitoring the effect of those interventions.  
Funding for methodological research is very limited. As Table 15 demonstrates, the only funders 
with a dedicated methodological research funding programme are NIHR and MRC. ZonMw is 
planning a methodological research programme on research integrity. Some funding agencies 
undertake methodological research as part of their internal work e.g. NIHR and NIH. Other funding 
agencies are supporting research groups that prioritise methodological research e.g. the French 
ministry of health supporting the French Cochrane Centre. Beyond our survey, there is also limited 
                                                          
9
 Meta-research, or the scientific study of research practices, aims to characterize existing standards and 
ultimately improve the quality and reliability of scientific research (http://collections.plos.org/meta-research-
reproducibility)  
on research 
projects 
through other 
funding 
schemes; Red – 
they have no 
programme, 
White – Unclear 
Note: 
* This refers to “research on research”, or methods to improve research production such as reporting guidelines. 
We did not include those open funding calls which don’t target or specifically encourage “research on research”. 
Some of these funders have funded methodology research in the past (e.g. ZonMw and NIH). However, they did not 
have a prioritised or targeted research scheme for that and “research on research” projects had to compete with 
other research projects. Some of these funders (e.g. NIHR and NIH) also have internal departments or research 
groups that engage with research on research. 
** Examples of projects where CIHR was involved include: 
http://www.rand.org/randeurope/research/projects/mental-health-retrosight.html 
http://www.rand.org/pubs/monographs/MG1079.html 
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funding available from other agencies that support methodological research. For example, in the 
UK, in addition to the MRC, the Chief Scientist’s Office in Scotland and the Cochrane 
Methodological Innovation Fund (the Cochrane Collaboration) have funded methodological 
research. 
An issue to consider is whether methodological research should be conducted by internal staff of 
funding agencies to inform their practices or should be an external funding programme to which 
independent researchers can apply. I believe that both are necessary. It is important that funding 
agencies monitor their internal practices and identify approaches to improving them. However, it is 
crucial to enable independent researchers to identify and raise questions that affect the wider 
research community. Independent researchers should also be encouraged to conduct 
methodological research on the performance of funding agencies independent from the funding 
agencies themselves. 
 
Impact of the projects on funders’ research: 
I presented the results of this project at several research conferences and meetings. This helped to 
engage research funders and to establish a Funders’ Forum. The initial results of the study were 
first presented at the inaugural meeting of the Evidence-Based Research Network in Bergen, 
Norway, in December 2014. Further results were presented at the REWARD conference in 
Edinburgh, Scotland in October 2015.  
Several funding agencies have shown interest in the results of the project. The National Institute 
for Health Research (NIHR) invited me to present the results at a meeting in November 2015 along 
with ZonMW (the main funder of healthcare research in The Netherlands) and the French Ministry 
of Health, and then to discuss how issues raised by the project could be addressed. The project was 
also presented in the Cochrane Colloquium (October 2016) in Vienna, both as a panel and as a 
special session which I led on using systematic reviews to inform future research. Both events 
evoked considerable interest, which resulted in broad agreement that it would be useful to 
conduct a research project to examine how research funders are using - and should use - 
systematic reviews in the process of informing primary research. I was invited afterwards, to 
present the data at a conference to celebrate NIHR’s 10th anniversary in London in May 2016. The 
discussions during this meeting led to the idea of establishing a funders’ forum to address some 
issues raised by the evaluation (in which I have a key role). The Funders’ Forum aims to enable 
funding agencies to exchange experiences in addressing issues and create working groups to 
address them. The Forum had its first meeting on 27 January 2017 in London. It is co-convened by 
individuals from three major research funders: NIHR (UK), ZonMW (Netherlands) and Patient-
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Centered Outcomes Research Institute (PCORI; USA). The forum was officially launched as part of 
the 5th International Conference on Research Integrity in The Hague in May 2017. The next 
meeting will be later in 2017 hosted by PCORI in Washington. The forum is called “Ensuring Value in 
Research (EViR) Funders’ collaboration and Development Forum”. 
Next steps: 
I am working with colleagues on the following research projects as next steps following from the 
projects that comprise this dissertation. Some projects are at the design stage, while others are at 
the data collection stage: 
Research Priority Setting 
1) Conducting informal interviews with individuals working on priority setting across the 
Cochrane Collaboration to identify the barriers and facilitators to implementing more 
structured approaches to setting priorities for Cochrane Reviews (design stage) 
2) Conducting a systematic review of qualitative and quantitative studies that describe or 
evaluate research priority setting projects (data collection stage) 
Funding agencies 
3) Evaluating a wider range of funding agencies including international funders and funding 
agencies based in developing countries (data collection stage) 
4) Developing a conceptual framework for how systematic reviews can be used to inform 
future research in a funding agency (design stage) 
5) Evaluating the REF 2014 impact stories that focus on clinical trials on whether the 
underlying research met some key criteria of the reduce research waste framework (design 
stage) 
Final note: 
Previous studies have shown that robust analysis of what has worked in research can be beneficial 
to inform the allocation of future research funding. Better ways of evaluating the impact of 
research and funding organisations can inform decisions on prioritisation and allocation of funding. 
Although several funding agencies have taken the initiative to evaluate their work, little is being 
done to identify and compare methods and approaches to the evaluation of research impact (98).  
A key problem across most of these organisations is a lack of transparency and accountability, 
which obscures the extent to which their priority setting processes achieve their goals and targets. 
A good example is the current situation in the Cochrane Collaboration. Following publications by 
myself and others and the work of the Cochrane Priority Setting Methods Group, the governing 
board of the Cochrane Collaboration announced a policy requiring all review groups to set priorities 
for topics of systematic reviews. However, it soon became clear that these groups have different 
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goals and opinions about what is best for the Cochrane Collaboration as a whole. I am helping to 
organise a meeting of leaders of Cochrane Review Groups to address these issues. My evaluation of 
funding agencies found a similar lack of transparency and accountability in the context of 
conflicting values among stakeholders that decreases the possibility of accountability and scrutiny 
by researchers and their institutions.  
Research priority setting is almost always a group activity that leads to decisions about topics and 
key questions to investigate and to fund. These decisions define the quality and implications of the 
evidence, and syntheses of it, that become available to patients, public health professionals and 
policy makers to help them make better-informed decisions. It is important that we understand 
how, why and by whom such priority setting decisions are made. My projects and the publications 
they have generated document the characteristics and limitations of the research priority setting 
process in selected key organisations and how research priority setting is related to the allocation 
of resources in these organisations. My research projects demonstrated that a key problem across 
most of these organisations was a lack of transparency and accountability about whether priority 
setting processes are achieving the goals and targets of the organisations. Conversations with 
several of the stakeholders about the results of this project revealed that conflicting views among 
those involved in these processes are a significant cause of this problem. These individuals have 
different views, values and principles. My recommendation is that organisations that set priorities 
for systematic reviews improve how they integrate the diversity of these views and values within 
their processes and structures.  
Regular collection of data is required to monitor whether funding agencies achieve the objectives 
of reducing research waste and enhancing value. It is important that the evaluation is external to 
the organisation to ensure that it is valid and independent. However, it is also necessary to have a 
collaboration with the funders as the internal staff have access to internal data and information 
that external researchers don’t have. The members of EViR forum have developed a set of guiding 
principles based on the different dimensions of reduce research waste framework. I am currently 
working with them in developing ways to measure the performance of the organisations in 
achieving these principles. My recommendation will be that all stakeholders in the research system 
identify measurements to monitor their performances in reducing research waste and regularly 
collect these data to inform their future work.   
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Appendix 1 Selected research output relevant to this PhD  
 MAJOR HONOURS & DISTINCTIONS 
Honour/distinction Date awarded 
2nd place, British Dental Editors Forum (BDEF); Young Dental Communicator 
Award 2014 from the British Dental Journal  for evidence summary 
publications  in British Dental Journal based on a priority setting exercise  
2014 
Bill Silverman Prize awarded by Cochrane for the JCE priority setting papers 2012 
 
 POSTGRADUATE SUPERVISION relevant to projects related to this PhD  
Student/staff Degree and title of thesis Start date Completion 
date (or 
proposed 
completion 
date) 
Anastasios Plessas 
(Director of studies) 
ResM, Impact of stress on the practice of 
dentistry 
 
The topic was selected as part of a research 
priority setting exercise with a systematic 
review followed by primary studies  
Oct 2015 2018 
Zoe Allen (third 
supervisor) 
PhD, Exploring the referral interface between 
general dental practice and salaried dental 
services 
 
The topic was selected as part of a need 
identified by clinicians with a systematic 
review followed by primary studies  
Jan 2013 2018 
Agatha Haines 
(second supervisor) 
PhD, Ideas exchange: Understanding the 
human object – www.cognovo.eu 
 
The project amongst other issue explored how 
the concept of human object affects what 
research questions that researchers ask. 
April 2014  2018 
Dr. Jaysan 
Charlesford  
Postdoctoral fellow, Impact of a community 
and patient-centred dental school on the 
existence and gradient of oral health 
inequalities in Devon and Cornwall 
 
The project was identified as priorities by 
local decision makers and the project explores 
the mismatches between scientific 
expectations and members of public  
May 2017 Nov 2019 
 
 
 
 RESEARCH ACTIVITY  
a) Summary of current research 
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a) Summary of current research 
- Conducing meta-research on how research funders contribute to reducing research waste 
- Meta-research is an evolving scientific discipline that aims to evaluate and improve 
research practices. I lead the work around funding agencies as part of the wider Reduce 
Research Waste initiative (REWARD – www.researchwaste.net). The REWARD initiative is 
an international collaboration with academics from around the world e.g. Stanford 
University (USA), Toronto University (Canada), Bond University (Australia), University of 
Edinburgh (Scotland). For the funding project, I work with ZonMW (a key health care 
research funder in Netherlands), National Institute for Health Research (NIHR) (a key health 
care research funder in UK), French ministry of Health, James Lind Alliance (UK), Queen’s 
University Belfast (Northern Ireland), Bond University (Australia), Norwegian Institute of 
Public Health (Norway), Bergen University College (Norway) and University of Southern 
Denmark (Denmark). I have published the results of this project in Lancet (impact factor 
2015 is 46.119). The project already had clear outputs and impact on the work of other 
organisations and will be part of a new impact story for REF 2020. 
- Oral Health Inequalities - Measuring the impact of the Peninsula Dental Social Enterprise 
(PSDE) and the Dental School on oral health inequalities in Devon and Cornwall. I received 
funding from PDSE to conduct this project. The project involves working with local policy 
makers and academics but also international collaborators from Ottawa University, 
Canada. 
- Cochrane Priority Setting Methods Group (http://priority.cochrane.org): I conduct 
methodological and implementation research as part of an international collaboration of 
researchers and stakeholders with an interest in research priority setting methodology. 
This also included an interdisciplinary project as part of the larger Cognovo project 
(www.cognovo.eu) with colleagues from the arts, humanities and cognitive science. The 
project looked at how the interactive design approach to biomedicine can raise new ways 
to approach research questions that to address clinical problems. The Cochrane Priority 
Setting Methods group is an international collaboration led by me between Plymouth 
University, John Hopkins University (USA), Cambridge University (UK), UCL (UK), Ottawa 
University (Canada), Bihar Monitoring and Evaluation Project (India), Modena University 
(Italy), Melbourne University (Australia). The Journal of Clinical Epidemiology agreed to 
devote a special issue to research priority setting to publish my work along with my 
research collaborators. The results of this project were part of a REF impact story that was 
submitted in 2014 and praised by the REF panel for its reach and significance. There are 
organisations around the world that use the publications to implement new approaches to 
set priorities in their organisation.  
- Conducting and implementing systematic reviews on the effectiveness of healthcare 
interventions and develop methods in this field - (e.g. rehabilitation of astronauts as part 
of the newly established aerospace medicine systematic review group, local consensus 
process for implementing guidelines, updating the mandibular fracture review, updating 
the community-based interventions for promoting child oral health review), developing 
new methods on how to conduct systematic reviews (e.g. developing methods on the use 
of systematic reviews to inform future research, comparing the Cochrane Library with the 
Global Burden of Disease). These projects are part of international collaborations with 
Norwegian Knowledge Centre (Norway), University of Melbourne (Australia), UCL (UK), 
Northumbria University (UK), European Space Agency (Germany), University of Colorado 
(USA), University of Washington (USA) and the Royal Dental Hospital of Melbourne 
(Australia). I have published these projects in well-known academic journals e.g. the BMJ 
(impact factor 2015- 19.697), the Cochrane Library (impact factor 2015- 6.035) and JAMA 
dermatology (impact factor 2015 - 5.097). I am also on the Steering group of “the Global 
Health Trials Methodology Research Agenda: a priority setting exercise” project. The 
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a) Summary of current research 
project intends to identify priorities on trial methodology. The other steering group 
members are based in University of Birmingham (UK), University of Oxford (UK), University 
of Bristol (UK), Queen’s University of Belfast (Northern Ireland), South African Medical 
Research Council (South Africa), Cochrane Innovations (UK), University of College London 
(UK), University of Liverpool (UK), Tianjin University of Traditional Chinese Medicine 
(China).  
- Interdisciplinary research to address priority research questions – I worked with 
academics from different fields to address questions that were prioritized as part of a 
process of stakeholder engagement. One such project, as mentioned above, was 
methodological research on how research priorities are set. Others were priority questions 
identified through consultation with dentists: environmental sustainability in dental 
practices working with experts in this field in the faculty of health; and, in collaboration 
with psychologists, looking at the impact of fear and anxiety on dentists’ performance. 
 
b) Summary of research in the previous three years 
- My work on research priority setting, interdisciplinary research to address priority research 
questions, and systematic reviews has been a key theme in my research over the past 10 
years. Specific highlights from the past three years are: 
- Conducting methodological research on research priority setting – as part of the Cochrane 
Priority Setting Methods Group, I conduct meta-research or evaluation projects in this field. 
A major focus was to evaluate priority setting tools to improve attention to equity in this 
process.  
- Conducting systematic reviews on the effectiveness of healthcare interventions 
(mandibular fractures, approaches to oral health promotion, bonded amalgam for dental 
restorations, understanding differential attainment across medical training pathways) 
- Conducting research on the methodology of systematic reviews: e.g. developing methods 
for dealing with conflicting systematic reviews, and to evaluate the quality and reporting of 
epidemiological studies  
 
d) Relevant research grants and contracts 
Dates Award holder(s) Funding body Title Value 
2016-
2019 
Mona Nasser 
(PI), David Moles 
(CoI) 
Peninsula 
Dental Social 
Enterprise 
(PDSE) 
Impact of a community and patient-centred 
dental school on the existence and gradient of 
oral health inequalities in Devon and Cornwall  
£92,922 
2016-
2017 
David Moles (PI), 
and other co-
investigators, 
(Mona Nasser – 
CoI) 
Dental 
Education and 
Training 
limited 
Developing sustainability in dental practice 
and education through an action research 
approach  
£8,000 
2015-
2018 
Tom Thompson 
(PI) 
And other co-
investigators 
(Mona Nasser – 
CoI) 
National 
Institute for 
Health 
Research 
(NIHR) 
A systematic review of physical activity for 
alcohol and substance use disorders: evidence 
synthesis with stakeholder engagement to 
formulate practical recommendations 
£149,946 
2015 Sam de Regan General Understanding differential attainment across £34,837 
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de Bere (PI) and 
other co-
investigators 
(Mona Nasser – 
CoI) 
Medical 
Council (GMC) 
medical training pathways 
2014-
2015 
Elizabeth Kay 
(PI) and other 
co-investigators 
(Mona Nasser – 
CoI) 
National 
Institute for 
Health and 
Care 
Excellence 
(NICE) 
Production of an evidence review of 
approaches for conveying oral health 
promotion messages by dental teams  
 
£54,628 
2014-
2019 
Stuart Logan (PI) 
and other co-
investigators, 
(Mona Nasser – 
Collaborator) 
National 
Institute for 
Health 
Research 
(NIHR) 
Peninsula Collaborations for Leadership in 
Applied Health Research and Care (CLAHRCs) – 
Theme Evidence synthesis for policy and 
practice 
£10 million 
2014 Janet 
Richardson (PI) 
and other co-
investigators 
(Mona Nasser – 
coI) 
Institute for 
Sustainability 
Solutions 
Research 
(ISSR) small 
collaborative 
award (ISSR 
has been re-
structured as 
Sustainable 
Earth Institute) 
How can dentistry be sustainable? an 
explorative study 
£9,790 
2013-
2017 
Sue Denham (PI) 
and other co-
investigators 
(Mona Nasser – 
CoI) 
EU FP7 Marie 
Curie Initial 
Training 
Network (FP7-
PEOPLE-2013-
ITN-IDP 
604764 
Cognovo: Cognitive Innovation  €4.1m 
2012 David Moles (PI) 
and other co-
investigators 
(Mona Nasser – 
collaborator) 
NHS North 
Devon 
A mixed-method study to investigate the 
referral behaviours and attitudes of NHS 
general dental practitioners in making 
referrals from primary dental care to specialist 
surgical services for the extraction of teeth in 
North Devon 
£5,989 
2011-
2012 
Mona Nasser 
(PI) 
International 
Research, 
Networking 
and 
Collaboration, 
Round 3 
scheme – 
Plymouth 
University  
 
Developing a research programme for 
empirical studies on health research priority 
setting methodology 
£9,574 
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2008- 2011 I worked in the German Institute for Quality and Efficiency in Health care (IQWIG) – the 
German version of National Institute of Clinical Excellence (NICE). As it was a government research 
institute, we were not allowed to apply for external research grants and we were a funder of systematic 
reviews in Germany.  
2007-
2008 
Peter Tugwell 
(PI), and other 
co-investigators. 
Mona Nasser 
(CI) 
The Cochrane 
Collaboration 
Prioritisation 
Fund 
Prioritising Cochrane review topics to reduce 
the know-do gap in low- and middle-income 
countries 
£17,000 
2004-
2005 
Zohreh Ahangari 
(PI), Mahvash 
Oskoi (CI), Mona 
Nasser (CI) 
Iranian Centre 
for Dental 
research, 
Shahid 
Beheshti 
University of 
Medical 
Sciences 
(Tehran, Iran) 
Antimicrobial Activity of Mineral Trioxide 
Aggregate (MTA), Portland cement and 
Calcium  Hydroxide against five oral 
microorganisms. 
The funding 
awarded 
was two 
million 
Iranian 
Toumans, 
equivalent 
at that time 
to about 
£1,400 
 
PUBLICATIONS 
Books - Short Works 
Green LW, Nasser M. Chapter 15: Further Dissemination and Implementation Research: The Need 
for Attention to External validity. In: Brownson RC, Colditz GA, Proctor EK (eds). Dissemination and 
Implementation Research in Health: Translating Science to Practice. New York: Oxford University 
Press; 2012. ISBN13: 9780199751877, ISBN10: 0199751870 (an update will be published in 2017)  
Departmental/Research Working Papers 
Regard De Bere S, Nunn S, Nasser M. Understanding differential attainment across medical training 
pathways: A rapid review of the literature Final report prepared for The General Medical Council 
(GMC). Available at: http://www.gmc-
uk.org/GMC_Understanding_Differential_Attainment.pdf_63533431.pdf 
Journal Letters 
1) Nasser M, Clarke M, Chalmers I, Brurberg KG, Nykvist H, Lund H, Glasziou P. What are 
funders doing to minimise waste in research? Lancet. 2017 Mar 11;389(10073):1006-1007. 
doi: 10.1016/S0140-6736(17)30657-8. 
2) Guyatt G, Montori V, Schunemann H, Alonso-Coello P, Dahm P, Brito Campana JP, Brozek J, 
Nasser M, Meerpohl J, Rind D, Jaeschke R, Fack-Ytter Y, Norris S. Letter reply to GRADE 
guidelines articles 14 and 15. J Clin Epidemiol. 2014 Feb;67(2):240. 
3) Nasser M, Welch V. Prioritisation of systematic reviews leads prioritisation of research gaps 
and needs. J Clin Epidemiol. 2013 May;66(5):522-3. 
4) Nasser M, Welch V, Ueffing E, Crowe S, Oliver S, Carlo R. Evidence in agenda setting: new 
directions for the Cochrane Collaboration. J Clin Epidemiol. 2013 May;66(5):469-71. 
5) Nasser M, Fedorowicz Z. Guest Editorial - Grading the quality of evidence and strength of 
recommendations: the GRADE approach to improving dental Clinical Guidelines. J Appl Oral 
Sci. 2011 Feb;19(1). 
6) Nasser M. Cochrane Column: Best Evidence from The Cochrane Library. Arch Iranian Med 
2007; 10 (2): 285–286. 
7) Nasser M, Tibi A. Ibn Hindu and the science of medicine. Journal of the Royal Society of 
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Medicine 2007; 100:11-05.1–2. 
8) Aljufari H. Nasser M. THC Registers with the Cochrane Handsearching Program. Journal of 
Tehran University Heart Center. 2007; 2 (2): 67.  
9) Nasser M, Nasseri-Moghadam S. "Cochrane Column: Systematic Reviews for Better 
Practice" Archives of Iranian Medicine 2007; 10(1): 135-136. 
Journal Papers - Academic Journals 
1) Winnard A, Nasser M, Debuse D, Stokes M, Evetts S, Wilkinson M, Hides J, Caplan N. 
Systematic Review of countermeasures to minimise physiological changes and risk of injury 
to the lumbopelvic area following long-term microgravity. Musculoskeletal Science and 
Practice. Available online 19 Dec 2016 in press 
http://www.sciencedirect.com/science/article/pii/S2468781216300078  
2) Agnihotry A, Fedorowicz Z, Nasser M, Gill KS. Resorbable versus titanium plates for 
orthognathic surgery. Cochrane Database Syst Rev. 2017 Oct 4;10:CD006204. doi: 
10.1002/14651858.CD006204.pub3. Review. PubMed PMID: 28977689. 
3) Richter C, Braunstein B, Winnard A, Nasser M, Weber T. Human Biomechanical and 
Cardiopulmonary Responses to Partial Gravity - A Systematic Review. Front Physiol. 2017 
Aug 15;8:583. doi: 10.3389/fphys.2017.00583. eCollection 2017. Review. PubMed PMID: 
28860998; PubMed Central PMCID: PMC5559498. 
4) Garner P, Hopewell S, Chandler J, MacLehose H, Schünemann HJ, Akl EA, Beyene J, Chang S, 
Churchill R, Dearness K, Guyatt G, Lefebvre C, Liles B, Marshall R, Martínez García L, 
Mavergames C, Nasser M, Qaseem A, Sampson M, Soares-Weiser K, Takwoingi Y, Thabane 
L, Trivella M, Tugwell P, Welsh E, Wilson EC; Panel for updating guidance for systematic 
reviews (PUGs). When and how to update systematic reviews: consensus and checklist. 
BMJ. 2016 Jul 20;354:i3507. 
5) de Silva AM, Hegde S, Akudo Nwagbara B, Calache H, Gussy MG, Nasser M, Morrice HR, 
Riggs E, Leong PM, Meyenn LK, Yousefi-Nooraie R. Community-based population-level 
interventions for promoting child oral health. Cochrane Database Syst Rev. 2016 Sep 
15;9:CD009837. 
6) Moher D, Glasziou P, Chalmers I, Nasser M, Bossuyt PM, Korevaar DA, Graham ID, Ravaud 
P, Boutron I. Increasing value and reducing waste in biomedical research: who's listening? 
Lancet. 2016 Apr 9;387(10027):1573-86. 
7) Richardson J, Grose J, Manzi S, Mills I, Moles DR, Mukonoweshuro R, Nasser M, Nichols A. 
What's in a bin: A case study of dental clinical waste composition and potential greenhouse 
gas emission savings. Br Dent J. 2016 Jan 22;220(2):61-6. doi: 10.1038/sj.bdj.2016.55.  
8) Grose J, Richardson J, Mills I, Moles D, Nasser M. Exploring attitudes and knowledge of 
climate change and sustainability in a dental practice: A feasibility study into resource 
management. Br Dent J. 2016 Feb 26;220(4):187-91. doi: 10.1038/sj.bdj.2016.136. 
9) Karimkhani C, Trikha R, Aksut B, Jones T, Boyers LN, Schlichte M, Pederson H, Okland T, 
DiGuiseppi C, Nasser M, Naghavi M, Vos T, Yoong SL, Wolfenden L, Murray CJ, Dellavalle 
RP. Identifying gaps for research prioritisation: Global burden of external causes of injury as 
reflected in the Cochrane Database of Systematic Reviews. Injury. 2016 Jan 12. pii: S0020-
1383(15)00835-9. 
10) Agnihotry A, Fedorowicz Z, Nasser M. Adhesively bonded versus non-bonded amalgam 
restorations for dental caries. Cochrane Database Syst Rev. 2016 Mar 8;3:CD007517 
11) Ahangari Z, Nasser M, Mahdian M, Fedorowicz Z, Marchesan MA. Interventions for the 
management of external root resorption. Cochrane Database Syst Rev. 2015 Nov 
24;11:CD008003. doi: 10.1002/14651858.CD008003.pub3. Review. PubMed 
PMID:26599212. 
12) Sequeira-Byron P, Fedorowicz Z, Carter B, Nasser M, Alrowaili EF. Single crowns versus 
conventional fillings for the restoration of root-filled teeth. Cochrane Database Syst Rev. 
2015 Sep 25;9:CD009109. 
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13) Bhaumik S, Karimkhani C, Czaja CA, Williams HC, Rani M, Nasser M, Boyers LN,Dmitruk S, 
Dellavalle RP. Identifying gaps in research prioritisation: The global burden of neglected 
tropical diseases as reflected in the Cochrane database of systematic reviews. J Family Med 
Prim Care. 2015 Oct-Dec;4(4):507-13. doi:10.4103/2249-4863.174266. 
14) Bhaumik S, Rana S, Karimkhani C, Welch V, Armstrong R, Pottie K, Dellavalle R, Dhakal P, 
Oliver S, Francis DK, Nasser M, Crowe S, Aksut B, Amico RD. Ethics and equity in research 
priority-setting: stakeholder engagement and the needs of disadvantaged groups. Indian J 
Med Ethics. 2015 Apr-Jun;12(2):110-3. Epub 2015 Mar 16.  
15) *Pederson H, Okland T, Boyers LN, Karimkhani C, Rosenfeld RM, Nasser M, Yoong SL, 
Wolfenden L, Kyu HH, Serina PT, Coggeshall M, Dellavalle RP. Identifying otolaryngology 
systematic review research gaps: comparing Global Burden of Disease 2010 results with 
Cochrane Database of Systematic Review content. JAMA Otolaryngol Head Neck Surg. 2015 
Jan;141(1):67-72. 
16) Karimkhani C, Boyers LN, Prescott L, Welch V, Delamere FM, Nasser M, Zaveri A, Hay RJ, 
Vos T, Murray CJ, Margolis DJ, Hilton J, Maclehose H, Williams HC, Dellavalle RP. Global 
Burden of Skin Disease as Reflected in Cochrane Database of Systematic Reviews. JAMA 
Dermatol. 2014 May 7. doi: 10.1001/jamadermatol.2014.709. [Epub ahead of print] 
17) Shamliyan T, Ansari MT, Raman G, Berkman N, Grant M, Janes G, Maglione M, Moher D, 
Nasser M, Robinson K, Segal J & Tsouros S. Development and Implementation of the 
Standards for Evaluating and Reporting Epidemiologic Studies on Chronic Disease Incidence 
or Prevalence. American Journal of Public Health Research, 2013; 1 (7):183-190. DOI: 
10.12691/ajphr-1-7-7 http://pubs.sciepub.com/ajphr/1/7/7/ - This is a peer reviewed 
publication of part of an AHRQ report which also is peer reviewed and has a range of 
consultation that I was involved http://www.ncbi.nlm.nih.gov/books/NBK53272/. 
18) Fedorowicz Z, van Zuuren EJ, Nasser M, Carter B, Al Langawi JH. Oral rinses, mouthwashes 
and sprays for improving recovery following tonsillectomy. Cochrane Database Syst Rev. 
2013 Sep 10;9:CD007806. doi: 10.1002/14651858.CD007806.pub4. PubMed PMID: 
24022333. 
19) Nasser M, Pandis N, Fleming PS, Fedorowicz Z, Ellis E, Ali K. Interventions for the 
management of mandibular fractures. Cochrane Database Syst Rev. 2013 Jul 8;7:CD006087. 
20) (T) Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, Rind D, 
Montori VM, Brito JP, Norris S, Elbarbary M, Post P, Nasser M, Shukla V, Jaeschke R, Brozek 
J, Djulbegovic B, Guyatt G. GRADE guidelines: 15. Going from evidence to recommendation-
determinants of a recommendation's direction and strength. JClin Epidemiol. 2013 
Jul;66(7):726-35. doi: 10.1016/j.jclinepi.2013.02.003. Epub 2013 Apr 6. PubMed PMID: 
2357074 
21) Nasser M, Ueffing E, Welch V, Tugwell P. An equity lens can ensure an equity-oriented 
approach to agenda setting and priority setting of Cochrane Reviews. J Clin Epidemiol. 2013 
May;66(5):511-21. 
22) (T) Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, Nasser M, Meerpohl 
J, Post PN, Kunz R, Brozek J, Vist G, Rind D, Akl EA, Schünemann HJ. GRADE guidelines: 14. 
Going from evidence to recommendations: the significance and presentation of 
recommendations. J Clin Epidemiol. 2013 Jul;66(7):719-25.  
23) *Nasser M, Welch V, Tugwell P, Ueffing E, Doyle J, Waters E. Ensuring relevance for 
Cochrane reviews: evaluating processes and methods for prioritizing topics for Cochrane 
reviews. J Clin Epidemiol. 2013 May;66(5):474-82. 
24) Fedorowicz Z, Nasser M, Sequeira-Byron P, de Souza RF, Carter B, Heft M. Irrigants for non-
surgical root canal treatment in mature permanent teeth. Cochrane Database Syst Rev. 
2012 Sep 12;9:CD008948. doi: 10.1002/14651858.CD008948.pub2. Review. PubMed PMID: 
22972129. 
25) Fedorowicz Z, Nasser M, Jagannath VA, Beaman JH, Ejaz K, van Zuuren EJ. Beta2-
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adrenoceptor agonists for dysmenorrhoea. Cochrane Database Syst Rev. 2012 May 
16;5:CD008585. PubMed PMID: 22592732. 
26) de Souza RF, Lovato da Silva CH, Nasser M, Fedorowicz Z, Al-Muharraqi MA. Interventions 
for the management of temporomandibular joint osteoarthritis. Cochrane Database Syst 
Rev. 2012 Apr 18;4:CD007261. PubMed PMID: 22513948. 
27) Nasser M, van Weel C, van Binsbergen JJ, van de Laar FA. Generalizability of systematic 
reviews of the effectiveness of health care interventions to primary health care: concepts, 
methods and future research. Fam Pract. 2012 Apr;29 Suppl 1:i94-i103. 
28) Nasser M, Javaheri H, Fedorowicz Z, Noorani Z. Carnitine supplementation for inborn errors 
of metabolism. Cochrane Database Syst Rev. 2012 Feb 15;2:CD006659 
29) Nasser M. Evidence summary: can plastics used in dentistry act as an environmental 
pollutant? Can we avoid the use of plastics in dental practice? Br Dent J. 2012 Jan 
27;212(2):89-91. doi: 10.1038/sj.bdj.2012.72. PubMed PMID: 22281636. 
30) Bastian H, Scheibler F, Knelangen M, Zschorlich B, Nasser M, Waltering A. Choosing health 
technology assessment and systematic review topics: the development of priority-setting 
criteria for patients' and consumers' interests. Int J Technol Assess Health Care. 2011 
Oct;27(4):348-56. PubMed PMID: 22004776. 
31) Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Falck-
Ytter Y, Jaeschke R, Vist G, Akl EA, Post PN, Norris S, Meerpohl J, Shukla VK, Nasser M, 
Schünemann HJ; GRADE Working Group. GRADE guidelines: 8. Rating the quality of 
evidence--indirectness. J Clin Epidemiol. 2011 Dec;64(12):1303-10. Epub 2011 Jul 30. 
PubMed PMID: 21802903. 
32) Nasser M. Evidence summary: which dental liners under amalgam restorations are more 
effective in reducing postoperative sensitivity? Br Dent J. 2011 Jun 10;210(11):533-7. doi: 
10.1038/sj.bdj.2011.461. PubMed PMID: 21660022.  
33) Kerr AR, Warnakulasuriya S, Mighell AJ, Dietrich T, Nasser M, Rimal J, Jalil A, Bornstein MM, 
Nagao T, Fortune F, Hazarey VH, Reichart PA, Silverman S, Johnson NW. A systematic 
review of medical interventions for oral submucous fibrosis and future research 
opportunities. Oral Dis. 2011 Apr;17 Suppl 1:42-57. 
34) Shamliyan TA, Kane RL, Ansari MT, Raman G, Berkman ND, Grant M, Janes G, Maglione M, 
Moher D, Nasser M, Robinson KA, Segal JB, Tsouros S. Development quality criteria to 
evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic 
diseases: pilot study of new checklists. J Clin Epidemiol. 2011 Jun;64(6):637-57. doi: 
10.1016/j.jclinepi.2010.08.006. Epub 2010 Nov 11. PubMed PMID: 21071174. 
35) Nasser M. Evidence summary: is smoking cessation an effective and cost-effective service 
to be introduced in NHS dentistry? Br Dent J. 2011 Feb 26;210(4):169-77. 
36) Pedrazzi V, de Oliveira-Neto JM, Sequeira P, Fedorowicz Z, Nasser M. Hand and ultrasonic 
instrumentation for orthograde root canal treatment of permanent teeth. J Appl Oral Sci. 
2010 Jun;18(3):268-72. 
37) Pedrazzi V, Oliveira-Neto JM, Sequeira P, Fedorowicz Z, Nasser M. Hand and ultrasonic 
instrumentation for orthograde root canal treatment of permanent teeth. Cochrane 
Database of Systematic Reviews 2008, Issue 4. Art. No.: CD006384. DOI: 
10.1002/14651858.CD006384.pub3. 
38) Nasser M, Aljufairi H, McKerrow WS, Fedorowicz Z. Antihistamines as an adjunct to topical 
nasal steroids for intermittent and persistent allergic rhinitis in children. Cochrane 
Database of Systematic Reviews 2008, Issue 1. 
39) de Souza RF, Chaves Cde A, Nasser M, Fedorowicz Z. A quantitative and qualitative 
evaluation of reports of clinical trials published in six Brazilian dental journals indexed in 
the Scientific Electronic Library Online (SciELO). J Appl Oral Sci. 2010 Apr;18(2):104-9. 
40) Sharif MO, Fedorowicz Z, Drews P, Nasser M, Dorri M, Newton T, Oliver R. Interventions for 
the treatment of fractures of the mandibular condyle. Cochrane Database of Systematic 
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Reviews 2010, Issue 4. 
41) Chalkidou K, Tunis S, Lopert R, Rochaix L, Sawicki PT, Nasser M, Xerri B. Comparative 
effectiveness research and evidence-based health policy: experience from four countries. 
Milbank Q. 2009 Jun;87(2):339-67. 
42) Al-Muharraqi MA, Fedorowicz Z, Al Bareeq J, Al Bareeq R, Nasser M. Botulinum toxin for 
masseter hypertrophy. Cochrane Database of Systematic Reviews 2009, Issue 1. 
43) Dorri M, Nasser M, Oliver R. Resorbable versus titanium plates for facial fractures. 
Cochrane Database of Systematic Reviews 2009, Issue 1.  
44) Nasser M, Tibi A, Savage-Smith E. Ibn Sina's Canon of Medicine: 11th century rules for 
assessing the effects of drugs. J R Soc Med. 2009 Feb;102(2):78-80. 
45) Fedorowicz Z, Aljufairi H, Nasser M, Outhouse TL, Pedrazzi V. Mouthrinses for the 
treatment of halitosis. Cochrane Database of Systematic Reviews 2008, Issue 4. 
46) Nasser M, Fedorowicz Z, Khoshnevisan MH, Shahiri Tabarestani M. Acyclovir for treating 
primary herpetic gingivostomatitis. Cochrane Database of Systematic Reviews 2008, Issue 
4. Art. No.: CD006700. 
47) Nasser M, Eisinga A, Al-hajeri A, Fedorowicz Z. Identifying search terms likely to retrieve 
report of randomized trials in Iranmedex – a pilot project. Bahrain Medical Bulletin 2008. 
30 (3). 
48) Nasser M, Eisinga A, Al-hajeri A, Fedorowicz Z. Assessment of methodological quality for 
reporting of randomized trials in four Iranian healthcare Journals. Bahrain Medical Bulletin 
2008. 30 (3). 
49) Fedorowicz Z, Chan Shih-Yen E, Dorri M, Nasser M, Newton T, Shi L. Interventions for the 
management of oral submucous fibrosis. Cochrane Database of Systematic Reviews 2008. 
Issue 4. 
50) Nasser M, Fedorowicz Z, Ebadifar A. A Cochrane systematic review finds no reliable 
evidence for different management options for the fractured edentulous atrophic 
mandible. Gen Dent. 2008 May-Jun;56(4):356-62. 
51) Nasser M, van Binsbergen J, Javaheri H, Yassiny K. Diet and nutrition advice from The 
Cochrane Library: is it useful for the consumers and family physicians? Fam Pract. 2008 Oct 
26. 
52) Nasser M, Fedorowicz Z, Newton JT, Nouri M. Interventions for the management of 
submucous cleft palate. Cochrane Database of Systematic Reviews 2008, Issue 1. 
53) Fedorowicz Z, Waters E, Tugwell P, Nasser M. Health research priority setting in developing 
countries of the Eastern Mediterranean region: partnering with the Cochrane 
Collaboration. Eastern Mediterranean Health Journal. 2007; 13 ( 3); 727-730.  
54) Nasser M, Al Hajeri A. A comparison of handsearching versus embase searching of the 
archives of Iranian medicine to identify reports of randomized controlled trials. Arch Iran 
Med. 2006 Jul; 9(3):192-5. 
55) Ahangari Z, Ashraf H, Oskooi M, Soltani Sh, Nasser M. Antibacterial activity of three 
endodontic sealers with various bases. Beheshti Univ Dent J 2005; 22(Special issue):1-6. 
Official Reports: Whole Report 
1) Shamliyan TA, Kane RL, Ansari MT, Raman G, Berkman ND, Grant M, Janes G, Maglione M, 
Moher D, Nasser M, Robinson KA, Segal JB, Tsouros S. Development of Quality Criteria To 
Evaluate Nontherapeutic Studies of Incidence, Prevalence, or Risk Factors of Chronic Diseases: 
Pilot Study of New Checklists [Internet]. Rockville (MD): Agency for Healthcare Research and 
Quality (US); 2011 Jan. Available from 
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=methresdisease 
2) Nasser M, Sawicki P. Institute for Quality and Efficiency in Health Care: Germany. Issue Brief 
(Commonw Fund). 2009 Jul;57:1-12. The full report was published on the Commonwealth fund 
website on 28 July 2009 
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http://www.commonwealthfund.org/Content/Publications/Other/2009/Comparative-
Effectiveness-Across-Countries.aspx  
Other Publications – Research 
1) Karimkhani C, Boyers LN, Nasser M, Dellavalle R. Mapping research prioritisation by The 
Cochrane Collaboration to Global Burden of Disease 2010 data. Cochrane Methods. Issue 
September 2014. 
http://www.thecochranelibrary.com/SpringboardWebApp/userfiles/ccoch/file/Files/Coch_
Methods2014.pdf  
2) Nasser M, Crowe S, Welch V, Ueffing E. Proposed Agenda setting and priority setting 
methods group. Cochrane Methods. Cochrane DB Syst Rev 2011 Suppl 1: 37-38. 
http://www.cochrane.org/sites/default/files/newsletters/coch_meth_2011.zip 
3) Nasser M. Priority setting in the Cochrane Collaboration. Cochrane Methods. Cochrane DB 
Syst Rev 2010 Suppl 1: 6. 
http://www.cochrane.org/sites/default/files/uploads/Newsletters/Cochrane%20Methods
%202010.pdf 
4) Fox DM, Nasser M. Informing the politics of prioritizing (and funding) systematic reviews: 
another potential step for the Agenda and Priority Setting Methods Group. Cochrane 
Methods Supplement 2013. ISSN: 2044-4702. 
http://www.thecochranelibrary.com/SpringboardWebApp/userfiles/ccoch/file/Files/Cochr
ane%20Methods%202013.pdf 
5) Pooler J, Nasser M. Challenges in conducting priority setting exercises for Cochrane 
entities. Cochrane Methods Supplement 2013. ISSN: 2044-4702. 
http://www.thecochranelibrary.com/SpringboardWebApp/userfiles/ccoch/file/Files/Cochr
ane%20Methods%202013.pdf 
6) Nasser M, Tibi A, Savage-Smith E. Ibn Sina’s Canon of Medicine: 11th century rules for 
assessing the effects of drugs. The James Lind Library. (www.jameslindlibrary.org). 
Accessed Sunday 6 July 2008. 
7) Nasser M, Tibi A (2006). Ibn Hindu and the science of medicine. The James Lind Library 
(www.jameslindlibrary.org). 
Other Publications - Research Equivalent 
I wrote blog post for the following websites 
1) Cochrane Blog - What is a good topic for a Cochrane Review? What is a “real uncertainty”? 
http://www.cochrane.org/news/blog/what-good-topic-cochrane-review-what-
%E2%80%9Creal-uncertainty%E2%80%9D 
2) British Medical Journal (BMJ) blogs - How can research publication be improved? 
http://blogs.bmj.com/bmj/2015/09/30/mona-nasser-how-can-research-publication-be-
improved/ 
3) ISSR blog (currently ISSR is called Earth Sustainability Institute) - Uncertainties, knowledge 
gaps and research priorities. Uncertainties, knowledge gaps and research priorities 
http://issrplymuni.blogspot.co.uk/2013/08/june-2013-uncertainties-knowledge-gaps.html  
Other Media - Research 
There is a short interview with me in the Anniversary video of Cochrane talking about the Priority 
Setting Methods Group http://www.youtube.com/watch?v=iaAmnAXOSwA#t=102 at time 1:40. I 
have also been asked by the Pan American Health Organisation (PAHO), which serves as the 
regional office for World Health Organisation (WHO) in the Americas, to host and run four webinars 
on my work on research priority setting. I ran the webinars but did not edit or prepare the videos. 
 
1) Session one – Meet the Methods Group: An introduction to the Cochrane Priority Setting 
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Methods Group - http://www.youtube.com/watch?v=Y1bCO3wNZOY 
2) Session two – An Equity Lens for Priority-Setting Approaches in Systematic Reviews 
http://www.youtube.com/watch?v=0OT2C0bMO5Y 
3) Priority Setting for Cochrane Review Groups: Tips, Tricks, and Case Studies 
http://www.youtube.com/watch?v=WlP0V96uubI 
 
Public Appearances (research-related only) 
 Interviews - I have been interviewed about my work with Cochrane by state TV in Bosnia (I 
was keynote speaker at the first Cochrane symposium in Bosnia). In 2007, I was 
interviewed for my work to get patient and consumers involved in systematic reviews in 
Iran (Cochrane Consumer Network https://youtu.be/HvXNN8gUexI). I have also been 
interviews as part of a series for videos to celebrate the 20th Anniversary of Cochrane. It 
celebrates the work of researchers like me who designed and implemented projects that 
contributed to the goal of the Collaboration (www.cochrane.org), the leading evidence 
based health organisations in the world. I have been interviewed in three videos: 
o Cochrane Authors https://youtu.be/fAmepEVL4cs 
o Working together in the Collaboration https://youtu.be/IJInSOZG6vQ 
o Happy Anniversary Cochrane Collaboration IV https://youtu.be/iaAmnAXOSwA  
 Social Media - I run a personal blog http://monanasser.workdpress.com and a twitter 
account @monalisa1n. I talk about my research along with my personal interests in 
aviation. This makes the public more engaged. With others, I also run research focus 
twitter accounts @capsmg (priority setting) @ebrnetwork (evidence based research 
network) and sometimes curate twitter chats on issues faced by Cochrane authors 
(#cochraneauthor). As part of this project, I curated other research-focused twitter 
accounts. These are the reports: 
o Introduction - Smiling wide and flying high – Mona Nasser joins Real Scientists 
http://realscientists.wordpress.com/2014/07/13/smiling-wide-and-flying-high-mona-nasser-
joins-real-scientists/ 
o Final report - Crowdsourcing the best in science: thanks and farewell to Mona Nasser 
http://realscientists.wordpress.com/2014/07/20/crowdsourcing-the-best-in-science-thanks-
and-farewell-to-mona-nasser/  
o Curating @wepublichealth 22-28 Sep 2014 
http://blogs.crikey.com.au/croakey/wepublichealth-an-experiment-in-citizen-journalism-
meets-public-health/  
o Curating @wethehumanities 12-19 Jan 2015 
https://wethehumanities.wordpress.com/2015/01/10/12th-19th-january-mona-nasser/ 
 Press Releases- There were a few press releases based on my research: 
o International lecture links 10th-century medical philosophy to computer simulation in 
medical research: This was picked up by a few other websites for example: Medical Express, 
Science newsline. It was even translated and reported in an Iranian journal. 
o Review addresses value and waste in biomedical research: This was picked up by other news 
sources like Science Daily 
o Plymouth academic to support Bosnian-Herzegovinian scientists on setting priorities for 
medical research. The event was also reported in an editorial “Mahmic-Kaknjo M, Novo A, 
Krleza-Jeric K. FIRST BH COCHRANE SYMPOSIUM HELD. Mater Sociomed. 2016 Feb;28(1):74-
6.” 
o International role for dental school academic: This was picked up by other news sources like 
dentistry.co.uk 
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c) Conferences 
Major conferences attended over the last three years (including current year) plus any significant participation in previous years. – I marked the one that I 
was invited speaker in blue 
Dates Title Nature of involvement 
30 November - 1 
December 2017 
Funding bodies and late 
modern science,  Utrecht 
University, Cultural History 
Research Group and Descartes 
Centre,  
Oral presenter 
Nasser M, Reijmerink W. How research funders respond to the call for reducing research waste and 
ensuring responsible research conduct 
5 Oct 2017 Health and Care Research 
Wales conference 2017, 
Cardiff. 5 Oct 2017 
Invited Speaker  
Nasser M. How research funders respond to the call for reducing research waste and ensuring 
responsible research conduct. Health and Care Research Wales conference 2017, Cardiff. 5 Oct 
2017 
25-29 Sep 2017 68th International 
Astronautical Congress, 
Adelaide, Australia 
Contributor to an oral presentation that was accepted 
Velho R, Winnard A, Nasser M, Gradwell D, Winnard A, Boudreau E Introducing an aerospace 
medicine systematic review group. 
13-16 Sep 2017 Global Evidence Summit, Cape 
Town, South Africa 
Contributor to a poster presentation - Nasser M, Winnard A, Velho R, Welch V. Introducing an 
aerospace medicine systematic review group. 
16-18 august 
2017 
Off the lip, Plymouth, UK Oral presentation-  Nasser M. The concept of creativity and innovation in setting priorities 
for research 
28-31 May 2017 Work Research integrity 
conference, Amsterdam, 
Netherlands 
Invited speaker - How can research funders add value to research as part of a special session on 
responsible research conduct for funding agencies 
29 April – 4 May 
2017 
ASMA - 88th Annual Scientific 
Meeting of the Aerospace 
Medical Association, Denver 
USA, 
Contributor to an oral presentation that was presented 
Winnard A, Nasser M, Gradwell D, Winnard A, Velho R, Boudreau E Introducing an aerospace 
medicine systematic review group.  
7-9 Dec 2016 International Evidence-Based 
Health Care Society Congress, 
Keynote speaker – “Our roles and responsibilities in reducing research waste.”  
I also helped in the negotiation between Cochrane and the Ministry of Health in Iran to establish 
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Kish, Iran Cochrane Iran 
23 -27 Oct 2016 Cochrane Colloquium in Seoul, 
South Korea.  
 
I organised and presented in a special session focusing on reducing research waste. I gave a talk on 
how funders can contribute to reducing research waste. As part of the preparation of the special 
session, I worked with Sylvia De Haan to organise a survey to inform the session.  
Nasser M, Wood J, De Haan S, Glasziou P – Special Session: Cochrane and REWARD –Is there more 
we can do to address the problem. Cochrane Colloquium 23-27 Oct 2016, Seoul, South Korea 
A blog post was written by Sylvia De Haan following session 
http://community.cochrane.org/news/reducing-research-waste-%E2%80%93-messages-cochrane-
community  
In another session I gave a long oral presentation on how funders currently contribute to reducing 
research waste  
(Nasser M, Clarke M, Chalmers I, Bruberg KG, Nukvist H, Lund H, Glasziou P. What funders do to 
minimize waste in research. Cochrane Colloquium 23-27 Oct 2016, Seoul, South Korea). 
I organised two workshops, one focusing on reporting guidelines for priority setting and the other 
one on using systematic reviews to inform future research. I also organised and chaired the 
meetings for the Cochrane Priority Setting Methods Group and Evidence-Based Research Network. 
As I am a member of the Governing Board and a Trustee of Cochrane, I also attended a 3-day board 
meeting during the Colloquium in Seoul.  
18 May 2016 NIHR 10th year anniversary Invited speaker - I gave a talk on role of funders in reducing research waste in a special meeting 
during the conference celebrating 10 years of NIHR.  
12th Oct 2015 “Prospect of Evidence- Based 
Medicine and Cochrane in 
Bosnia and Herzegovina”, 
Sarajevo, Bosnia and 
Herzegovina 
http://mf.unsa.ba/podaci/kon
gresi_seminari_skupovi/Cochr
ane_program.pdf  
Invited speaker – title of talk – “Setting priorities in Clinical Research”. We issued a press release 
associated with it. https://www.plymouth.ac.uk/news/plymouth-academic-to-support-bosnian-
herzegovinian-scientists-on-setting-priorities-for-medical-research 
2 Oct 2015 2015 Annual Cochrane 
Methods Symposium, Vienna, 
Invited speaker – “Towards an evidence informed approach to set priorities for topics of systematic 
reviews.”  
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Austria 
3-7 Oct 2015 Cochrane Colloquium in 
Vienna, Austria 
I had two oral presentations: 
Nasser M et al. “EBRNetwork – a call to action for more (efficient) systematic reviews”, 3-7th Oct 
2015, Cochrane Colloquium, Vienna, Austria. 
Nasser M, Glasziou P, Chalmers I, Clarke M. “Do international funders use systematic reviews to 
inform future funding decisions?” Special Session: “Systematic reviews guiding future research: 
opportunities and challenges”. 3-7th Oct 2015, Cochrane Colloquium, Vienna, Austria.  
I organised a special session on using systematic reviews to inform future research involving 
different stakeholders, including funders, journal editors, etc. I presented the funder project again 
as part of the special session. I also organised and chaired the Priority Setting Methods Group 
meeting and Evidence-Based Research Network meeting and organised the following workshops: 
Akl E, Brunnhuber K, Lund H, Mbuagbaw L, Nasser M, Robinson K, Schuenneman H. Using Cochrane 
reviews to inform future research (workshop), 3-7th Oct 2015, Cochrane Colloquium, Vienna, 
Austria. 
Bhaumik S, Crowe S, Morley R, Nasser M, Pardo J, Synnot A, Tong A, Welsh E. Practical approaches 
to conducting an evidence-informed research priority-setting exercise (workshop).  
Bhaumik S, Dellavalle, Karimkhani, Nasser M. Using Global Burden of Disease database to inform 
priority setting (workshop), 3-7th Oct 2015, Cochrane Colloquium, Vienna, Austria. 
As I am a member of the Governing Board and a Trustee of Cochrane, I also attended a 3-day board 
meeting during the Colloquium in Vienna 
28-30 Sep 2015 The inaugural 
EQUATOR/REWARD 
Conference, Edinburgh, 
Scotland. 
I gave an oral presentation during this conference 
Nasser M, Glasziou P, Chalmers I. Do international funders use systematic reviews to inform future 
funding decisions, 28-30 Sep 2015 the inaugural EQUATOR/REWARD conference, Edinburgh, 
Scotland. I also helped in advocating the use of social media to encourage reduced research waste, 
and by giving interviews and organising discussions.  
14-16 Sep 2015 British Social of Orofacial and 
Dental Research conference 
I gave an oral presentation . Nasser M, Karimkhani C, Dellavalle R. Global burden of oral and 
oropharyngeal diseases in 2010 as reflected in Cochrane Database of Systematic Reviews 
(16.09.2015), 14-16 Sep BSODR 2015, Cardiff, UK. 
My PhD student also gave an oral presentation.  Allen Z, Nasser M, Stenhouse E, Richardson J, 
Moles, DR. Referral pathways from general dental services to other primary dental care services in 
the UK: A systematic review and critical interpretive synthesis (15.09.2015), 14-16 Sep BSODR 2015, 
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Cardiff, UK. 
4 June 2015 Fifth and final event of 
Avicenna: a strategy for in 
silico clinical trials, Barcelona, 
Spain 
http://avicenna-
isct.org/events/event-5/  
http://avicenna-isct.org/wp-
content/uploads/2015/02/Avi
cenna-Event-5-Agenda.pdf  
Invited speaker – “Avicenna’s Canon of Medicine: rules for assessing the effectiveness of drugs” 
3 Dec 2014 1st Evidence Based Research 
Network Symposium  
http://ebrnetwork.org/wp-
content/uploads/2015/02/Mo
na-Nasser.pptx  
Invited speaker – Survey of funders 
16 June 2014 The Campbell Colloquium, 
Belfast, Northern Ireland 
Invited speaker to give the opening plenary on research priority setting. The talk is available on 
youtube https://www.youtube.com/watch?v=YaB074Rgg7w 
2 May 2014 The Third Annual ISSR 
Sustainability Research Event 
2014. Challenge Accepted! 
Creating Solutions for Horizon 
2020 
http://www1.plymouth.ac.uk/
research/issr/Pages/The-
Third-Annual-ISSR-
Sustainability-Research-Event-
2014.aspx 
 
Invited speaker – “Using Research Priority Setting Methods to identify uncertainties on 
sustainability issues: an example from the dental school” 
 
The Presentation is available on youtube https://www.youtube.com/watch?v=5b3_qGu2URY 
 
19-23 Sep 2013 21th Cochrane Colloquium in 
Quebec City, Canada. 19-23 
Workshop - Nasser M, Crowe S, Welch V, Ueffing E, Li T. Priority Setting Exercise for a Cochrane 
entity. 21th Cochrane Colloquium in Quebec City, Canada. 19-23 Sep 2013. 
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Sep 2013. I also organised and presented in a special session on Developing evidence in a responsive 
approach. I gave a talk on Prioritisation of topics in Cochrane at the micro, meso and macro level 
and chaired the discussion 
I organised and chaired the Priority Setting Methods Group meeting 
There are blog posts available on those sessions 
http://methods.cochrane.org/prioritysetting/blog/special-session-developing-evidence-responsive-
approach 
http://methods.cochrane.org/prioritysetting/blog/special-session-developing-evidence-responsive-
approach 
As I am a member of the Governing Board and a Trustee of Cochrane, I also attended a 3-day board 
meeting during the Colloquium in Quebec. 
 
9-11 Sep 2013 BSODR Annual Meeting – 
Bath, UK 9-11 Sep 2013 
Poster - Nasser M, Javaheri H. Oral Health Research Priority setting: systematic review with 
interpretive analysis (Poster) BSODR Annual Meeting – Bath, UK 9-11 Sep 2013 
28 - 31 August 
2013 
ADEE, 28 - 31 August 2013, 
Birmingham, UK. 
Two posters: 
Nasser M, Moles DR. An evidence-informed approach to developing a postgraduate dental 
education module (Poster). 39th ADEE ANNUAL MEETING, Electronic Learning @ADEE, 28 - 31 
August 2013, Birmingham, UK. 
Nasser M, Moles DR. An evidence-informed approach to developing a mentorship programme for 
dental academic trainees (Poster). 39th ADEE ANNUAL MEETING, Electronic Learning @ADEE, 28 - 
31 August 2013, Birmingham, UK. 
30 Sep – 3 Oct 
2012 
Cochrane Colloquium 30 Sep – 
3 Oct 2012, Auckland, New 
Zealand 
Oral presentation - Nasser M, Carlo R, Crowe S, Welch V. Challenges in conducting priority-setting 
exercises for Cochrane entities (oral) Cochrane Colloquium 30 Sep -3 Oct 2012, Auckland, New 
Zealand. 
Workshop - Nasser M, Crowe S, Li Tianjing. Personalising research priority-setting exercises: 
developing a research priority-setting exercise to achieve the objectives of a Cochrane entity 
(workshop) Cochrane Colloquium 30 Sep – 3 Oct 2012, Auckland, New Zealand 
I organised and chaired the Cochrane priority setting methods group meeting 
As I am a member of the Governing Board and a Trustee of Cochrane, I also attended a 3-day board 
meeting during the Colloquium in Auckland 
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12-15 Sep 2012 IADR/PER, 12-15 Sep 2012, 
Helsinki, Finland. 
Oral presentation - Nasser M, Fedorowicz Z, Sequeira-Byron P, Freitas de Souza R, Carter B, Heft M. 
Endodontic Irrigants in Root Canal Treatment: a Comparative Effectiveness Review. IADR/PER, 12-
15 Sep 2012, Helsinki, Finland. 
19-22 October 
2011 
Cochrane Colloquium 2011, 
Madrid, Spain.  
 
Nasser M, Ueffing E, Tugwell P, Welch V, Chalkidou K, Sawicki P, Crowe S. Evaluating research 
priority setting approaches: tools for a Cochrane methodology review. (oral) Cochrane Colloquium 
2011, Madrid, Spain. 
Nasser M, Welch V, Crowe S, Oliver S, Liberati A. Cochrane agenda setting and priority setting 
methods group: establishing a research methods program (oral) Cochrane Colloquium 2011, 
Madrid, Spain.  
Nasser M, van Weel C, van Binsebergen JJ, van de Laar F, Buechter R. External validity of systematic 
reviews in primary care: adapting the methodology to conduct reviews (poster) Cochrane 
Colloquium 2011, Madrid, Spain.  
I also chaired and organised the Cochrane priority setting methods group meeting. 
As I am a member of the Governing Board and a Trustee of Cochrane, I also attended a 3-day board 
meeting during the Colloquium in Madrid. 
12-15 Sep 2011 BSODR/IADR, 12-15 Sep 2011, 
Sheffield, UK. 
Poster - Nasser M, Fedorowicz Z. External validity of trials on smoking cessation in Dental Practice. 
BSODR/IADR, 12-15 Sep 2011, Sheffield, UK. 
Dec 2010 "Practice-based Evidence for 
Weight Management: Alliance 
between Primary Care and 
Public Health" sixth Heelsum 
workshop, Heelsum 
Collaboration, Heelsum, 
Netherlands 
Invited speaker - External validity and generalizability of systematic reviews in primary health 
care: adapting the methodology to conduct the review 
18 - 22 October 
2010 
Cochrane Colloquium 2010, 
Keystone, Co, USA 
1) Nasser M, Tugwell P, Welch V, Ueffing E, Oliver S, Crowe S, Buckley B, Rader T, Lydiatt A. 
Agenda setting: Evidence & Equity. (workshop) Cochrane Colloquium 2010, Keystone, Co, USA. 
2) Rader T, Lyddiatt A, Cattivera C, Gunderson J, Idzerda L, Nasser M, Maxwell L, Tanjong-
Ghogomu E. International Panel for Consumers in Arthritis Research: an initiative of the 
Cochrane Musculoskeletal Group. (Oral) Cochrane Colloquium 2010, Keystone, Co, USA. 
3) Nasser M, van Binsbergen JJ, van de Laar F, van Weel C, Fedorowicz Z, Newton TJ. Evaluating 
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external validity, applicability and transferability of evidence to primary care setting. (Poster) 
Cochrane Colloquium 2010, Keystone, US. 
4) Nasser M, Fedorowicz Z, de-Souza RF, Owaise-Sharif M, Hu N, Sequeira P, Pedrazzi V. 
Evaluating three informal capacity building networks for systematic reviews. (Poster) 
Cochrane Colloquium 2010, Keystone, US. 
5) Nasser M, Fedorowicz Z, Sequeira P. Ideal conditions or usual practice? The position of trials 
from two Cochrane reviews within the pragmatic - explanatory continuum. (Poster) Cochrane 
Colloquium 2010, Keystone, US. 
Oct 2009 Prioritising Cochrane review 
topics to reduce the know-do 
gap in low and middle income 
countries (Special session) 
XVII Cochrane Colloquium 11-
14 October 2009, Singapore. 
1) Krleza-Jeric K, Djulbegovic B, Nasser M, Reveiz L, Huic M, Lemmens T, Sim I, Armstrong W, Metz 
C, Elemam K, Wager E. International standards for Public Reporting of Clinical Trial Outcomes 
and Results (PROCTOR): a proposal to increase the quality of evidence produced by systematic 
reviews. XVII Cochrane Colloquium 11-14 October 2009, Singapore. 
2) Nasser M, Welch V, Tugwell P, Waters L, Doyle J, Ueffing E. Priority setting for The Cochrane 
Collaboration: methods, challenges and opportunities (workshop) XVII Cochrane Colloquium 11-
14 October 2009, Singapore. 
3)  De Souza R, Sequeira P, Nasser M, Fedorowicz Z, Shahiri M. Is Google Translate useful for the 
selection of studies to be included in Cochrane reviews. (poster) XVII Cochrane Colloquium 11-
14 October 2009, Singapore. 
4)  Bastian H, Waltering A, Nasser M. Thumps up, thumps down: An analysis of online user ratings 
of summaries of systematic reviews (poster) XVII Cochrane Colloquium 11-14 October 2009, 
Singapore. 
5)  Nasser M, Welch V, Tugwell P, Ueffing E, Bastian H. An Equity Lens for identifying priority 
topics for Cochrane reviews (Oral) XVII Cochrane Colloquium 11-14 October 2009, Singapore 
6)  Nasser M, Bastian H, Knelagen M, Waltering A. Does the message still reflect the evidence? 
(Poster) XVII Cochrane Colloquium 11-14 October 2009, Singapore. 
7)  Nasser M, Fedorowicz Z, Sequeira P, Newton T, Souza RD, Javaheri H. Evaluating the impact of 
the ViTaMIN (Virtual Training and Mentoring International Network) project (Poster) XVII 
Cochrane Colloquium 11-14 October 2009, Singapore. 
5-7 March 2009 10 Jahrestagung des 
Deutschen Netzweks 
Evidenzbasierte Medizin, 
Nasser M, Fedorowicz Z, Gruen R, Tavender E, Mayhew A. Komplexität bei der Durchführung 
systematischer Übersichten zur Versorgung im Gesundheitssystem. (poster) Evidenz und 
Entscheidung: system unter Druck. 10 Jahrestagung des Deutschen Netzweks Evidenzbasierte 
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Berlin Medizin. Berlin. 5-7 March 2009. 
Nasser M, Türp JC, Antes G, Motschall E. Systematische Übersichten in der Zahnmedizin: Eine 
Landkarte der zahnmedizinischen Evidenz. (poster) Evidenz und Entscheidung: system unter Druck. 
10 Jahrestagung des Deutschen Netzweks Evidenzbasierte Medizin. Berlin. 5-7 March 2009. 
3-7 October 2008  XVI Cochrane Colloquium 3-7 
October 2008, Freiburg, 
Germany 
Piennar E, Cahill K, Kjeldstrom M, Nasser M. RevMan 5 for Cochrane Intervention review authors – 
learn to use all the features hands – on. (workshop) XVI Cochrane Colloquium 3-7 October 2008, 
Freiburg, Germany. 
Mahdian M, Nasser M. Assessment of the methodological quality of reporting of randomized trials 
in Iranian dental journals (poster) XVI Cochrane Colloquium 3-7 October 2008, Freiburg, Germany. 
Shahiri M, Nasser M, Javaheri H. Developing a sensitive search strategy in Farsi for retrieving 
reports of randomized trials in Iranmedex (poster) XVI Cochrane Colloquium 3-7 October 2008, 
Freiburg, Germany. 
Nasser M, Türp JC, Antes G, Motschall E. Panoramic overview of systematic reviews in Oral Health. 
(poster) XVI Cochrane Colloquium 3-7 October 2008, Freiburg, Germany. 
Bastian H, Knelangen M, Lange S, Nasser M. Cochrane versus non-Cochrane reviews: An exploration 
of discordance, comparative quality and relevance for patient information. XVI Cochrane 
Colloquium 3-7 October 2008, Freiburg, Germany. 
Mahdian M, Nasser M, Fedorowicz Z. How do clinicians decide treatment when there is no 
evidence? (poster). XVI Cochrane Colloquium 3-7 October 2008, Freiburg, Germany. 
Nasser M, Khoshnevisan M, Ahangari Z, Houshmand B, Nouri M, Shakhssalim N, Hajebrahimi S, 
Javaheri H, Yassiny K. Evidence production and dissemination in Iran: the Iranian Cochrane Informal 
Network. (poster). XVI Cochrane Colloquium 3-7 October 2008, Freiburg, Germany. 
 de Souza RF, Chaves CAL, Nasser M, Fedorowicz Z. Brazilian Oral Health Journals in Scielo: an open 
access tropical treasure? (poster). XVI Cochrane Colloquium 3-7 October 2008, Freiburg, Germany. 
Nasser M, Fedorowicz Z, Bastian H. Comparing the priorities in oral health with the existing 
evidence in the Cochrane Library (poster). XVI Cochrane Colloquium 3-7 October 2008, Freiburg, 
Germany. 
Nasser M, Tugwell P, Welch V, Morris E, Waters E, Doyle J. Ensuring relevance and building 
enthusiasm for Cochrane reviews: determining appropriate methods for identifying priority topics 
for future Cochrane reviews (workshop). XVI Cochrane Colloquium 3-7 October 2008, Freiburg, 
Germany. http://www.equity.cochrane.org/Files/Priority_Setting_Minutes_2008.pdf 
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25-26 Dec 2008 Iranian Section of 
International Association of 
Dental Research Congress, 
Tehran, Iran. 
Nasser M, Fedorowicz Z, Khoshnevisan MH. A Cochrane Collaboration workshop. Iranian Section of 
International Association of Dental Research Congress. 25-26 Dec 2008, Tehran, Iran 
Sep 2008 WONCA Europe, Istanbul, 
Turkey 
Invited plenary speaker - Cochrane Primary Health Care Field: Introduction to systematic reviews 
and the Cochrane Primary Health Care Field, WONCA Europe, Istanbul, Turkey 
June 2008 Iberoamerican Cochrane 
Network conference, Costa 
Rica, June 2008 
Invited speaker - the Cochrane Developing Countries Network  
Dec 2007 “Creating supportive 
Environments for Nutrition 
Guidance: towards a Synergy 
between Primary Care, and 
Public Health.” Fifth Heelsum 
workshop, Heelsum 
Collaboration, Heelsum, 
Netherlands 
Invited speaker - Diet and nutrition advice from The Cochrane Library: is it useful for the consumers 
and family physicians? 
23-27 October 
2007 
XV Cochrane Colloquium, Sao 
Paulo, Brazil. 
Poster - Nasser M, Ortiz Z, Berenstein G, Garcìa Dieguez M, Angel Exposito J, Pardo J. Guidelines for 
preparing Cochrane Reviews relevant to Developing Countries. XV Cochrane Colloquium 23-27 
October 2007, Sao Paulo, Brazil. 
Oral presentation - Nasser M, van Binsbergen JJ, Javaheri H, Yassiny K. Nutritional Guidance for 
Cochrane Reviews: A Consumer Approach. XV Cochrane Colloquium 23-27 October 2007, Sao Paulo, 
Brazil. 
Oral presentation Nasser M, Lodge M, Fedorowicz Z. The relevance of Cochrane Reviews to the 
Cancer Priorities in Iran. XV Cochrane Colloquium 23-27 October 2007, Sao Paulo, Brazil. 
23-26 Oct 2006 Cochrane Colloquium, Dublin, 
Ireland 
Poster - Nasser M, Al-Hajeri A, Eisinga A, Fedorowicz Z. Developing a sensitive search strategy for 
retrieving reports of randomized trials in Iranmedex. 138. 23-26 Oct 2006 Cochrane Colloquium, 
Dublin. 
Poster - Nasser M, Al-Hajeri A, Eisinga A, Fedorowicz Z. Assessment of the methodological quality of 
reporting of randomized trials in Iranian healthcare journals. 120. 23-26 Oct 2006 Cochrane 
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Colloquium, Dublin. 
June 28 - July 1, 
2006 
84th General Session & 
Exhibition of the IADR 1st 
Meeting of the Pan-Asian-
Pacific Federation 
(Australian/New Zealand, 
Chinese, Korean, Japanese, 
and Southeast Asian Divisions 
of the IADR), Brisbane, 
Australia.. 
Nasser M, Oskoui M, Ahangari Z. Antimicrobial Activity of MTA, Portland cement and Calcium 
Hydroxide. 2153. 3.84th General Session & Exhibition of the IADR 1st Meeting of the Pan-Asian-
Pacific Federation (Australian/New Zealand, Chinese, Korean, Japanese, and Southeast Asian 
Divisions of the IADR), Brisbane, Australia.. 
Jan 2006 Shiraz University of Medical 
Sciences on the third Regional 
Conference on Medical 
Journals in the Eastern 
Mediterranean Region 
WHO/EMAME, Shiraz, Iran 
Workshop on Evidence-Based Medicine 
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Appendix 2 –An overview of reviews on priority setting strategies 
 
Citation Description Summary of the results 
Noorani 2007 (42) A systematic 
review of methods 
for priority setting 
for the 
assessment of 
new or diffused 
health 
technologies 
(a) Twelve priority setting systems from 11 health technology 
assessment (HTA) agencies. (b) Most processes used a panel 
or committee to advise the agencies regarding priorities and 
mostly involved health care system funders, health 
professionals, and researchers. (c) Consumers were involved 
only in some of these processes. (d) Each agency used 3-10 
criteria for the prioritisation process. (e) Most of the agencies 
used criteria that addressed clinical impact, economic impact 
and budget impact. 
Oxman 2006(99) A review of 
priority setting 
strategies to 
inform future 
policies in the 
World Health 
Organisation 
(WHO) 
They recommended that the WHO should consider the 
following criteria for prioritisation (1) "Problems associated 
with a high burden of illness in low and middle-income 
countries, or new and emerging diseases. (2) No existing 
guidelines or recommendations of good quality. (3) The 
feasibility of developing recommendations that will improve 
health outcomes, reduce inequities or reduce unnecessary 
costs if they are implemented. (4) Implementation is feasible, 
will not exhaustively use available resources, and barriers to 
change are not likely to be so high that they cannot be 
overcome. (5) Additional priorities for WHO include 
interventions that will likely require system changes and 
interventions where there might be a conflict in choices 
between individual and societal perspectives” 
Considering the process, they recommended that a 
prioritisation process should be part of a routine budgeting 
process and should consider the following issues: “1. Criteria 
for establishing priorities should be applied using a systematic 
and transparent process. 2. Because data to inform 
judgments are often lacking, unmeasured factors should also 
be considered explicitly and transparently. 3. The process 
should include consultation with potential end users and 
other stakeholders, including the public, using well-
constructed questions, and possibly using Delphi-like 
procedures. 4. Groups that include stakeholders and people 
with relevant types of expertise should make decisions. Group 
processes should ensure full participation by all members of 
the group. The process used to select topics should be 
documented and open to inspection.”  
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IOM 2008(35) An overview 
comparing the 
methods of 
identifying topics 
in different 
national and 
international 
organisations. 
The new IOM report recommends five guiding principles to be 
considered in future priority setting projects: consistency, 
efficiency, objectivity, responsiveness, and transparency. They 
recommend that the priority setting process should be open, 
transparent, efficient, and timely and should consider the 
impact of evidence-based medicine on improving health 
outcomes across life spans, reducing the burden of disease 
and health inequities, and reducing undesirable practice 
variations. The economic burden of the disease and the 
intervention should be considered. The priority setting 
advisory committee needs to include individuals with 
different expertise and interests and strategies need to be 
placed to minimize conflict of interest 
Stewart 2008 (43) The James Lind 
Alliance aimed to 
develop a 
systematic map of 
studies focusing 
on patients' and 
clinicians' research 
priorities. 
 258 relevant studies. 
 In the identified studies, the role of the clinicians and 
patients in setting the research agenda varied from a more 
passive consultative role to a more active and 
collaborative approach. 
 In most of the studies, the clinicians were more involved 
than the patients and they were usually working 
separately rather than collaboratively. 
Montorzi 2009 
(34) 
An overview of 
the methods for 
priority setting of 
research. 
Divides methods to priority setting in two sections: methods 
to identify priority topics and methods to rank the priority 
topics. Methods to identify priority topics were further 
categorized into: (a) methods that focus on using existing 
data like burden of disease or cost effectiveness and 
resources (compound approaches); and (b) methods that 
consider future health research priorities (foresighting 
approaches) such as horizon scanning which is used explore 
novel and unexpected issues along with persistent problems 
and trends in health care. 
Viergever 2010 
(41) 
The World Health 
Organisation 
aimed to develop 
an overview of the 
methods for 
research priority 
setting exercises 
in their 
departments and 
also quantifies the 
volume of 
research priority 
setting work done 
in certain health 
areas. 
 Most of the work was done in infectious disease and 
communicable diseases.  
 They found a wide variety of methodological approaches 
but were not able recommend certain strategies over 
others. 
 There was an expressed need for further methodological 
guidance and coordination in this field. 
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Swingler 2005 
(100) 
Evaluating 
national child 
health research 
priorities in sub-
Saharan Africa. 
 Four studies had children as a separate group but 
addressed specific areas of child health like school health 
or perinatal care. 
 Four studies looked at research priorities for both children 
and adults but had included specific categories of child 
health. 
 The research of the priority setting strategies did not 
distinguish children from adults. 
 The authors concluded that there are few national 
research priority exercises for child health done and those 
with combined groups may not adequate covered 
children’s interest. 
Rylance 2010 
(101) 
Reviewing priority 
setting strategies 
on tuberculosis. 
 33 research agendas for tuberculosis published between 
1998 and 2010. 
 Two clear research priorities: development and testing of 
both new drugs and treatment regimens, and new 
diagnostic tests for tuberculosis. 
 The other priority areas were epidemiology, health 
services research, basic research, and vaccine 
development and use. 
 The methods to reach these priorities vary. 
Myers 2011 (102) Pubmed search 
1990-2010 for 
studies on 
research 
prioritisation and 
value of 
information 
analysis along with 
searching US 
based funding 
organisations 
Outside of the UK NICE/HTA program, systematic reviews 
were rarely cited as important sources for identifying 
evidence gaps for research prioritisation. Cost-effectiveness 
and VOI analyses were the most commonly used modelling-
based methods, but, outside of the UK, it is unclear to what 
degree the priorities identified by these methods were 
translated into actual research funding. Stakeholders in our 
two case studies found modelling and VOI to be potentially 
useful tools, but there are a variety of methodological and 
operational issues that need to be considered and resolved if 
these methods are to be used to assist with prioritizing 
research gaps identified through systematic reviews. These 
include identifying ways to compare the impact of different 
prioritisation methods on the likelihood that priority 
questions will be answered through research, identifying the 
appropriate resources (including technical expertise) to 
conduct the analyses, defining the appropriate timing of the 
modelling and analyses, and identifying the appropriate level 
of modelling complexity. 
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Tomlinson 2011 
(103) 
A review of 
selected research 
priority setting 
processes at 
national level for 
low and middle 
income countries. 
Data were 
gathered from 
presentations at a 
meeting held at 
the World Health 
Organisation 
(WHO) in 2008 
and a web-based 
search. Based on 
this literature 
review a number 
of criteria were 
developed to 
evaluate the 
priority setting 
processes. 
 Methods used by the countries in their priority setting 
processes ranged from ones developed by the countries 
themselves to the use of existing methodologies. These 
included the Combined Matrix Approach CAM) ; the Council 
on Health Research and Development (COHRED) ; and the 
Child Health and Nutrition Research Initiative (CHNRI). 
 Countries have used a variety of approaches to include 
different stakeholders.  
 Intentionally include only individuals with diverse and 
relevant experiences and view- points as opposed to 
including representatives from a variety of societies and 
associations. 
 A small Executive Committee that guides the process and 
decision making; while a larger decision making group 
(comprised of stakeholders) would then be charged with 
implementing the chosen methodology and to make 
decisions. An Advisory Council comprising a much larger 
number of stakeholders (possibly separated into smaller 
groups) might also be created in order to advise, deliberate, 
pro- vide viewpoints, and to provide support to the smaller 
decision making groups.  
 Establishment of a communication channel with neigh- 
boring countries about the priority setting process. This 
serves as a gesture of goodwill, but may also aid the priority 
setting process. 
Bitter 2011 (104) The focus of the 
review of 
reviewing the 
multi-stakeholder 
involvement in 
research priority 
setting. Searching 
of databases was 
conducted along 
with cross 
referencing. They 
used two 
conceptual 
frameworks to 
evaluate the 
outcomes 
Eight different stakeholder involvement approaches: 
1. Delphi technique,  
2. nominal group approach,  
3. Dialogue model,  
4. listening model,  
5. James Lind Alliance Partnerships, 
6. the approach of the Scandinavian Rheumatism 
Associations,  
7. focus groups, and  
8. the Primary Health Care Research Evaluation and 
Development Strategy 
 
4 approaches were executed on the level of partnerships:  
1 on the level of placation, 3 on the level of consultation 
 
Diversity not only in the methods but also implementation 
and execution; affected by objective and vision of the 
stakeholder involvement. 
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Appendix 3 - An introduction to Research Priority Setting (RPS) for 
research groups in Cochrane  
Guidance sheet -1 - What is research priority setting and what you need to do before starting? (105)  
Written by: Mona Nasser & Sally Crowe 
What is research priority setting? 
A collective activity for deciding which uncertainties are most worth trying to resolve through 
research; uncertainties considered may be problems to be understood or solutions to be developed 
or tested; across broad or narrow areas (Sandy Oliver). 
Figure 4 is providing the steps that a RPS exercise might include. All RPS exercises that we have 
identified up to now have included all or some of these steps in their approach (however, they do 
not necessarily report all steps in one report). 
 
Figure 4 - Wheel of Research Priority Setting exercises (1, 2) 
A RPS exercise is initiated, designed and implemented in a specific context, setting and population 
with specific principles, values and preferences. A research group selects different methods to fulfil 
each of the steps of a RPS exercises as outlined in Figure 4. It is important that methods are 
selected that have a reasonable chance to help the group in achieving their objectives. If the 
Defining 
Objectives/ 
scope 
Identifying and 
partnering with 
Stakeholders 
Selecting method 
and tools to engage 
with stakeholders, 
identifying and rank 
topics/questions 
uncertainties 
Defining or 
recording criteria 
for differentiating 
or weighting 
different topics 
Situation 
analysis (scoping 
/mapping/ need 
assessment) Identifying 
Questions/ 
Uncertainities/ 
Topics 
Reaching 
consensus on the 
prioritised 
questions/Topics 
Uncertainities 
Translating 
prioritised 
topics/questions/u
ncertainties into 
research 
proposals 
Conducting 
research and 
working on 
implementing the 
results of the 
project 
Evaluating the 
RPS exercise 
with an 
integrated appeal 
and feedback 
mechanism 
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objective of a RPS exercise is to engage with stakeholders from disadvantaged groups in a 
developing country, an online Delphi consensus approach has a limited chance to reach them. 
Ideally  selection of the methods needs to be done based on the most recent empirical evidence 
(see our commentary in Journal of clinical epidemiology that gives some indication of recent 
empirical research (5)).  
Similar to any project, the research team needs the required skills to effectively conduct certain 
methods, and also effectively manage the project. It is common that research teams not consider 
adequately the role of a chair or facilitator for the stakeholder engagement step, so that diverse 
groups of stakeholders can be effectively engaged and involved in the priority setting process. 
Research teams and associated stakeholders are people with a certain social and cultural 
background and bring their own views, values and preferences in their group. The social dynamics 
and power relation between these individuals affect the conduct and results of a RPS exercise, 
Figure 5 
  
Figure 5- Wheel of RPS exercises (2) 10 
RPS exercises could be as a decision making tool to improve the management of an organisation 
and support better decision making. However, they are also a research tool aiming to minimize bias 
in the research agenda in a certain health care field.  
RPS exercises could help in identifying overall gaps in the research agenda (imbalance in the 
number of high quality research projects conducted in drug related topics versus behavioural 
                                                          
10
 from Nasser M, Cochrane Agenda and Priority Setting Methods Group. International workshop on Research Priority 
Setting Methods, June 2012, Plymouth. UK. Available at: 
http://capsmg.cochrane.org/sites/capsmg.cochrane.org/files/uploads/Plymouth%20workshop%20%28Mona%20Nasser%
29%5B1%5D.pdf 
Methods 
Context 
Skills 
Social Dynamics 
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intervention topics) or the construct of a research question (imbalance in the number of high 
quality research focusing on biomedical outcomes versus patient relevant outcomes). 
Before starting a RPS exercise: 
Step –1 -Defining the level of RPS 
Macro-level: identifying and prioritising broad topic areas for the group to define the general 
direction of the group in a specific field 
Meso-level: identifying and prioritising research questions for the group. The questions might be 
broad and narrow depending on the data (qualitative or quantitative) derived from the exercise 
Micro-level: identifying and prioritising focused clinical questions for systematic reviews. The 
questions are constructed to be addressed either by a Cochrane Systematic Review or Cochrane 
Overviews of Review. However, this is the most difficult one as there are still a lot of open 
methodological questions how we best can translate uncertainties of our stakeholders into focused 
questions for systematic reviews.  
Step 2 – Setting up systems to collect the required data to inform the RPS exercise 
The quality of your research priority setting exercise partially depends on the quality and 
availability of the necessary data to inform your decisions. Examples of data that are collected: 
Cochrane groups usually have registries of clinical trials and defining areas in which we have a large 
amount of clinical trials; Cochrane Fields tag Cochrane groups based on topic areas e.g. Child health 
and provide a map on potential gaps in the current reviews; Wiley (the publisher of the Cochrane 
Library) collects data on the use of Cochrane reviews. There are other types of data that review 
groups can collect to inform their work: (a) collecting data on research priorities identified by 
research priority setting exercises outside the collaboration (b) burden of disease data in their own 
clinical area (c) regular survey engaging with the stakeholders of Cochrane groups.  
Step 3 – Building the group to establish partnerships with stakeholders 
Research priority setting is a collective social activity. The research group needs to define who 
needs to be part of this collective activity and to whom is the RPS exercise accountable. Engaging 
with stakeholders usually requires building longer term relations between different stakeholders 
groups, understanding the best approaches to communicate and engage with them, sharing 
respective views and understanding about research and sustaining communication and updates 
during the process to maintain momentum and interest. This might require some capacity building 
or discussion workshops to ensure that different stakeholders have the same understanding on the 
definition and structure of the related research projects. Some groups might find a mapping 
exercise whereby drawing a diagram of actual and potential stakeholders and drawing lines 
representing the relationships (strong, weak, influential, etc) as a useful first step to identify the 
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stakeholders that they work with. It is also important to reflect the cultural, ethnical and 
organisational differences in the stakeholders that might affect the process of reaching a consensus 
in research priority setting. Moreover, the group requires having a clear idea of the level of 
engagement that the group is planning to have with those groups. The ladder of citizen 
participation can be a good guide on reflecting on the mechanism of engaging with stakeholders. 
Depending on the complexity of the topic, you might 
require several informal meetings and discussions with 
stakeholders groups so that concerns can be elicited, 
and their complexity revealed and understanding the 
areas that might be more controversial than 
others(106). It is important that you are clear with 
your stakeholders that you are focusing on concerns 
and uncertainties that they have around health care 
rather than their opinion about research. The 
discussion should aim to identify the most pressing 
uncertainties/problems that stakeholders face and the 
areas of practice or policy that shapes (or could shape) 
those pressing problems. 
Figure 6 - a ladder of citizen participation (Arnstein 1969) (107) 
The nature of the prior engagement with stakeholders might differ depending on the topic itself 
and controversies around it along with the social and political context in which the discussions are 
conducted. Sometimes, there is a need for processes of negotiation preceding the prioritisation to 
prepare the grounds to ensure a constructive discussion in a research priority setting exercise. 
Step 4 – Clarity and transparency on the objectives of the exercise  
The objectives of the exercise define should the methods and approaches that are used to 
construct the research priority setting exercises. As RPS exercises sit in the overall pathway of 
constructing, conducting and implementing research, therefore, the sole aim of a RPS exercises is 
not limited to developing a list of research questions. They provide additional value for example 
changing the power relations, or how the allocation of resources in research are decided (either 
financial resources or human resources), provide opportunities for mutual learning between 
stakeholders, facilitate establishing partnerships and make the group more accountable and 
transparent towards their stakeholders and users of systematic reviews. The success of a RPS 
exercise depends on the ability of the team in developing clear objectives and having a coherent 
plan in selecting methods and process have the highest chance in achieving these objectives.  
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What are you looking for in a RPS exercise? 
As explained beforehand, you need to have clarity about the objectives of your research priority 
setting project and how you conceptualize the engagement of different stakeholders. This also 
extends to what is the question/topic that you are looking for in in priority setting process, is it a 
broad area or a specific question? If you ask a group of people, what do you think should be 
research priorities; they might associate research with some fancy, futuristic (maybe even sci-fi like 
in TV/movies). I once asked a dentist what he thinks should be our research priorities and he gave 
me an example of something that he had tried on a monkey and was wondering whether we could 
do the same research on humans. In reality, dentistry is an area where there is huge amount of 
uncertainty around the effectiveness of conventional dental interventions. However, the 
misconception of the dentist (whom I approached) that research is focused on something new and 
innovative that nobody has tried, rather than looking back on our uncertainties was interesting.  
I had a similar situation when asking a member of the public about dental research and she asked 
me why isn’t there more research on a vaccine for dental caries. If you ask the same people, what 
are your uncertainties and questions around the dental care that you practice or received. They 
come up with a lot of critical questions on their uncertainties. Both approaches can be potentially 
valid depending what you are hoping to achieve from a research priority setting exercise.  
In Cochrane, we usually conceptualize questions in the form of PICO (or variations of it with other 
questions). Some Cochrane groups use a more a more detailed approaches to conceptualize and 
construct questions using the GRADE working group methodology (108). Some research priority 
setting initiatives like James Lind Alliance and PenCLAHRC tried to use the PICO structure to collect 
questions from stakeholders with different level of success (PenCLAHRC attempted to enhance the 
engagement of stakeholders by accompanying the PICO with a plain language summary description 
of the questions)11. The James Lind Alliance initiative conceptualizes the topics that they gather in a 
priority setting exercise as uncertainties about the effects of treatments and give some generic 
examples to help people (although people do not necessarily always adhere to it)12. Previous 
experience by James Lind Alliance has shown that complex surveys using PICO or incorporating lots 
of demographic info increases the attrition rate and yield with much less useful information. Many 
of the research priority setting exercises do not report that they have attempted to conceptualize 
the question/topic beforehand and leave it to stakeholder to decide. This can be a potential source 
of problems especially in a diverse group of stakeholders. People’s interpretation of the concept 
“research questions” might vary (this could be people who are sharing their views or people who 
are analysing data to derive with new questions) and makes it more complicated to find consensus. 
                                                          
11 http://clahrc-peninsula.nihr.ac.uk/submit-question.php 
 http://www.library.nhs.uk/duets/ 
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This lack of clarity and discordance can potentially adversely affect the research priority setting 
exercises and results in questions that are difficult to interpret, aggregate, prioritise and more 
critically be used by researchers. The finalised list of questions might end up being uninformative 
for researchers and research organisations. 
The research priority setting group needs to also decide how much contextualised information (and 
the nature of the information) they want collect along with the questions. This information can be 
valuable to understand why the question is important, why it needs to be prioritised. It can also 
help future researchers (if the question is prioritised) to understand how to refine, construct and 
design the research questions. In the question/topic identification step, this information can be 
used in two ways (a) translating the topic/question into a more coherent structure: in some priority 
setting exercises, the group translate the topic/question into a more coherent and harmonized 
structure and this requires some understanding on the context to ensure that the question doesn’t 
get ‘lost in translation’. This applies both to a situation in which the question is derived from 
engaging with stakeholders and from the data analysis (b) ranking the topic/questions, the 
information can be used to inform a consensus group to rank the topic or used in analysing the 
data to rank them. This collaboration (and discussion) around the contextual information around 
the question also provides a wider “mutual learning” opportunity between the researchers and 
stakeholders (information derived from the data).  
Some groups might prefer to develop a strict structure how they collect questions to prioritise but 
others might prefer to engage with stakeholders first (as part of your preparation step) and discuss 
how they mutually conceptualize research questions and what they are intending to get from your 
exercises. This can be helpful in establishing a shared understanding on this topic between 
stakeholders and has the additional benefit that the group would have an opportunity to capture 
some of the complexity that might come up in some questions that might be lost if you restrict 
people to a clear structure. Obviously, this approach can only be useful if you have a smaller 
number of stakeholders that you engage with in person and wouldn’t work as part of a big online 
survey. 
Research questions can be derived from stakeholders (e.g. the six “Ps” of patient, practitioner, 
public, policy maker, private sector, and press) (109) but they can also be derived from other data 
sources. Most Cochrane reviewers are familiar with the ‘implications for research’ part of a review 
that can be constructed in a structure form and can be used in a research priority setting exercises 
as a source of questions for primary research. For systematic reviews, you might have structured or 
unstructured recommendations for future systematic reviews from overview of reviews or clinical 
guidelines. Other data-driven sources of research questions are burden of disease, research 
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use/health information use data (in the case of the collaboration, library use data). Most of the 
ways to conceptualize questions that are suggested here focus on the concept of finding gaps on 
what we know, and filling them as a priority. Another way to conceptualize is to identify ideas that 
could be important in the future but are not necessarily big now (“foresighting” approach). This can 
be of relevance to the collaboration in prioritising methodological innovation or even in the field of 
review groups around prospective meta-analysis.  
The conceptualization of research questions/topics as part of the prioritisation also guides and 
defines the methods to translate the topics into a focused research questions for a Cochrane 
Review. There is a remarkable amount of work done on the issue around “outcome selection” 
inside and outside the collaboration as part of this translation (or refinement of the topic) outside a 
prioritisation process. However, the possibilities to use them as part of constructing research 
questions are not adequately explored. The James Lind Alliance Eczema partnership (which was 
triggered by lack of evidence in a Cochrane Review and used to guide future primary research) also 
provided some steps in engaging through a workshop(110). Other organisations used also intensive 
approaches to refine and translate questions e.g. AHRQ (111). 
Step 5 – Available Resources and Timeline 
Research priorities change over time. Therefore, it is critical that they are regularly conducted, or 
preferably there is a continuous plan to conduct a RPS exercises in specific time points. The group 
needs a clear idea on the available resources, as these are limiting factor in defining the methods 
and processes that can be used to conduct a RPS exercise. A resource intensive RPS exercises that 
takes a few years to be conducted might end up with out of date priorities.   
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Appendix 4 – Equity guide for developing a priority setting strategy for 
Cochrane Review Groups 
 
Authors: Mona Nasser, Erin Ueffing 
Introduction 
As described in the prioritisation and Cochrane Review Groups draft (that was submitted for the 
mid-year Steering group meeting in Split, Croatia), prioritisation for the Cochrane Review Groups 
(CRGs) can broadly occur at three levels: 
 Selecting the titles that a CRG would consider essential to their portfolio, so that they can 
be actively commissioned 
 Selecting from titles that have been submitted  
 Deciding which reviews are most important to update 
The implementation of prioritisation can occur in two stages in defining an overall research agenda 
for the work of the CRG as part of a strategic planning or more specifically a prioritisation strategy 
in identifying topics/titles for Cochrane Reviews (both conducing new ones and updating ones). 
 The draft for the steering group also highlights the importance of incorporating the views of a 
broad and inclusive network of stakeholders including end users and funders in the work of the 
CRG and incorporating the concept of health equity in the work of the CRG. Moreover, it recognizes 
that the views of certain stakeholders are, in practice, under-valued in the work of the CRG if no 
active attempts are made to gather these viewpoints.  
 The current draft intends to highlight strategies and approaches that CRG could use to ensure that 
priorities of diverse group of stakeholders including disadvantaged group are considered in the 
development of prioritisation strategies. Moreover, it intends to guide CRGs to incorporate the 
concept of equity in their prioritisation strategy. 
Equity Lens: 
The proposed priority setting and agenda setting methods group along with the Campbell-
Cochrane Equity Methods Group has developed an equity lens to guide future prioritisation and 
agenda setting strategies that could guide CRGs in developing a prioritisation strategy. CRGs could 
also contact the members of the proposed methods group for further guidance (1). Depending on 
the clinical context, one or more of the questions might not be completely applicable for the 
prioritisation strategy. The equity lens is supposed to act as a guide to help CRGs to identify 
important topics and is not needed that all questions are fulfilled. 
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1. Are different stakeholders who might be affected by the choice of research (review) topics 
involved in the prioritisation process (different age, sex, sexual orientation, disability, 
ethnicity, and religion, place of residence, occupation, education, socioeconomic status, 
and social capital groups)? In which steps are they involved? 
2. Does the prioritisation project consider reducing inequity as part of its objectives? 
3. Are the selected methods and tools to identify prioritize, implement, disseminate, and 
communicate research topics understandable, transparent and relevant for different 
stakeholders (different age, sex, sexual orientation, disability, ethnicity, religion, place of 
residence, occupation, education, socioeconomic status, and social capital groups)? 
4. Are specific strategies considered to minimize the barriers to reach disadvantaged or less 
accessible populations? 
5. In the stage of situation analysis (evaluating the current health research coverage, 
identifying gaps, evaluating healthcare needs, etc.), does the analysis consider the 
differences in the prevalence, severity and urgency of health problems along with potential 
differences in the impact or value of the health care interventions assessed across different 
subgroups (age, sex, sexual orientation, disability, ethnicity, religion, place of residence, 
occupation, education, socioeconomic status,  
6. Do the criteria for prioritisation consider the potential differences in the severity and 
urgency of health problems in disadvantaged populations or less accessible groups as 
opposed to the health problems in privileged populations?  
7. Do the criteria for prioritisation consider the potential differences in the impact of a health 
care intervention in disadvantaged populations as opposed to the health problems in 
privileged populations?  
8. Do the criteria for prioritisation consider that different population groups might have 
different values and preferences? 
9. Are different stakeholder groups (representing age, sex, sexual orientation, disability, 
ethnicity, and religion, place of residence, occupation, education, socioeconomic status, 
and social capital groups) provided with an opportunity to provide feedback and appeal the 
process and results of the prioritisation process? 
10. Did the prioritisation result in more research topics (in this case Cochrane Reviews) that are 
relevant to disadvantaged groups?  
11. Did the dissemination and implementation strategy increase the likelihood that funders 
and research institutes become aware of the prioritised research topics and consider them 
as part of their research agenda or strategic planning? 
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12. Did the dissemination and implementation strategy increase the likelihood that the 
prioritised research topics that are relevant to disadvantaged groups get funded and 
conducted?  
13. Did the dissemination and implementation strategy increase the likelihood that researchers 
who work with disadvantaged groups conduct or get involved in the prioritised research 
projects (in this case the research project is a Cochrane systematic review review)? 
14. Did the dissemination and implementation strategy increase the likelihood that 
disadvantaged groups or decision makers or practitioners who work with disadvantaged 
groups get involved in the prioritised research topics?  
15. Does the dissemination and implementation strategy increase the likelihood that policy 
makers and decisions makers who work with disadvantaged groups use the result of the 
prioritised research topics?  
16. Did the results of the prioritised research topics changed policies, legislation or clinical 
practice in favour of disadvantaged groups? 
17. Did the appeal and enforcement strategy increase the likelihood that disadvantaged groups 
or decision makers, researchers and practitioners who work with disadvantaged group had 
provided feedback and comments on the prioritisation process or results? (Nasser 2011) 
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How can equity be considered as part of the recommendation made by the Editorial unit 
Recommendation 
from the editorial 
unit 
Suggestion on incorporating an equity-oriented approach 
Evaluating the extent 
coverage of key 
question areas in their 
discipline  
1) Selecting the dimensions of the PROGRESS PLUS mnemonic that is 
relevant to the discipline in which the prioritisation is done 
2) Identifying the major relevant clinical problems/issues related to the 
selected dimensions of PROGRESS PLUS mnemonic in step 1. Potential 
sources to acquire this information is: 
a. Priorities in the clinical field: Conducing a systematic review 
of current prioritisation strategies in the specific discipline 
and exploring whether the priorities of those dimensions 
that were selected in step had been considered example 
Rylance J, Pai M, Lienhardt C, Garner P. Priorities for 
tuberculosis research: a systematic review. Lancet Infect Dis. 
2010 Dec;10(12):886-92 (101). 
b. Collecting information on the burden of disease, urgency of 
the health problem or potential differences in the impact or 
value of the health care interventions for different 
stakeholders considering the dimensions identified in step 1. 
c. Consulting a group of stakeholders which can represent the 
priorities of disadvantage individuals considering the 
dimensions identified in step 1 
3) Mapping the topics of the Cochrane Reviews against the clinical 
problems/issues identified in step 1 and demonstrates potential gaps. 
4) Developing plans on how to address this gap. 
How the group aims to 
identify unaddressed 
and important 
questions 
1) Revising the research agenda and strategic planning of the CRG 
based on the evaluation of extend coverage of key questions in the 
area of their discipline. 
2) Identifying stakeholders who can represent the views that are 
currently under-valued in the work of the CRG and involving them 
3) Developing and conducing a priority setting strategy using the 
equity lens for priority setting and agenda setting. 
How the group seeks 
to identify review 
teams to address 
identified review 
questions 
1. Allocation centralized resources e.g. staff that focus on supporting 
review teams which work on prioritised topics (One of the CRGs 
had developed a research funding proposal that included 
conducting a prioritisation strategy and funding a centralized 
research team that would support volunteer authors working on 
these reviews. 
2. Building collaboration and networks with research institutes and 
individual researchers who focus on research project that were 
identified as research priorities in the previous steps or institutes 
and practitioners who have experience working with the identified 
target disadvantaged groups as identified in the previous steps. 
This can be in a form of an informal collaboration, advisory group 
or establishing a satellite. This can facilitate recruiting authors, peer 
reviewers and editors who can help in ensuring the relevant of the 
Cochrane Reviews. Recruiting researchers and practitioners who 
have experience working with specific disadvantaged groups as 
authors, peer reviewers or editors. Transparent process in 
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selecting, prioritisation or rejecting titles increases the 
accountability of the topic selection process in Cochrane and 
probably increases the interest of the stakeholders in the work of 
it. 
How submitted titles 
are prioritised  
1. If the research agenda and priorities of the CRG is transparently 
provided for the authors. The authors could provide description 
how their topics relate to the research agenda. The infectious 
diseases group for example provides an opportunity for the authors 
to explain how their titles can help in achieving the Millennium 
development goals (MDGs). 
2. The CRG could provide the editorial team with specific criteria to 
guide them in prioritising the submitted titles. This could include 
criteria that incorporate the aspect of health equity for example a 
possible criteria could be “would you say that the underprivileged 
would be the most likely to benefit from the results of the 
proposed review after its implementation” (112). One possibility is 
that the CRG do not respond immediately to a title request and do 
it in certain time periods e.g. 6 months and prioritise the titles that 
they receive in this timeframe. As many author teams are 
volunteers, flexibility in the process is crucial to ensure continuity 
and sustainability. 
 
Prioritising Clinical Content: 
In this draft, we used the different dimensions of the PROGRESS-PLUS acronym which is an 
extension of Evans and Browns framework PROGRESS to highlight the diversity of the stakeholders. 
This includes PROGRESS: Place of residence; Race/ethnicity; Occupation; Gender; Religion; 
Education; Socioeconomic status; and Social capital, with “PLUS” representing additional 
dimensions such as age, sexual orientation, and disability (113, 114). However, some of these 
dimensions might be more relevant in certain clinical fields compared to the others. Each CRGs 
would need to make a decision which of these dimensions are more relevant to their clinical field 
and what is the best approach to incorporate these dimensions in the work of the CRG. For 
example, there is much more research done on sexual differences in the field of cardiovascular 
research compared to restorative dental research and based on the current evidence base the 
former one seems be much more crucial than the latter one.  
Process and politics: 
We mentioned in previous sections the importance of stakeholder involvement. However, 
involvement of stakeholders covers a broader aspect and could include a passive involvement that 
assumes the stakeholders lacks sufficient knowledge or capacity to get involved in the process to 
an active model in which the stakeholder is directly involved in the process (115). This is especially 
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important in the involvement of patients in the process. The James Lind alliance has extensive 
experience in involving patients in the prioritisation process. 
The Prioritisation cycle: 
Prioritisation strategies do not end with selecting the prioritisation topics. Prioritisation is a cycle 
that starts in selecting priority topics, implementing, disseminating, evaluating and afterwards 
updating the prioritisations. Stakeholders who were involved in the prioritisation strategy could be 
further involved in the work of the CRG as peer reviewers to ensure that their views are also 
considered in conducting the Cochrane Reviews.  
Updating and upgrading Cochrane Reviews: 
The Cochrane editorial unit provides a framework for updating Cochrane Reviews. Some additional 
issues that might be considered are the priorities of disadvantage groups and how much they are 
addressed in the current reviews. The equity checklist developed by the Campbell-Cochrane equity 
methods group could help authors in identifying the gaps in their finished Cochrane Reviews that 
they might want to consider in updating their reviews. 
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